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Abstract 
During the last years, the excessive and improper use of commercially 
available antibiotics has contributed to the development of resistant microbial 
pathogens, which represent a serious problem for the world public health. 
Among these microorganisms, the Gram-negative bacterium Pseudomonas 
aeruginosa is one of the most difficult to eradicate due to its ability to form 
sessile communities, named biofilms, which cause chronic infections, 
especially in the lungs of cystic fibrosis (CF) patients. 
Naturally occurring antimicrobial peptides (AMPs), characterized by a 
different mechanism of action, represent a promising alternative to the 
commonly used drugs. AMPs are evolutionally conserved molecules 
produced by almost all living organisms as a first line of immune defense and 
amphibian skin is one of the richest sources.  
The studies carried out in this thesis focused on two peptides: 
Esculentin-1a(1-21)NH2, [Esc(1-21) GIFSKLAGKKIKNLLISGLKG-NH2], 
derived from the N-terminal region of the frog skin AMP esculentin-1a, and 
its diastereomer, Esc(1-21)-1c, containing two D-amino acids at positions 14 
and 17 (i.e., D-Leu and D-Ser, respectively). This latter was designed with the 
purpose to reduce the peptide’s cytotoxicity and to increase its stability to 
proteolytic enzymes. 
The results achieved in this thesis have indicated that compared to Esc(1-21), 
the diastereomer is: i) significantly less toxic towards mammalian cells, in 
agreement with its lower α-helical structure, as determined by circular 
dichroism spectroscopy and nuclear magnetic resonance studies; ii) more 
effective against the biofilm form of P. aeruginosa (either reference or 
clinical isolates from CF patients) while maintaining high activity against the 
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free-living form of this pathogen; iii) more effective in killing Pseudomonas 
cells once internalized into bronchial cells expressing either the functional or 
the ΔF508 mutant of the CF transmembrane conductance regulator; iv) more 
resistant to bacterial and human elastases, which are abundant in CF lungs. In 
addition, the diastereomer was found (i) to have a higher activity than the all-
L peptide in promoting migration of bronchial epithelial cells and presumably 
in favoring re-epithelialization of damaged lung tissue; (ii) to disaggregate 
and detoxify the bacterial lipopolysaccharide (LPS) and to inhibit 
cyclooxygenase-2 (COX-2) synthesis, albeit less than the wild-type peptide.  
Based on its interesting biological properties, Esc(1-21)-1c is a promising 
candidate for the development of a new drug that not only eliminates 
microbial pathogens, but also restores the integrity of a damaged tissue, such 
as the lung of CF patients, following Pseudomonas respiratory infections. 
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Abbreviations 
AMP  Antimicrobial peptide 
BrdU  Bromodeoxyuridine 
CD  Circular dichroism 
CF  Cystic Fibrosis  
CFTR  Cystic Fibrosis Transmembrane Conductance Regulator 
CFU  Colony-forming units 
COX-2 Cyclooxygenase-2  
CxF  Carboxyfluorescein  
DMEMg Dulbecco’s modified Eagle’s medium supplemented with 2 
mM glutamine 
DPC  Dodecylphosphocholine  
EGFR  Epidermal Growth Factor Receptor 
FBS  Fetal Bovine Serum  
LB  Luria-Bertani broth 
LPS  Lipopolysaccharide 
MEMg  Minimum Essential Medium supplemented with 2 mM  
glutamine 
MMP  Matrix metalloproteinase  
MTT  3(4,5-Dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide 
NMR  Nuclear Magnetic Resonance 
PBS  Phosphate buffered saline 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  
POPE  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine  
POPG  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
RP-HPLC Reversed-Phase High-Performance Liquid Chromatography  
SDS  Sodium-dodecylsulfate 
TNF-α  Tumor Necrosis Factor α  
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1. Introduction 
1.1 Antibiotic resistance 
An antibiotic is a natural or synthetic compound with antimicrobial activity, 
able to kill or block the growth of microorganisms. Antibiotics represent one 
of the most significant medical achievements of the twentieth century. In 
fact, the treatment of microbial infections with antibiotics has resulted in the 
reduction of human mortality, thus improving human health and increasing 
the life expectancy (WHO 2017; Nordqvist 2017). 
However, since the discovery of antibiotics, over several decades, their 
excessive and indiscriminate use for clinical and veterinary purposes, has 
significantly contributed to the selection and spread of the so-called 
“superbugs”, bacterial strains resistant to conventional antibiotics, e.g. β-
lactams, aminoglycosides, tetracyclines and fluoroquinolones (WHO 2014; 
O’Neill 2016; Davies and Davies 2010; Livermore 2011; Schmieder and 
Edwards 2012). Nowadays, according to the latest World Health 
Organization reports, multidrug-resistant (MDR) bacterial infections are 
actually one of the most complex global health challenges, causing almost 
50,000 deaths per year in Europe and in the US, a number expected to grow 
up to tenfold by 2050, killing more than cancer (O’Neill 2016) (Fig. 1). 
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Fig. 1 Deaths attributable to antimicrobial resistance every year by 2050 (from O’Neill, 
2014).  
 
There are several mechanisms by which bacteria develop resistance to 
antibiotics. These mechanisms consist of biochemical modifications that alter 
bacterial cell properties that normally render the cell sensitive to drugs. 
Antibiotic resistance can be classified into natural (intrinsic) and acquired 
resistance. 
Intrinsic resistance refers to non-responsiveness to an antibiotic that has been 
acquired by the organism as a feature of its species. Each species is 
intrinsically resistant to a group of antibiotics. For example, Gram-negative 
bacteria are naturally resistant to vancomycin as it is unable to cross their 
outer membrane, while Gram-positive bacteria are resistant to β-lactam 
antibiotics (e.g. cephalosporins and penicillins), due to the production of β-
lactamase or penicillin-binding proteins (PBP), enzymes involved in the 
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peptidoglycan synthesis of the bacterial cell wall, that have low affinity for 
penicillin binding (Chen et al. 2011). 
Otherwise, the resistance may be acquired when deriving from mutations in 
existing genes (vertical evolution) or the acquisition of new genes (horizontal 
gene transfer) from other strains or microbial species by transferring of 
mobile genetic elements, such as phages, plasmids and transposons 
(Schmieder and Edwards 2012). 
The main strategies by which bacteria counteract antibiotic activity include: 
• diminished intracellular drug concentration by decreased cell 
permeability and increased efflux by both the cytoplasmic and the outer 
membrane 
• drug inactivation for example by neutralization of the antimicrobial agent 
by enzymes (proteolytic cleavage) 
• antibiotic modification by enzymes able of adding different chemical 
groups to antibiotics 
• modification or complete elimination of the target by the creation of 
alternative metabolic pathways (Chen et al. 2011) (Fig. 2). 
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Fig. 2 Mechanisms of antibiotic resistance in bacteria. The classes of antibiotics affected by 
each of the mechanisms are listed in the boxes (modified by Mukerji et al. 2017 and 
Schmieder and Edwards 2012). 
 
1.2 Antimicrobial peptides (AMPs) and innate immunity 
The absence of antibiotics with new mechanisms of action that counteract the 
spread of MDR strains requires the development of new antimicrobial 
strategies. For this reason, especially in the last two decades, antimicrobial 
peptides (AMPs) have received the attention of the international scientific 
community, representing new possible compounds to be used for 
antimicrobial therapy (Mangoni 2011; Alba et al. 2012; Fjell et al. 2011). 
AMPs, also called “host defense peptides” (HDP), are evolutionally 
conserved molecules widely distributed in almost all living species, including 
bacteria, fungi, insects, plants, amphibians as well as higher eukaryotes such 
as mammals (Ageitos et al. 2016).  
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A significant growth of AMP research started in the 1980s due to the 
discoveries of insect cecropins by Hans Boman, human α-defensins by 
Robert Lehrer and magainins by Michael Zasloff (Wang et al. 2016a).  
According to the Antimicrobial Peptide Database (APD) 
(http://aps.unmc.edu/AP/main.php), the isolated and characterized AMPs so 
far are more than 2900. 
AMPs have a protective function as a first line of immune defense against a 
wide range of infectious agents, such as Gram-positive and Gram-negative 
bacteria, viruses, fungi and some parasites, before the adaptive immune 
system is activated. While the innate immune system, which is present in all 
organisms, is rapid and does not change during repeated infections, the 
adaptive immune system, that evolved most recently in vertebrates, is highly 
specific for pathogens. 
Specifically, in order to prevent colonization of host tissues by pathogens, 
AMPs are mainly secreted by tissues that form a barrier against the external 
environment, such as skin and mucous membranes. They are also stored in 
granules within the phagocytes, where they participate in the killing of 
phagocytized microorganisms (Boman 1991; Hancock and Diamond 2000; 
Zasloff 2002; Mangoni et al. 2016). AMPs can be produced constitutively or 
induced by microbial molecules and cytokines that trigger a signaling 
transduction cascade leading to the activation of NF-kB-controlled genes, 
including those encoding for AMPs (Thaiss et al. 2016). 
Besides their antimicrobial activity, AMPs from higher eukaryotes have been 
found to have additional biological properties that are involved in the 
modulation of the host immune system: stimulation of chemotaxis 
(Mookherjee and Hancock 2007), suppression of proinflammatory cytokine 
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release (Afacan et al. 2012), immune cell differentiation (Davidson et al. 
2004), promotion of angiogenesis and wound healing (Wu et al. 2010) (Fig. 
3). 
 
Fig. 3 Multiple functions of antimicrobial peptides in host defense.  
Abbreviations: AMP, antimicrobial peptide; DC, dendritic cell; LPS, lipopolysaccharide; 
pDC, plasmacytoid dendritic cell; PMN, polymorphonucleocyte; TLR, Toll-like receptor 
(from Lai and Gallo 2009). 
 
Innate immunity is activated when signal molecules, such as those of 
bacterial cells (e.g. lipopolysaccharide, LPS), are recognized by pattern 
recognition receptors (PRRs), including Toll-like receptors (TLRs), mainly 
expressed by mononuclear cells and macrophages. Following the interaction 
between LPS micelles (the biologically active form of the endotoxin) and the 
LPS-binding protein (LBP), the LPS–LBP complex interacts with the CD14, 
the primary receptor of LPS, and together they bind and activate the TLR4-
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mediated intracellular signalling pathway, which activates the NF-kB 
transcription factor. This results in the production and secretion of pro-
inflammatory cytokines (e.g., “tumor necrosis factor α”, TNF-α). Some 
peptides can bind and disaggregate LPS micelles to smaller size particles, 
thus preventing the production of TNF-α (Fig. 4). If TNF-α is produced in 
high amounts because of a prolonged activation of the immune system, it can 
lead to a systemic inflammatory syndrome or sepsis, which, in extreme cases, 
leads to death (Hancock and Sahl 2006; Mangoni and Shai 2011; D’Este et 
al. 2012). 
 
Fig. 4 Schematic representation of the LPS-neutralizing activity of AMPs (from Mangoni 
and Shai 2011). 
 
1.3 AMPs: general features and classification 
AMPs generally contain less than 100 amino acids (Ganz 2003). Unlike 
conventional antibiotics, synthesized by microorganisms through several 
steps, each one catalyzed by a different enzyme (Boman 1995), AMPs are 
encoded by genes and ribosomally synthesized as pre-propeptides of 60-170 
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amino acids, consisting of an N-terminal signal for endoplasmic reticulum, an 
anionic pro-segment and a C-terminal cationic peptide that acquires 
antimicrobial activity after its cleavage from the rest of the molecule by 
different kind of proteases (Bals 2000). Cationicity is an important feature for 
electrostatic interaction of AMPs with negatively charged membrane 
phospholipids of bacterial cells or other microorganisms (Yeaman and Yount 
2003). 
Pre-propeptides typically undergo some post-translational modifications, 
such as glycosylation, C-terminal amidation (a very common modification in 
linear AMPs from frog skin) (Mangoni et al. 2006; Nicolas and El Amri 
2009), aminoacidic isomerization, halogenation, cyclization, N-terminal 
acetylation and hydroxylation, that modify their activity (Zasloff 2002; Wang 
2012).  
AMPs typically have a positive charge, at neutral pH, from +2 to +9 due to 
the presence of Lys and/or Arg residues, and a substantial portion (≥ 30%) of 
hydrophobic residues that confers to the AMPs an amphipathic character 
(Zasloff 2002; Rinaldi 2002; Hancock and Sahl 2006). Following interaction 
with hydrophobic environments such as biological or artificial membranes, 
they often fold into amphipathic conformations (Powers and Hancock 2003). 
According to their secondary structure, AMPs are generally classified into 
four families: peptides with α-helices, β-sheets, non-α- or β-structures 
(extended) and with a hairpin-loop structure (Fig. 5) (Mojsoska and Jenssen 
2015). 
• α-helical peptides (Fig. 5A) are often unstructured in aqueous solution, 
but they adopt an amphipathic helical structure in contact with biological 
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membranes (Yeaman and Yount 2003). Among them, some peptides are 
well known: the human cathelicidin LL-37, the frog skin magainins and 
the insects cecropins (Boman 1995; Zanetti et al. 2002; Mahlapuu et al. 
2016; Huang et al. 2010). 
• Peptides consisting of mixed structure made of β-sheets, connected by 
one or more intramolecular disulfide bridges (Fig. 5B), include defensins 
which are produced in neutrophils, macrophages and epithelial cells (Lai 
and Gallo 2009) and protegrins, first discovered in porcine leukocytes 
(Taylor et al. 2008). Due to their rigid structure, the β-sheet peptides are 
more ordered in aqueous solution and do not drastically change 
conformation as helical peptides upon membrane interaction (Yeaman 
and Yount 2003). 
• Extended/random-coil linear peptides (Fig. 5C) often contain a high 
content of arginine, proline, tryptophan, and/or histidine residues. They 
fold into amphipathic structures after contact with a membrane 
(Takahashi et al. 2010; Nguyen et al. 2011). The best studied peptides in 
this group are indolicidin, produced by bovine leukocytes (Powers and 
Hancock 2003), and bactenecins. 
• Peptides exhibiting a hairpin-loop structure (Fig. 5D) interconnected by at 
least one disulfide bridge include thanatin (Ma et al. 2016). 
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Fig. 5 Representative secondary structures of AMPs (modified by Mojsoska and Jenssen 
2015). 
 
1.4 AMPs: mechanism of action  
Based on their mechanism of microbicidal activity, AMPs can be divided into 
two classes: membranolytic peptides and non-membrane active peptides. 
Most AMPs are cationic molecules that adopt an amphipathic α-helical 
structure in membrane environments (Powers and Hancock 2003; Jenssen et 
al. 2006). Cationicity and amphipathicity are the two crucial chemical-
physical factors, especially for the mechanism of action of α-helical AMPs, 
which is generally based on the perturbation of the target microbial 
membrane (Bechinger and Gorr 2017).  
Before reaching the microbial membrane, the first event that occurs is the 
electrostatic interaction of the positively charged AMPs with the negatively 
A B
C D
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charged components of the microbial cell surface, such as the 
lipopolysaccharides (LPS), in the outer membrane of Gram-negative bacteria, 
or acidic polysaccharides (teichoic and teichuronic acids), in the 
peptidoglycan layer of Gram-positive bacteria (Brogden 2005) (Fig. 6). 
 
Fig. 6 Schematic representation of the cell wall of Gram-positive and Gram-negative 
bacteria. 
 
The passage of AMPs through the outer membrane of Gram-negative bacteria 
occurs by a mechanism called “self-promoted uptake pathway” (Fig. 7). The 
cationic peptides interact with the binding sites of the bivalent ions Ca2+ and 
Mg2+ on the surface of the LPS and move them from their position. This 
results in the outer membrane damage and access of the peptides to the 
periplasmic space (Hancock 1997; Zasloff 2002). 
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Fig. 7 Self-promoted uptake of cationic peptides across outer membranes of Gram-negative 
bacteria (from Hancock 1997). 
 
Once reached the periplasmic space, AMPs target the plasma membrane. 
Peptide-membrane interaction is the most important step controlling the 
selectivity of AMPs toward microbial membranes, which are much richer in 
anionic phospholipids, such as phosphatidylglycerol, cardiolipin, and the 
electrically-neutral (zwitterionic) phosphatidylethanolamine, compared to 
those of mammalian cells mainly made of zwitterionic lipids, such as 
phosphatidylcholine, sphingomyelin and cholesterol (Lohner 2009) (Fig. 8). 
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Fig. 8 Molecular basis of cell selectivity of AMPs. AMPs form amphipathic structures with a 
positively charged face (red) and a hydrophobic face (green). Electrostatic interaction 
between the positive charges of AMPs and negatively charged components (yellow) at the 
eukaryotic cell surface (left) and bacterial surface (right) is the major driving force for 
cellular association (from Zasloff 2002). 
 
In addition, the transmembrane potential of bacteria, ranging from -130 to -
150 mV, contributes to the increasing attraction of positively charged 
peptides and to their insertion into the membrane or their translocation in the 
cytoplasm, unlike mammalian cells which exhibit a difference in membrane 
potential between -90 and -110 mV (Powers and Hancock 2003; Yeaman and 
Yount 2003). 
Nevertheless, different studies revealed that not only peptide charge and 
amphipathicity are essential factors for antimicrobial activity and mechanism 
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of action of AMPs, but also several other features such as the size, the 
primary structure, the conformation and the hydrophobicity of the peptide 
(Guilhelmelli et al. 2013). 
Moreover, the peptides ability to traverse the lipid bilayer can be influenced 
by the concentration of the peptide itself, its tendency to self-assemble or to 
oligomerize, the phospholipid composition and the fluidity of the target 
membrane.  
The permeabilization of the membrane is a fundamental step in the 
microbicidal activity of AMPs. Several models that explain membrane 
disruption by AMPs have been proposed: 
• Barrel-stave model (Ehrenstein and Lecar 1977) 
AMPs are inserted perpendicularly to the plane of the membrane bilayer 
forming a pore like a stave (Fig. 9). The hydrophobic surfaces of the helices 
interact with the fatty acid chains of the membrane phospholipids, while the 
hydrophilic surfaces point inward, producing a transmembrane pore. The 
recruitment of additional peptide monomers, before the insertion of AMPs in 
the membrane, leads to an increase of the pore size (Shai 1999). In this 
model, the membrane does not display significant curvature and the 
hydration of the membrane remains unchanged (Li et al. 2017). As few as 
three molecules are needed to form a transmembrane pore.  
• Toroidal pore model (Ludtke et al. 1996; Matsuzaki et al. 1996) 
Unlike the “barrel-stave” model, transmembrane pores are delimited by 
peptide molecules intercalated to membrane lipids. The peptides are always 
in contact with the polar heads of the membrane phospholipids, even when 
they are perpendicularly inserted into the lipid bilayer (Brogden 2005) (Fig. 
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9). The polar faces of the peptides associate with the polar head groups of the 
lipids. As the AMPs penetrate deeper into the membrane, the head groups of 
the lipids are dragged into the lipid tail region to form toroidal shaped pores 
while the lipid tails are packed away from the surface of the pore, resulting in 
significant lipid disorder and membrane curvature change. Toroidal pores are 
also accompanied by enhanced membrane hydration, as evidenced by 
significant water penetration into the membrane (Li et al. 2017). The pore is 
lined by both the peptides and the lipid head groups, which are likely to 
screen and mask cationic peptide charges. 
• Carpet-like model (Shai 1999; Pouny et al. 1992) 
Some AMPs, that not necessarily assume the amphipathic α-helix 
conformation, line parallel to the membrane surface via electrostatic 
interactions with the anionic heads of the membrane phospholipids. The 
peptide molecules cover the membrane surface in a “carpet”-like manner 
without being inserted into its hydrophobic core (Fig. 9). Afterwards, the 
peptides reorient themselves such that their hydrophobic face is toward the 
lipids and the hydrophilic face toward the phospholipid headgroups. When 
their surface concentrations reach a critical value, the AMPs cause a 
detergent-like solubilization of the lipid bilayer in micelles (Shai 2002). 
• Disordered toroidal pore model  
The pore formation is more stochastic and involves fewer peptides (Sengupta 
et al. 2008) (Fig. 9). 
• Membrane thinning/thickening affection model 
The thickness of the bilayer can be affected by the presence of the peptides or 
the membrane itself can be remodeled to form domains rich in anionic lipids 
surrounding the peptide (Grage et al. 2016) (Fig. 9). 
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Fig. 9 Schematic representation of some mechanisms of action of membrane-active AMPs 
(modified by Nguyen et al. 2011). 
 
Therefore, the main mechanism to kill bacteria, especially for peptides with 
an α-helical structure, is the permeabilization of the membrane without 
involving stereospecific interaction with chiral targets (such as receptors). 
These peptides are already active at very low concentrations, in the order of 
μM. Thanks to this general mechanism of action, based on the unspecific 
interaction of cationic AMPs with anionic phospholipids of microbial 
membranes, the emergence of microorganisms resistant to such molecules is 
very limited and significantly lower than that to the conventional antibiotics 
(Zasloff 2002; Kraus and Peschel 2006). In fact, the development of 
resistance to AMPs would lead to a drastic change in the lipid composition of 
an essential element of the cell, such as the cytoplasmic membrane, with a 
consequent serious damage to the microorganism survival. 
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However, recent studies demonstrate that there are non-membrane active 
antimicrobial peptides that can effectively cross the membrane barrier 
without disrupting it. These AMPs can exhibit their antimicrobial modes of 
action through the inhibition of intracellular processes, such as (i) synthesis 
of nucleic acids; (ii) synthesis of proteins, enzymatic activity or folding; (iii) 
synthesis of the cell wall or microbial septum formation (Yeung et al. 2011; 
Nguyen et al. 2011; Mojsoska and Jenssen 2015). 
 
On the other hand, three mechanisms have been proposed to explain how 
AMPs activate mammalian cells (Lai and Gallo 2009) (Fig. 10): 
• Trans-activation model 
AMPs stimulate the release of a membrane-bound growth factor, which then 
binds to its high affinity receptor and activates it. It is the case of HB-EGF 
(heparin binding epidermal growth factor) and the EGF receptor (EGFR). 
• Alternate ligand model 
Some AMPs, such as defensins and cathelicidin, directly bind to a specific 
receptor, triggering the signaling pathway. This has been proposed for 
chemokine receptor 6 (CCR6) and formyl peptide receptor 1 (FPRL-1). 
• Membrane disruption model 
AMPs associate with and modify the membrane in a region containing the 
receptor, thus indirectly changing receptor function. In fact, the receptor may 
trigger the signaling cascade without a ligand or become insensitive to 
binding by its specific ligand. EGF receptors may be involved because of the 
disruption of ordered lipid domains, called lipid rafts, where these receptors 
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are located (Pike et al. 2005) and the consequent inhibition of ligands binding 
to EGFR and its activation. 
 
Fig. 10 Alternative models for host activation by antimicrobial peptides (from Lai and Gallo 
2009). 
 
1.5 Frog-skin antimicrobial peptides 
The amphibia skin is among the richest sources of biologically active 
compounds, including biogenic amines, complex alkaloids and peptides, that 
play different roles, either in the regulation of physiological or defensive 
functions. 
AMPs are stored in dermal serous glands, mainly located in the skin of the 
dorsal region of the animal, surrounded by myocytes and innervated by 
sympathetic fibers (Fig. 11). Adrenergic stimulation of myocytes, upon stress 
or physical injury, causes compression of the serous glands and discharge of 
their contents by a holocrine-like mechanism (Simmaco et al. 1998; Conlon 
et al. 2004). 
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Fig. 11 Histological preparation of frog skin (from Mangoni 2006). 
 
Each frog species synthesizes its own unique set of AMPs. On the basis of 
structural similarities, amphibian AMPs are grouped into different families, 
e.g. magainins, temporins, brevinines -1 and -2, ranalexins, ranacyclins, 
bombinins and esculentins-1 and -2 (Conlon 2004; Conlon et al. 2009; 
Mangoni et al. 2003; Morikawa et al. 1992) (Table 1). Since Zasloff isolated 
the magainins in the 1980s, many AMPs have been isolated and identified 
from different amphibian species belonging to the species Xenopus laevis, 
Bombina variegata, Bombina orientalis, Phyllomedusa sauvagei and 
different species of Rana (Ladram and Nicolas 2016). 
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Table 1 Primary structure of some frog-skin AMPs. C-terminal amidation is marked by  
-NH2. 
GENUS PEPTIDE AND SEQUENCE 
Xenopus 
Magainin-1 
GIGKFLHSAGKFGKAFVGEIMKS 
Magainin-2 
GIGKFLHSAKKFGKAFVGEIMNS 
Bombina 
Bombinin 
GIGALLSAAKVGLKGLAKGLAEHFAN-NH2 
Bombinin H1 
IIGPVLGMVGSALGGLLKKI-NH2 
Rana 
Temporin A 
FLPLIGRVLSGIL-NH2 
Brevinin-1 
FLPVLAGIAAKVVPALFCKITKKC 
Brevinin-2 
GLLDSLKGFAATAGKCVLQSLISTASCKLAKTC 
Ranalexin 
FLCCLIKIVPAMICAVTKKC 
Ranaciclin-T 
GALRGCWTKSYPPKPCK-NH2 
Esculentin-1 
GIFSKLGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
Esculentin-2a 
GILSLVKGVAKLAGKGLAKEGGKFGLELIACKIAKQC 
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1.6 Esculentins and Esc(1-21) 
The esculentin-1 family was first isolated and purified from the skin secretion 
of the European frogs belonging to Pelophylax lessonae/ridibundus 
(previously known as Rana esculenta) (Conlon 2008) specimen (Fig. 12) by 
reverse phase high performance liquid chromatography (RP-HPLC) 
(Simmaco et al. 1993). All members of this family have a highly conserved 
amino acid sequence consisting of 46 residues and characterized by a C-
terminal loop stabilized by a disulphide bridge forming a hepta peptide ring 
(Simmaco et al. 1994). They have a net charge of +5 at neutral pH and an 
amphipathic α-helical structure in membrane mimetic environments 
(Mangoni et al. 2015; Wang et al. 2016b). 
 
Fig. 12 A specimen of Pelophylax lessonae/ridibundus. 
 
Esculentins-1 have a broad spectrum of action against Gram-positive and 
Gram-negative bacteria, including Pseudomonas aeruginosa, and fungal 
species, such as Candida albicans (lethal concentrations ranging from 0.1 to 
1.5 μM). They also show low toxicity on mammalian cells (Simmaco et al. 
1993; Ponti et al. 1999; Mangoni et al. 2015). 
Table 2 shows the amino acid sequences of some members of esculentins-1 
family and their derivatives. 
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A fragment corresponding to the 19-46 portion of esculentins-1, named 
Esculentin-1a(19-46), was also isolated from skin secretions. It was devoid of 
antimicrobial activity, presumably due to its low net positive charge (+1 
versus +5 of the whole molecule) at neutral pH (Simmaco et al. 1994). 
Since no antimicrobial activity was detected for this fragment, the 1-18 
portion of esculentins (which was not found in the HPLC fractionation of the 
secretion possibly because of its proteolytic degradation) was chemically 
synthesized and its antimicrobial activity was analyzed. The synthetic 
peptide, Esc(1-18), (Table 2) was amidated at the C-terminus to maintain a 
net charge of +5 at neutral pH and to increase its stability (Mangoni et al. 
2003). It was found that the Esc(1-18) adopted an α-helical structure in lipid 
vesicles mimicking the anionic character of microbial membranes. Moreover, 
its antimicrobial activity resulted to be comparable to that of the full-length 
peptide (Mangoni et al. 2003) showing that this activity was in its N-terminal 
portion, and that the first 18 residues are required to maintain antimicrobial 
properties. 
Since the minimum length for a peptide in α-helix conformation to span a 
phospholipid bilayer (∼30 Å thick) is about 20 amino acids (Gamberi et al. 
2007), a longer analog named esculentin-1a(1-21)NH2, [Esc(1-21)], was 
further synthesized and characterized for its biological properties (Table 2).  
Esc(1-21) has the same first 20 residues of the natural esculentin-1a followed 
by an amidated glycine (Islas-Rodrìguez et al. 2009). Differently from Esc(1-
18), Esc(1-21) carries the substitution Leu-11-Ile and three additional C-
terminal residues (Leu-Lys-Gly) which give it a higher net positive charge 
(+6) at neutral pH, an important feature for the electrostatic interaction with 
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the negatively charged membranes of microbial cells (Gellatly and Hancock 
2013; Mangoni et al. 2015). 
Esc(1-21) has a potent antimicrobial activity, mainly against Gram-negative 
bacteria, e.g. P. aeruginosa (Luca et al. 2013). In particular, Esc(1-21) 
showed the same efficacy against reference and clinical isolates of P. 
aeruginosa as indicated by the similar minimal peptide concentration which 
inhibits microbial growth (MIC) (4 μM) and the comparable bactericidal 
concentration causing 99.9% killing of these strains (0.5 μM or 1 μM) (Luca 
et al. 2013). Differently, Esc(1-21) showed a weaker activity against Gram-
positive bacteria (Kolar et al. 2015) and a lower toxicity against human 
erythrocytes (Islas-Rodriguez et al. 2009; Luca et al. 2013). 
Table 2 Primary structure of Esc-1a(1-21)NH2 and Esc-1b(1-18)NH2 and the corresponding 
full-length natural esculentin-1 peptides. 
PEPTIDE DESIGNATION and SEQUENCE
a 
Net charge at 
neutral pH 
Esculentin-1a 
GIFSKLAGKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
+5 
Esculentin-1a(19-46) 
LKNVGKEVGMDVVRTGIDIAGCKIKGEC 
+1 
Esculentin-1a(1-21)NH₂ 
GIFSKLAGKKIKNLLISGLKG-NH₂ 
+6 
Esculentin-1b 
GIFSKLAGKKLKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
+5 
Esculentin-1b(1-18)NH₂ 
GIFSKLAGKKLKNLLISG-NH₂ 
+5 
a Basic and acidic amino acids are indicated by red and blue letters, respectively. 
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1.7 Pseudomonas aeruginosa and cystic fibrosis 
P. aeruginosa is a ubiquitous and opportunistic Gram-negative bacterium that 
colonizes abiotic and biological surfaces, particularly moist environments. In 
fact, it thrives in soil and aquatic habitats, colonizes medical devices (e.g. 
catheters and implants) and the surfaces of plants, animals and humans 
(Klockgether and Tümmler 2017). 
P. aeruginosa can cause a wide range of local or systemic infections in 
humans; in most cases, these are life-threatening infections, such as keratitis, 
otitis, pneumonia and skin (burn wounds) infections, primarily in 
immunocompromised and hospitalized patients (Gellatly and Hancock 2013; 
Wu et al. 2011). 
This bacterium is intrinsically resistant to a wide range of antimicrobials, 
including β-lactams, aminoglycosides and fluoroquinolones, because of its 
low membrane permeability and multidrug efflux pumps (Smith et al. 2017). 
It is also equipped with a large repertoire of virulence factors and a complex 
regulatory network of intracellular and intercellular signals, that allow the 
bacteria to develop resistance to antimicrobial agents and to escape host 
defense. This is likely due to the selection of mutations in chromosomal 
genes or to the horizontal acquisition of resistant determinants (Morita et al. 
2014; Ruiz-Garbajosa and Cantón 2017; Klockgether and Tümmler 2017; 
Rodrigo-Troyano and Sibila 2017). 
P. aeruginosa can be found either as planktonic or sessile form (Fig. 13). The 
latter is called biofilm and corresponds to a bacterial community of cells 
which adheres to biological or inert surfaces embedded in a self-produced 
matrix of extracellular polymeric substances, including polysaccharides, 
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proteins, lipids and extracellular DNA. This confers bacteria a greater 
resistance to physical and chemical factors, including conventional 
antibiotics, and to immune cells, favoring colonization of nearby surfaces 
(Flemming et al. 2016). 
 
Fig. 13 Electron microscopy images of P. aeruginosa free-living cells (A) and biofilm (B). 
 
One of the environments commonly colonized by P. aeruginosa is the 
respiratory tract of cystic fibrosis (CF) patients (Gaspar et al. 2013). CF is a 
genetic disorder that affects a wide range of populations (approximately 
75,000 individuals worldwide) and involves several organs, including 
pancreas, liver, gastrointestinal tract, reproductive system, sweat glands and, 
particularly, the respiratory system. This disease is caused by mutations in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene on 
chromosome 7 that lead to malfunctioning chloride channels. A deletion of 
phenylalanine in the amino acid position 508 is the most common mutation, 
but more than 2000 mutations have been reported, although not all of these 
have functional consequences (Fajac and Wainwright 2017). 
Specifically, the CFTR regulator acts as a channel that pumps chloride ions 
from the intracellular to the extracellular space through the apical membrane 
A B
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of the epithelial cells. Chloride ion transport partially controls the movement 
of sodium ions and water into the cell and consequently influences the 
production of a thin and low viscous mucus layer in order to protect the 
lungs, sweeping bacteria trapped in mucus outside, and to ensure gas 
exchange (Kreda et al. 2012; Folkesson et al. 2012) (Fig. 14). 
In CF sufferers, the dehydration of the mucus layer and its resulting thick and 
sticky consistency provides an environment for propagation of persistent 
bacterial biofilms, such as in the case of P. aeruginosa (Gaspar et al. 2013) 
(Fig. 14). 
Chronic lung infections cause an influx of cellular infiltrates and 
inflammatory cells that stimulate pro-inflammatory cytokine release 
impairing lung function.  
 
Fig. 14 Schematic representation of a functional (left panel) and non-functional CFTR (right 
panel). ENaC is the epithelial sodium channel. 
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1.8 Limitations of AMPs 
Despite the great potential of AMPs to work as new effective anti-infective 
agents, they still have several limitations for the development as therapeutics 
(Kang et al. 2014): 
• Toxicity against mammalian cells at therapeutic dosages 
While the bacterial cell membrane contains negatively-charged lipids (20-
25%), the human cell membrane possesses zwitterionic lipids and cholesterol 
(Dawson and Liu 2008). Usually, cationic AMPs use this difference for their 
selective antimicrobial activity by interacting with the negatively-charged 
bacterial membrane. However, several studies have shown that mammalian 
cells can also be the targets of these molecules. In fact, AMPs can directly 
bind to host cells and induce adverse effects (Zheng et al. 2010; de Sa et al. 
2010). Furthermore, the administration of broad-spectrum AMPs can 
eliminate the host microflora in humans, causing other infections due to the 
absence of protective function of the microflora. For these reasons, all 
clinical trials up to date are limited to topical application for surface 
infections rather than parenteral and oral administration (Mylne et al. 2010; 
Kang et al. 2014).  
• Physical instability under physiological conditions 
Potentially, AMPs show susceptibility to proteases, serum, salt, pH, etc.  
For example, the structural stability of AMPs can be affected by high ionic 
strength preventing their initial electrostatic interaction with the bacterial 
surface. 
The linear structure of AMPs can be easily attacked by host proteases and 
peptidases (Ganz 1999; Tossi et al. 2000; Tam et al. 2002). In fact, peptide 
drugs are generally characterized by low oral bioavailability and poor 
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penetration into the intestinal mucosa, thus making the oral administration 
not possible. Furthermore, systemic administration of peptides by, e.g., 
intravenous injection, is limited by a short half-life because of rapid 
degradation by serum proteases (Chan et al. 2006) and rapid removal from 
the circulation by the liver and kidneys (Vlieghe et al. 2010).  
Therefore, AMPs are usually used for the treatment of skin infections 
associated with burns, diabetic wounds or eyes infections (Mahlapuu et al. 
2016; Kang et al. 2014). 
• Production cost 
Compared to small chemical drugs, the production costs of AMPs are 
extremely high. It is known that the production of 1 g of peptide costs $100-
600 by solid phase peptide synthesis, the most commonly used method for 
chemical synthesis of therapeutic peptides (Amblard et al. 2006). Moreover, 
during manufacturing, there are numerous technical difficulties in the 
synthesis and purification processes (Hancock and Sahl 2006).  
 
1.9 Strategies for AMPs development as new therapeutics and synthesis 
of Esc(1-21)-1c 
To develop AMPs able to overcome the aforementioned drawbacks without 
causing a significant reduction in their antimicrobial efficacy, several 
strategies are adopted (Fjell et al. 2011). 
To reduce toxicity of AMPs the control of hydrophobicity and charge or the 
improvement of target cell-selectivity of AMPs are highly important (Kang et 
al. 2014). Indeed, high hydrophobicity is related to increased hemolytic 
activity (Yeaman and Yount 2003; Chou et al. 2008). 
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To reduce the susceptibility to degradation by peptidases/proteases, several 
methods have been introduced in AMPs synthesis:  
i) cyclization, by linking the N- and C-terminus, which is a well-known 
method to improve both microbicidal activity and serum stability, in 
comparison to the linear peptide form (Giuliani et al. 2007; Oyston et al. 
2009).  
ii) incorporation of D-amino acids and non-natural amino acids, since host 
proteases can recognize and hydrolyze natural L-amino acids. 
One of the non-natural amino acid mainly used to increase the stability of α-
helix conformation and presumably the spectrum of activity of AMPs, is the 
α-aminoisobutyric acid (Aib) (Bellanda et al. 2001; De Zotti et al. 2012). 
Moreover, the substitution of L-amino acids with the corresponding D-
enantiomers is often used to reduce AMPs cytotoxicity without negative 
effects on the peptide’s functionality (Giuliani and Rinaldi 2011). 
iii) modification by different natural amino acids. 
For example, changes in the proline content, because of low propensity of 
proline to form α-helical structures, may lead to alteration of the peptide 
conformation and a resulting reduction in the cytotoxicity (Zhang et al. 
1999).  
iv) acetylation and/or amidation of the N- and C-terminal ends. 
The N-acetylation of peptides enhances stability against proteases (Nguyen et 
al. 2005; Papo and Shai 2004). The C-amidation is frequently used to 
improve peptide activity and to decrease hemolytic activity by reducing the 
negative charge of the carboxylic group in the peptide and by stabilizing the 
amphipathic helix formation (Nguyen et al. 2010). 
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v) design of antimicrobial peptide conjugates. 
AMPs can be attached/incorporated to/into nano-micro systems (e.g. 
nanoparticles) to improve their biostability. This strategy does also allow the 
peptide to reach the infection site at high concentrations, thus minimizing 
potential side-effects and increasing its pharmacological effect reducing the 
number of administrations (Eckert 2011; d'Angelo et al. 2015a; d'Angelo et 
al. 2015b). 
Particularly interesting in this context is the use of biocompatible and 
biodegradable materials, such as lipids (e.g., phospholipids, triglycerides, 
cholesterol, and monoolein) and polymers [e.g., cellulose, chitosan, 
hyaluronic acid, poly lactic-co-glycolic acid (PLGA), and poly lactic acid 
(PLA)] or inorganic particles (such as gold or silver) for new therapeutic 
formulations (Rai et al. 2016; Ramesh et al. 2016; Ali et al. 2016). 
 
Regarding the cost of production, pharmaceutical companies have tried to 
develop AMPs of smaller size derived from more expensive and larger 
natural peptides (Aoki et al. 2012). 
 
In our case, with the aim to protect Esc(1-21) from proteolytic degradation 
and to reduce its toxicity against mammalian cells, without affecting its 
antimicrobial activity, an analogue named Esc(1-21)-1c was designed by 
replacing two L-amino acids with the corresponding D-amino acid 
enantiomers (Tab. 3). 
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Table 3 Primary structure of Esc(1-18), Esc(1-21) and Esc(1-21)-1c. D-amino acids are 
underlined and in italics. 
PEPTIDE 
DESIGNATION  
SEQUENCEa 
Net charge at 
neutral pH 
Esc(1-18) GIFSKLAGKKLKNLLISG-NH₂ +5 
Esc(1-21) GIFSKLAGKKIKNLLISGLKG-NH₂ +6 
Esc(1-21)-1c GIFSKLAGKKIKNLLISGLKG-NH₂ +6 
a Basic amino acids are indicated by red letters. 
 
The design of the diastereomer Esc(1-21)-1c was realized on the bases of the 
following considerations: 
- the reduction of α-helical content of a peptide correlates with its reduced 
ability in perturbing mammalian membranes causing cell lysis (Shai and 
Oren 1996; Strahilevitz et al. 1994); 
- D-amino acids are known to be α-helix breakers (Grieco et al. 2013a).  
 
Previous studies performed with the shorter analog of Esc(1-21), [Esc(1-18)], 
indicated that the C-terminal half of this latter adopted an α-helical 
conformation in a hydrophobic environment mimicking the electrically 
neutral membranes of mammalian cells (Manzo et al. 2014). Esc(1-18) 
differs from Esc(1-21) by a single amino acid in position 11 and lacks the 3 
residues tail at its carboxyl end. Since this tail contains two achiral glycine 
residues at positions 18 and 21, it is very unlikely that this region of Esc(1-
21) folds in a stable helical conformation. Therefore, replacement of two L-
amino acids, i.e. L-Leu14 and L-Ser17, with the corresponding D-
enantiomers, would break the first turn of the expected C-terminal α-helix of 
Esc(1-21) [please refer to the work attached at the end of the manuscript: “D-
Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1-
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21)NH2 is beneficial for its multiple functions.” By Di Grazia A, Cappiello F, 
Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, Mangoni ML]. 
Esc(1-21)-1c displayed potent bactericidal activity in vitro against the free-
living form of P. aeruginosa strains (either reference or clinical isolates from 
CF patients), even if this activity resulted to be slightly weaker than that of 
the all-L peptide. Esc(1-21), at 1 μM, reduced ≥3 log10 the number of viable 
bacterial cells within 30 min, compared to the untreated cells, while the 
diastereomer had the same efficacy at a concentration of 4 μM against all the 
examined bacteria. 
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2. Aims of the work 
To counteract antibiotic resistance caused by the widespread use of 
conventional antibiotics against bacterial infections, such as those caused by 
the Gram-negative bacterium P. aeruginosa in the lungs of patients with 
cystic fibrosis, the discovery of new classes of antimicrobial agents with a 
new mechanism of action is highly required. AMPs hold promise for the 
development of alternative therapeutics.  
Recently, a derivative of the frog-skin AMP esculentin-1a, that is Esc(1-21), 
was found to display a fast and potent killing activity against both the 
planktonic and biofilm forms of P. aeruginosa. However, the development of 
AMPs as new drugs has some limitations, including their high susceptibility 
to proteolytic degradation and cytotoxicity. Interestingly, one promising 
strategy to overcome these drawbacks is given by the incorporation of D-
amino acids in the peptide sequence, due to their resistance to enzymatic 
digestion and ability to disrupt the alpha-helical content of a peptide, which is 
expected to decrease its cytotoxicity. 
Therefore a diastereomer of Esc(1-21), named Esc(1-21)-1c, was designed 
and synthesized by replacing two L-amino acids in the C-terminal portion, i.e. 
L-Leu14 and L-Ser17, with the corresponding D-enantiomers.  
The aim of this work was to investigate and compare the effect of the two D-
amino acid substitutions on the peptide’s: 
(i) cytotoxicity;  
(ii) resistance to proteolytic enzymes;  
(iii) biological features including antipseudomonal activity, wound 
healing and anti-inflammatory properties. 
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Along with these aims, experimental protocols were developed and 
performed to evaluate: 
- the effect of both peptides on mammalian cell viability along with 
their ability to perturb model membranes; 
- their structural properties in membrane-mimicking environments; 
- their stability to elastase from P. aeruginosa and human neutrophils;  
- their ability in killing CF strains of P. aeruginosa either in their 
biofilm phenotype or once internalized into bronchial epithelial cells; 
- their ability to stimulate migration of bronchial epithelial cells and 
presumably to promote the repair of a damaged airway epithelium, 
which can be formed upon bacterial infections; 
- their ability to inhibit the production and secretion of pro-
inflammatory mediators from macrophages activated by P. 
aeruginosa LPS. 
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3. Materials and Methods 
3.1 Materials 
Synthetic Esc(1-21) and its diastereomer, Esc(1-21)-1c, as well as 
rhodamine-labeled peptides [rho-Esc(1-21) and rho-Esc(1-21)-1c], were 
purchased from Chematek Spa (Milan, Italy). Minimum essential medium 
(MEM), Dulbecco’s modified Eagle’s medium (DMEM), glutamine, heat-
inactivated fetal bovine serum (FBS), Hank’s buffer, non-essential amino 
acids (NEAA), sodium pyruvate and penicillin-streptomycin were from 
Euroclone (Milan, Italy); puromycin, gentamicin, 3(4,5-dimethylthiazol-
2yl)2,5-diphenyltetrazolium bromide (MTT), Triton X-100, Tyrphostin 
AG1478 inhibitor, 4’,6-diamidino-2-phenylindole (DAPI), rhodamine, 
Mowiol 4-88, Hoechst 33258, Phalloidin Fluorescein Isothiocyanate Labeled, 
carboxyfluorescein (CxF), LPS from P. aeruginosa serotype 10 (purified by 
phenol extraction), and elastase from human leukocytes were purchased from 
Sigma-Aldrich (St. Luis, MO). Elastase from P. aeruginosa, GM6001 
metalloproteinases inhibitor and Bromodeoxyuridine (BrdU) Cell 
Proliferation Assay Kit was from Millipore Merck (Merck, Milan, Italy). 
Trypsin–EDTA and agarose were purchased from Invitrogen (Life-
Technologies Europe, Monza, Italy). Mouse Tumor necrosis factor alpha 
(TNF-α) enzyme-linked immunosorbent assay kit was from eBioscience. The 
lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and cholesterol (Cho) were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). Sodium-
dodecylsulfate (SDS) and dodecylphosphocholine (DPC) were obtained from 
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Cambridge Isotope Laboratory (Tewksbury, MA). All other chemicals were 
reagent grade. 
 
3.2 Cell cultures 
The following cell cultures were employed: immortalized human bronchial 
epithelial cells derived from a CF patient (CFBE41o-) transduced with a 
lentiviral system to stably express ΔF508CFTR (ΔF508-CFBE) or functional 
CFTR (wt-CFBE) (Bebok et al. 2005); adenocarcinoma human alveolar 
epithelial cells (A549) and murine RAW 264.7 macrophage cell line (from 
the American Type Culture Collection). 
CFBE cells were cultured in MEM supplemented with 2 mM glutamine 
(MEMg), 10% FBS, antibiotics (0.1 mg/ml of penicillin and streptomycin) 
and puromycin (0.5 µg/ml or 2 µg/ml for wt-CFBE or ΔF508-CFBE, 
respectively) at 37 °C and 5% CO2 in 75-cm
2 ﬂasks.  
A549 and RAW 264.7 cells were cultured in DMEM supplemented with 2 
mM glutamine (DMEMg), 10% FBS and antibiotics (0.1 mg/ml of penicillin 
and streptomycin) at 37 °C and 5% CO2 in 75-cm
2 and 25-cm2 ﬂasks, 
respectively. In the case of RAW cells NEAA and sodium pyruvate (1 mM) 
were also added in the culture medium.  
 
3.3 Microorganisms 
The strains of P. aeruginosa used for the antimicrobial assays against 
biofilms were: the standard non-mucoid ATCC 27853 (Li et al. 2001) and the 
following ones from collection of the CF clinic Medizinische Hochschule of 
Hannover, Germany: the mucoid AA11 and the non-mucoid TR1 and KK1 
(Bragonzi et al. 2009).  
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P. aeruginosa KK1, an invasive clinical isolate from the early stage of 
chronic lung infection (Bragonzi et al. 2009; Lore et al. 2012), was also used 
for cell infection. 
 
3.4 Cytotoxicity assay  
The effect of Esc(1-21) and its diastereomer, Esc(1-21)-1c, on the viability of 
wt-CFBE, ΔF508-CFBE and RAW 264.7 cells was evaluated by the 
colorimetric method based on the intracellular reduction of the yellow 
tetrazolium salt (MTT) to a purple compound, called formazan, by 
mitochondrial dehydrogenases (Fig. 15A) (Grieco et al. 2013b). The intensity 
of this color transformation is directly proportional to the number of 
metabolically active cells (Fig. 15B). 
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Fig. 15 Reduction of the yellow tetrazolium salt (MTT) to purple insoluble formazan, by 
metabolically-active cells (A). The intensity of the purple dye is proportional to the number 
of viable cells. The transparent yellow color in the B11 well corresponds to MTT solution 
without cells (B). 
 
About 4 × 104 cells resuspended in the corresponding culture medium 
supplemented with glutamine and 2% FBS, without antibiotics, were plated 
in each well of a 96-well microtiter plate. After overnight incubation at 37 °C 
in a 5% CO2 atmosphere, the medium was removed and replaced in each well 
with 100 µl of fresh serum-free MEMg, DMEMg or Hank’s buffer (136 mM 
NaCl; 4.2 mM Na2HPO4; 4.4 mM KH2PO4; 5.4 mM KCl; 4.1 mM NaHCO3, 
pH 7.2, supplemented with 20 mM D-glucose) with or without the peptide at 
different concentrations. 
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After 2 h or 24 h at 37 °C in a 5% CO2 atmosphere, the medium was removed 
and replaced with 100 µl of Hank’s buffer containing 0.5 mg/ml MTT. The 
plate was incubated at 37 °C and 5% CO2 for 4 h, and the formazan crystals 
were dissolved by adding 100 µl of acidiﬁed isopropanol. Absorption of each 
well was measured using a microplate reader (Inﬁnite M200; Tecan, 
Salzburg, Austria) at 570 nm [please refer to the work attached at the end of 
the manuscript: “The frog skin-derived antimicrobial peptide esculentin-1a(1-
21)NH2 promotes the migration of human HaCaT keratinocytes in an EGF 
receptor-dependent manner: a novel promoter of human skin wound 
healing?” By Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, 
Picardo M, Paus R, Mangoni ML]. The percentage of metabolically active 
cells compared to control samples (cells not treated with peptide) was 
calculated according to the formula: 
(absorbancesample – absorbanceblank) / (absorbancecontrol – absorbanceblank) × 
100, 
where the blank is given by samples without cells and not treated with the 
peptide. 
 
3.5 Preparation of lipid vesicles and membrane perturbing assays 
3.5.1 Liposomes preparation  
Lipid films of POPC/Cho and POPE/POPG were prepared by dissolving 
lipids (2 mg of POPC/Cho mixture, 1:1, mol/mol or 2 mg of POPE⁄POPG, 
7:3, mol/mol) in chloroform/methanol (2:1, v/v). The solvents were then 
evaporated under reduced argon atmosphere until a thin film was formed. 
The lipid film was then hydrated with 500 µl of 10 mM phosphate buffer 
containing 140 mM NaCl and 0.1 mM EDTA, pH 7.4 (buffer A). For CxF 
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leakage experiments, the lipid film was hydrated with a CxF solution (Fig. 
16) at a self-quenching concentration, i.e. 30 mM in 10 mM phosphate buffer 
containing 80 mM NaCl and 0.1 mM EDTA, adjusted to pH 7.4 with NaOH. 
The liposome suspension was subjected to 10 freeze and thaw cycles and 
extruded for 31 times through two stacked polycarbonate membranes with 
100 nm pores to obtain liposomes. The free CxF (when present) was removed 
by gel filtration, using a 40 cm Sephadex G-50 at room temperature, 
equilibrated with buffer A. The final lipid concentration was determined by 
the Stewart phospholipid assay [please refer to the article attached at the end 
of the manuscript: “Membrane Perturbing Activities and Structural Properties 
of the Frog-skin Derived Peptide Esculentin-1a(1-21)NH2 and its 
Diastereomer Esc(1-21)-1c: Correlation With Their Antipseudomonal and 
Cytotoxic Activity.” By Loffredo MR, Ghosh A, Harmouche N, Casciaro B, 
Luca V, Bortolotti A, Cappiello F, Stella L, Bhunia A, Bechinger B, Mangoni 
ML].  
 
Fig. 16 Chemical structure of carboxyfluorescein. 
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3.5.2 Carboxyfluorescein leakage assay 
Peptide-membrane interaction can be investigated by the use of liposomes as 
model membranes, due to their bilayer structure, which is in principle 
identical to the lipid organization of biological membranes (Mouritsen 2011). 
CxF release from liposomes due to membrane permeation induced by the 
peptide was monitored at 37 °C by the fluorescence increase (excitation = 
488 nm; emission = 520 nm). A concentration of lipid vesicles of 200 µM 
was used and CxF leakage after peptide addition at 20 µM was monitored for 
30 min. Complete dye release was obtained using 0.1% Triton X-100, which 
causes total destruction of lipid vesicles (Marcellini et al. 2009; Makovitzki 
et al. 2006). The percentage of CxF leakage was calculated according to the 
following formula (Matsuzaki 1999): leakage (%) = 100(F1 – F0) ⁄ (Ft – F0), 
where F0 represents the fluorescence of intact vesicles, and F1 and Ft denote 
the intensities of the fluorescence achieved by peptide and Triton X-100 
treatment, respectively, at different time points, as indicated. A schematic 
representation of CxF-encapsulated liposomes is shown in (Fig. 17). 
48 
 
 
Fig. 17 Schematic representation of a CxF-encapsulated liposome. 
 
3.6 Circular dichroism spectroscopy 
In order to investigate the change in the secondary structure of Esc(1-21) and 
Esc(1-21)-1c in membrane mimicking environments, circular dichroism (CD) 
experiments were performed in DPC and SDS micelles using a Jasco J-815 
spectrometer (Jasco International Co., Ltd. Tokyo, Japan) with a Peltier cell 
holder and temperature controller unit accessory. CD spectra were recorded 
for both the peptides in water (25 µM) and in the presence of DPC (10 mM) 
and SDS (40 mM) at 37 °C. Both working concentrations of DPC and SDS 
micelles were above their critical micelle concentration as previously 
reported in the literature (Manzo et al. 2013). The far-UV spectra were 
scanned over a range of 190-260 nm with 1 nm data interval and averaged 
over 4 scans. Blank sample spectra were subtracted from the raw data and the 
CD values were converted to per residue molar ellipticity ([θ]) (deg cm2 
dmol-1). 
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3.7 Stability of peptides to proteolytic degradation 
Peptides were dissolved in 10 mM Tris-HCl, pH 7.5, at a final concentration 
of 1 mg/ml; afterwards, 130 µl were incubated with 4 µg of human or 
bacterial elastase (final enzyme concentration equal to 1 µM). At the 
indicated time intervals, 30-µl aliquots were withdrawn, diluted with 770 µl 
of 0.1% trifluoroacetic acid (TFA)–water, and analyzed by Reversed-Phase 
High-Performance Liquid Chromatography (RP-HPLC) and mass 
spectrometry. Liquid chromatography was performed on a Phenomenex 
Jupiter C18 analytical column (300 Å, 5 µm, 250 by 4.6 mm) in a 30-min 
gradient, using 0.1% TFA in water as solvent A and methanol as solvent B. 
Mass spectrometry analysis was performed with a Bruker Daltonic ultraflex 
matrix-assisted laser desorption ionization tandem time-of-flight (MALDI-
TOF/TOF) mass spectrometer on withdrawn samples as well as on HPLC-
eluted peaks. 
 
3.8 Antimicrobial assays 
3.8.1 Antibiofilm activity 
Biofilm formation was performed by adapting the procedure described in 
(Ceri et al. 2001; Falciani et al. 2012), using the Calgary Biofilm Device 
(Innovotech, Innovotech Inc. Edmonton, Canada). Briefly, 96-well plates, 
each well containing 150 μl of the bacterial inoculum [1 × 107 colony-
forming units (CFU)/ml)] in Luria-Bertani (LB) medium were sealed with 96 
peg-lids on which biofilm cells can build up. Afterwards, plates were placed 
in a humidified orbital incubator at 35 °C for 20 h under agitation at 125 rpm. 
Once biofilms were allowed to form, the pegs were rinsed twice with 
phosphate buffered saline (PBS) to remove planktonic cells. Each peg-lid 
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was then transferred to a “challenge 96-well microtiter plate”, each well 
containing 200 μl of a twofold serial dilution of peptide in PBS. The 
“challenge plate” was incubated at 37 °C for 2 h. Peptide activity was 
evaluated by determining the amount of viable biofilm cells by measuring the 
reduction of MTT to its insoluble formazan. Briefly, after peptide treatment, 
the pegs-lid was washed with PBS and used to close another 96-well 
microtiter plate, each well containing 200 μl of Hank’s buffer containing 1 
mg/ml MTT. The plate was incubated at 37 °C for 4 h. Afterwards, 50 μl of 
25% SDS were added to each well to dissolve formazan crystals. Bacterial 
viability was determined by absorbance measurements at 595 nm and 
calculated with respect to control cells (bacteria not treated with the peptide) 
(Mangoni et al. 2005). The percentage of viable cells was calculated 
according to the equation: (absorbancesample – absorbanceblank) / 
(absorbancecontrol – absorbanceblank) x 100, where the blank is given by 
samples without cells and not treated with the peptide. 
 
3.8.2 Cell infection and peptides’ effect on intracellular bacteria 
About 1 × 105 bronchial cells in MEMg supplemented with 10% FBS were 
seeded in 24-well plates and grown for 2 days at 37 °C and 5% CO2. The 
clinical isolate KK1 was grown in LB broth at 37 °C with mild shaking (125 
rpm) to mid-log phase (optical density of 0.8 at 590 nm) and subsequently 
harvested by centrifugation. The pellet was then resuspended in MEMg and 
properly syringed using a 21-gauge needle to avoid clump formation before 
infecting cells. A multiplicity of infection (MOI) of 100:1 (bacteria to cells) 
was used. Two hundred microliters of this bacterial suspension, containing 
about 1 × 107 CFU, was coincubated for 1 h with wt-CFBE/ΔF508-CFBE at 
37 °C and 5% CO2. After infection, the medium was removed and the cells 
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were washed three times with MEMg and then incubated for 1 h with a 
gentamicin solution (200 µg/ml in MEMg) to remove extracellular bacteria. 
Afterwards, the medium was aspirated and the infected cells were washed 
three times as described above. Two hundred microliters of Hanks’ solution 
with or without the peptide at different concentrations was added to each 
well, and the plate was incubated for 1 h at 37 °C and 5% CO2. After peptide 
treatment, cells were washed with PBS and lysed with 300 µl of 0.1% Triton 
X-100 in PBS for 15 min at 37 °C and 5% CO2. Each sample was then 
sonicated in a water bath for 5 min to break up possible bacterial clumps, and 
appropriate aliquots were plated on agar plates for counting of CFU after 24 
h at 37 °C. 
 
3.8.3 Localization of rhodamine-labelled peptides by fluorescence 
microscopy 
About 2 × 105 bronchial cells in MEMg supplemented with 10% FBS were 
seeded on 0.13- to 0.17-mm-thick coverslips which were put into 35-mm dish 
plates and incubated at 37 °C and 5% CO2. After 24 h, samples were washed 
with 1 ml PBS and treated with 4 µM rhodamine-labeled peptide or 
rhodamine (for control samples) in MEMg. After 30 min and 24 h of 
incubation at 37 °C and 5% CO2, cells were washed four times with PBS and 
fixed with 700 µl of 4% formaldehyde for 15 min at room temperature. 
Afterwards, they were washed twice with PBS and stained with DAPI (1 
µg/ml) for 5 min at room temperature to visualize the nuclei. After three 
additional washes, the coverslips were mounted on clean glass slides using 
Mowiol mounting medium and observed under an Olympus FV1000 
confocal microscope with a 60× objective lens (oil). Data analysis was done 
using Olympus Fluoview (version 4.1) and ImageJ. Results are reported as 
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the ratio between the fluorescence intensity of rhodamine-labeled peptides in 
the cytoplasm versus that in the nucleus. 
 
3.9 In vitro cell migration assays  
3.9.1 Pseudo-wound healing activity 
The ability of single peptides to stimulate migration of CFBE cells was 
evaluated by a modified scratch assay, as reported previously [please refer to 
the work attached at the end of the manuscript: “D-Amino acids incorporation 
in the frog skin-derived peptide esculentin-1a(1-21)NH2 is beneficial for its 
multiple functions.” By Di Grazia A, Cappiello F, Cohen H, Casciaro B, 
Luca V, Pini A, Di YP, Shai Y, Mangoni ML]. Briefly, special cell culture 
inserts for live cell analysis (Ibidi, Munich, Germany) were placed into wells 
of a 12-well plate. Alternatively, 35-mm dishes can also be used (Fig. 18). 
About 35,000 cells suspended in MEMg supplemented with 10% FBS were 
seeded in each compartment of the culture insert and incubated at 37 °C and 
5% CO2 for approximately 24 h to allow cells to grow to confluence. 
Afterwards, inserts were removed to create a cell-free area (pseudo-wound) 
of approximately 500 µm; 1 ml MEMg with or without the peptide at 
different concentrations was added to each well. Plates were incubated as 
described above to allow cells to migrate, and samples were visualized at 
different time intervals under an inverted microscope (Olympus CKX41) at 
4× magnification and photographed with a Color View II digital camera. The 
percentage of cell-covered area at each time was determined by the 
WIMASIS Image Analysis program. In another set of experiments, cell 
migration was evaluated in the presence of hydroxyurea alone or with 
peptides [Esc(1-21) or Esc(1-21)-1c] at the indicated concentration to 
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determine the involvement of proliferation. Furthermore, pseudo-wound 
closure assays were performed by pretreating cells for 30 min with 5 µM 
AG1478 or with 25 µM GM6001 to assess the implication of epidermal 
growth factor receptor (EGFR) or metalloproteinase activity in peptide-
induced cell migration, respectively. 
 
Fig. 18 Schematic representation for the usage of the Ibidi silicone culture inserts: placement 
of the insert into a 35-mm dish (1); cell seeding (2); removal of the insert (3); addition of 
treatments (4). 
 
3.9.2 Effect of the peptides on cell morphology 
A549 or CFBE cells (1.5 × 105) in 1 ml of DMEMg or MEMg, respectively, 
supplemented with 10% FBS, were seeded on 0.13- to 0.17-mm-thick 
coverslips put into 35-mm dish plates. The plates were incubated at 37 °C 
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and 5% CO2. After overnight incubation, A549 cells were washed with PBS 
and pretreated or not with 0.2 μM AG1478 before adding 10 μM Esc(1-21) or 
4 μM Esc(1-21)-1c in 1 ml of DMEMg supplemented with 2% FBS. Cells 
only pretreated with 0.2 μM AG1478 or without any treatment served as 
control.  
CFBE cells were washed with PBS and treated with 10 μM Esc(1-21) or 1 
μM Esc(1-21)-1c in 1 ml of MEMg.  
After 24 h incubation at 37 °C and 5% CO2, cells were washed with PBS. 
Then cells were fixed with 3.7% formaldehyde for 10 min at 4 °C or with 4% 
formaldehyde for 15 min at room temperature for A549 and CFBE cells, 
respectively. Afterwards, cells were washed with PBS, permeabilized with 
0.1% Triton X-100 in PBS for 10-15 min at room temperature, washed again 
and stained with phalloidin-fluorescein isothiocyanate (40 μM in PBS) for 
20-30 min at room temperature to visualize the cytoskeleton. The nuclei were 
stained by adding 50 μl of Hoechst 33258 (2 μg/ml) for 10 min or DAPI (1 
µg/ml) for 5 min at room temperature for A549 and CFBE cells, respectively. 
The coverslips were mounted on slides using buffered glycerol or Mowiol 
mounting medium, observed under the fluorescent microscope KOZO 
OPTICS XJF800 at 20× magnification and photographed with a Color View 
II digital camera. 
 
3.10 Cell proliferation studies  
About 2 × 104 wt-CFBE cells in MEMg supplemented with 10% FBS were 
seeded in each well of a 96-well microtiter plate. After overnight incubation 
at 37 °C and 5% CO2 atmosphere, the medium was replaced with 100 µl 
fresh MEMg supplemented with 10 µM Esc(1-21), 1 µM Esc(1-21)-1c, 250 
µM hydroxyurea or peptide combined with hydroxyurea for 24 h. Two hours 
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after the start of the treatment, cells were pulsed with BrdU. The percentage 
of cell proliferation was analyzed by BrdU Cell Proliferation Assay Kit (Fig. 
19) and normalized to that of cells growing in MEMg (100% cell 
proliferation; Ctrl). 
 
Fig. 19 Schematic representation of a BrdU Cell Proliferation ELISA to detect BrdU 
incorporated into cellular DNA during cell proliferation. When cells are incubated in media 
containing BrdU, the pyrimidine analog is incorporated in place of thymidine into the newly 
synthesized DNA of proliferating cells. Once the labeling media is removed, the cells are 
fixed and the DNA is denatured (denaturation of the DNA is necessary to improve the 
accessibility of the incorporated BrdU for detection). Afterwards, an anti-BrdU mouse 
monoclonal antibody is added followed by an Horseradish peroxidase (HRP) conjugated 
secondary antibody to detect the incorporated BrdU. The magnitude of the absorbance for 
the developed color is proportional to the quantity of BrdU incorporated into cells and can be 
directly correlated to cell proliferation. 
 
3.11 Anchored-independent growth assay (Soft Agar Colony Formation 
Assay) 
About 1 × 106 A549 cells in DMEMg supplemented with 10% FBS were 
seeded in 25-cm2 ﬂasks. After overnight incubation at 37 °C and 5% CO2 
atmosphere, medium was removed and replaced with fresh medium 
supplemented with 2% FBS and containing 10 µM Esc(1-21) or 4 µM Esc(1-
21)-1c for 24 h. As previously described in (Ranieri et al. 2016), 60mm 
dishes were coated with 5 ml/dish of 0.6% agar prepared in DMEMg 
supplemented with 10% FBS (complete medium) and allowed to solidify for 
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at least 5 min at room temperature. After 24 h treatment with the peptide, 
cells were trypsinized, resuspended (1.5 × 104 cells) in 3 ml of complete 
medium supplemented with 0.4% agar and poured on top of the 0.6% agar 
layer coating the 60-mm dish plate. The plates were then incubated for 2 
weeks at 37 °C and 5% CO2 atmosphere. Immediately after plating, only 
single cells were visible in each dish. To prevent desiccation, 0.5 ml of 
complete medium was added to each dish plate, twice per week. 
After two weeks, cells were stained with 0.001% crystal violet until they 
were clearly visible (Fig. 20). Quantitative analysis was performed counting 
visible colonies. 
 
Fig. 20 Representative scanned digital image of A549 colonies stained with crystal violet in 
a 60-mm dish. 
 
3.12 Anti-inflammatory assays 
3.12.1 Lipopolysaccharide (LPS)-neutralizing activity 
Macrophages were cultured overnight in 96-well plates (1 × 105 cells/well) in 
DMEMg supplemented with sodium pyruvate, NEAA and 10% FBS. The 
medium was then removed and replaced with fresh medium + 10% FBS 
containing 10 ng/ml LPS, derived from P. aeruginosa 10, in the presence of 
1, 5, 10, 20 μM Esc(1-21) or Esc(1-21)-1c. Samples were incubated at 37 °C 
for 4 h.  
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To verify if the peptides competed with LPS for binding to the LPS receptor, 
macrophages were stimulated with each peptide at the concentrations 
indicated above in fresh medium + 10% FBS, for 2 h at 37 °C and 5% CO2. 
Afterwards, the peptides were removed and the cells were stimulated with 10 
ng/ml LPS for 5 h.  
The medium was then collected and TNF-α concentration was evaluated 
using a mouse TNF-α enzyme-linked immunosorbent assay kit according to 
the manufacturer’s protocol (eBioscience, Affymetrix, San Diego, CA, USA) 
(Fig. 21). Cells that were stimulated with LPS alone and untreated cells 
served as controls. All experiments were done in triplicates. 
 
Fig. 21 Schematic representation of a sandwich enzyme-linked immunosorbent assay 
(ELISA). The plate is coated with a suitable capture antibody (1). Then the sample is added 
and the antigen present is bound to the capture antibody (2). A suitable biotin labeled 
detection antibody (BDAb), which binds to the antigen, is added (3). Avidin-Horseradish 
peroxidase HRP binds BDAb (4). Finally, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate is 
added and converted to a detectable form. 
 
3.12.2 Effect of the peptides on the structural organization of LPS  
Dynamic light scattering (DLS) is a well-known technique used to measure 
the Brownian motion (diffusion) and the size distribution of particles in 
solution. Here, the DLS machine (802 DLS manufactured by Viscotek) was 
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used to determine the size of LPS micelles in solution. To estimate the 
average size of the LPS particles, the measurements were done in wavelength 
of 830 nm, the detection was performed at 90°, temperature between 22 and 
25 °C (the refractive index was measured, respectively) and analyzed by the 
Software of OMNISIZE (Viscotek). LPS measurement was performed before 
and after peptides addition. LPS:peptide molar ratio was 1:1 and the solvent 
was filtered water.  
 
3.12.3 Western blotting analysis for cyclooxygenase-2 (COX-2) 
protein expression  
Macrophages were cultured overnight in 90 mm plates (1.5 × 106 cells/well) 
in DMEMg supplemented with sodium pyruvate, NEAA and 10% FBS. The 
medium was then removed and cells were stimulated with LPS from P. 
aeruginosa (20 ng/ml), Esc(1-21), Esc(1-21)-1c or both LPS and peptides for 
4 h. After treatment, the cells were washed and solubilized in lysis buffer 
[PBS 1X, 1% Tergitol-type NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
Protease Inhibitor Cocktail, 1 mM sodium orthovanadate (Na3VO4), 5 mM 
Dithiothreitol (DTT)] for 30 min on ice. The samples were centrifuged at 
1000 × g for 10 min and the supernatants were collected. Twenty µg of lysate 
protein from each sample were separated by SDS-PAGE on 10% gels and 
transferred to polyvinylidene fluoride (PVDF) membrane. After blocking 
overnight with buffer (5% non fat dry milk) the membranes were incubated 
with primary anti-COX-2 or anti-β-actin antibody for 1 h, washed in tris-
buffered saline-Tween 20 (TBST buffer) and incubated with HRP-conjugated 
secondary antibody for 1 h. Blots were developed by enhanced 
chemiluminescent (ECL) system. Densitometry analyses of bands were done 
by ImageJ gel system. 
59 
 
3.13 Statistical analyses 
Quantitative data, collected from independent experiments, were expressed as 
the means ± standard errors of the means (SEM) or standard deviation (SD). 
Statistical analysis was performed using one- or two-way analysis of variance 
(ANOVA) with PRISM software (GraphPad, San Diego, CA) or using 
Student’s t-test. Differences were considered to be statistically significant for 
a P value of <0.05. The levels of statistical significance are indicated in the 
legends to the figures. 
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4. Results 
4.1 Effect of Esc(1-21) and Esc(1-21)-1c on cell viability and mode of 
action on model membranes 
To investigate whether the incorporation of the two D-amino acids in the 
peptide sequence of Esc(1-21) was harmful to mammalian cells, the effect of 
the all-L peptide and its diastereomer on the viability of mammalian cells as 
well as on the perturbation of model membranes were assessed. 
4.1.1 Peptides’ effect on the viability of mammalian cells 
The effect of Esc(1-21) and its diastereomer Esc(1-21)-1c on the viability of 
human airway epithelial cells stably expressing either a functional or the 
most common CFTR mutation (ΔF508), as well as of murine macrophages 
(RAW 264.7 line), were evaluated by the MTT colorimetric assay in MEMg 
and DMEMg, respectively. 
The results obtained on CFBE cells are shown in Fig. 22. The two peptides 
were not toxic to wt-CFBE and F508-CFBE cell lines at a concentration 
range between 2 µM and 64 µM within 2 h. However, Esc(1-21) was toxic at 
128 µM, causing ~25% and 70% reduction in the amount of metabolically 
active wt-CFBE and ΔF508-CFBE cells, respectively (Fig. 22A and B). 
Furthermore, at a longer-term treatment (24 h), the cytotoxicity of Esc(1-21) 
became more pronounced, inducing about 20-25% killing of epithelial cells 
at 32 µM and 64 µM (Fig. 22C and D). At 128 µM, ~60% and 90% reduction 
of metabolically active wt-CFBE and ΔF508-CFBE cells was found, 
respectively. Importantly, the diastereomer did not induce any reduction in 
the percentage of metabolically-active cells at any concentration (Fig. 22). 
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Fig. 22 Peptides’ effect on the viability of bronchial epithelial cells. About 4 × 104 wt-CFBE 
(A and C) or ΔF508-CFBE (B and D) cells were plated in wells of a microtiter plate. After 
overnight incubation at 37 °C in a 5% CO2 atmosphere, the medium was replaced with 100 
µl fresh MEMg supplemented with the peptides at different concentrations. After 2 h or 24 h, 
cell viability was determined by MTT reduction to insoluble formazan. Cell viability is 
expressed as percentage with respect to the peptide untreated cells used as a control (Ctrl). 
All data are the mean from four independent experiments ± SEM. The levels of statistical 
signiﬁcance between the two peptides are P values of <0.05 (*), <0.01 (**), and <0.0001 
(****). 
 
In the case of RAW 264.7 cell line, both peptides gave rise to ~20% 
reduction in the number of metabolically-active cells when tested at a 
concentration range between 2 μM and 8 μM within 2 h. The cell viability 
decreased in a dose-dependent manner up to 128 μM, where 20% or 60% of 
viable cells were detected after incubation with Esc(1-21) or Esc(1-21)-1c, 
respectively (Fig. 23A). However, after 24 h treatment (Fig. 23B), Esc(1-21) 
induced more than 50% reduction in the number of metabolically active cells 
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at 64 μM and the complete cell death at 128 μM. In contrast, Esc(1-21)-1c 
induced only ~20% reduction of metabolically-active cells. 
 
Fig. 23 Peptides’ effect on the viability of RAW 264.7 macrophages. About 4 × 104 RAW 
264.7 cells were plated in wells of a microtiter plate. After overnight incubation at 37 °C in a 
5% CO2 atmosphere, the medium was replaced with 100 μl fresh DMEMg supplemented 
with the peptides at different concentrations. After 2 h or 24 h, cell viability was determined 
by MTT reduction to insoluble formazan. Cell viability is expressed as percentage with 
respect to the peptide untreated cells used as a control (Ctrl). All data are the mean from four 
independent experiments ± SEM. The levels of statistical signiﬁcance between the two 
peptides are P values of <0.05 (*), <0.01 (**), <0.001 (***), and <0.0001 (****). 
 
4.1.2 Membrane perturbation of lipid vesicles (Liposomes) 
To verify whether the lower cytotoxicity of the diastereomer in comparison 
to the all-L peptide reflected a weaker ability in destabilizing zwitterionic 
membranes, the leakage of a fluorescent marker from neutral lipid vesicles 
mimicking the composition of mammalian cell membranes was assessed and 
compared to what found for anionic vesicles mimicking the composition of 
bacterial membranes. 
A fluorescent molecule, i.e. CxF, entrapped in the water volume inside the 
lipid vesicles at high concentration, can be used to test the membrane 
permeability. This condition induces self-association and quenching of the 
dye (Stella et al. 2004). After peptide addition, the consequent membrane 
A B
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perturbation leads to probe release and dissociation with a resulting 
fluorescence increase.  
Both peptides were tested at a concentration of 20 µM on zwitterionic 
liposomes made of POPC/cholesterol (1:1, mol:mol) to simulate the neutral 
membrane of mammalian cells. As indicated in Fig. 24A, the diastereomer 
induced a 5-fold lower leakage of entrapped CxF compared to Esc(1-21) in 
line with its lower cytotoxicity. 
In comparison, when the two isomers were assayed on POPE/POPG 
liposomes (7:3 mol:mol, 200 µM), to mimic the lipid composition of the 
anionic membrane of Gram-negative bacteria, Esc(1-21) induced a 2-fold 
higher membrane-perturbing activity than that of the diastereomer within 30 
min after addition to the lipid vesicles (Fig. 24B). 
 
 
Fig. 24 CxF release from POPC/Cho liposomes (A) and POPE⁄POPG (B) (final lipid 
concentration 200 µM) during 30 min after addition of peptides (20 µM) at 37 °C. The 
percentage of leakage was calculated according to the formula: 100(Ft – F0) ⁄ (F1 – F0) as 
explained in the Materials and Methods. Data points are means of three independent 
measurements ± SD.  
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4.2 Structural studies 
Studies aimed at understanding the structural properties of the two peptides 
were performed by circular dichroism spectroscopy (CD) in the presence of 
DPC (solid line) and SDS micelles (broken line), mimicking the zwitterionic 
and the anionic composition of the outer leaflet of the cell membrane of 
mammalian cells and bacteria, respectively (Fig. 25A and B).  
CD spectra were measured in collaboration with Prof. Bhunia (Department of 
Biophysics, Bose Institute, India). 
In aqueous solution (black line), the two peptides assumed a random-coil 
conformation. Differently, in DPC and SDS, the spectral intensities typical of 
α-helices (two negative minima at 208 nm and 222 nm) were observed, but 
this was less pronounced for Esc(1-21)-1c (Fig. 25B), probably because of 
the presence of D-amino acids that break the α-helical structure.  
 
 
 
 
 
 
 
 
 
Fig. 25 Circular dichroism spectra of Esc(1-21) (A) and Esc(1-21)-1c (B), measured in the 
presence of aqueous solution (black line), SDS (broken colored line) and DPC (solid colored 
line) (25 µM peptide, 40 mM SDS or 10 mM DPC). 
 
 
A B 
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The conformational transition from random coil to α-helical structure in the 
presence of membrane-mimicking environments, as detected by CD spectra, 
prompted the exploration of the peptide structures at atomistic detail. DPC 
and/or SDS assemble as small size detergent micelles which provide 
appropriate systems for the structural analysis of AMPs in membrane 
mimetic environments by multidimensional nuclear magnetic resonance 
(NMR) spectroscopy. NMR studies were performed in the lab of Prof. 
Bhunia.  
In DPC micelles, Esc(1-21) resulted to adopt mainly an α-helical 
conformation with a tilt at the N-terminal end (Fig. 26A). The central region 
of the α-helix is straight and amphipathic due to the presence of several polar 
residues across one face of the helix, while hydrophobic residues (i.e. I2, F3, 
L6, A7, I11, L14, L15, I16 and L19) are along the other face of the helix 
(Fig. 26B). In contrast, Esc(1-21)-1c exhibits a partial α-helical conformation 
only at the N-terminal region but the helix breaks after residue N13, likely 
due to the presence of D-L14 and D-S17. The C-terminal region (N13-G21) is 
unstructured and adopts a flexible conformation (Fig. 27A and B).  
Unfortunately, it was not possible to determine the structure of both peptides 
in SDS micelles [please refer to the article attached at the end of the 
manuscript: “Membrane Perturbing Activities and Structural Properties of the 
Frog-skin Derived Peptide Esculentin-1a(1-21)NH2 and its Diastereomer 
Esc(1-21)-1c: Correlation With Their Antipseudomonal and Cytotoxic 
Activity.” By Loffredo MR, Ghosh A, Harmouche N, Casciaro B, Luca V, 
Bortolotti A, Cappiello F, Stella L, Bhunia A, Bechinger B, Mangoni ML]. 
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Fig. 26 Three dimensional solution structures of Esc(1-21) in DPC micelles. Cartoon 
representations of side chain orientation of a representative NMR structure of Esc(1-21) 
showing different residues (A). Electrostatic potential surface of Esc(1-21) showing the 
distribution of polar and non-polar residues (B). The hydrophobic and positively charged 
amino acid residues are indicated by green and blue, respectively, while all other residues are 
in white. These images were produced using the PyMOL and Chimera software (Pettersen et 
al. 2004). 
 
Fig. 27 Three dimensional solution structures of Esc(1-21)-1c in DPC micelles. Cartoon 
representations of side chain orientation of a representative NMR structure of Esc(1-21)-1c 
showing different residues (A). Electrostatic potential surface of Esc(1-21)-1c showing the 
distribution of polar and non-polar residues (B). The hydrophobic and positively charged 
amino acid residues are indicated by green and blue, respectively, while all other residues are 
in white. These images were produced using the PyMOL and Chimera software. 
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4.3 Peptide stability 
It is worth to mention that: (i) one of the reasons accounting for the limited 
development of AMPs as new therapeutics (e.g. for treatment of P. 
aeruginosa lung infection) is related to their susceptibility to enzymatic 
degradation (Midura-Nowaczek and Markowska et al. 2014; Nguyen et al. 
2010); and that (ii) the lung environment of CF patients is rich in proteases, 
i.e. elastase from host neutrophils and from P. aeruginosa (Liu et al. 1999; 
Lovewell et al. 2014; Mariencheck et al. 2003). Therefore, to investigate 
whether the replacement of two L-amino acids with the corresponding D-
enantiomers resulted in a higher resistance of the peptide to proteolytic 
digestion compared to the all-L Esc(1-21), the stability of both isomers in the 
presence of elastases was studied in collaboration with Prof. Pini 
(Department of Medical Biotechnology, University of Siena). 
4.3.1 Peptides’ susceptibility to human elastase 
When elastase from human leukocytes was used, Esc(1-21) was completely 
degraded within 5 h (Table 4). In contrast, the diastereomer was highly stable 
with 78% and 13% amount of non-degraded peptide after 5 h and 24 h 
incubation, respectively (Table 4). In comparison, when the human 
cathelicidin AMP LL-37 was used as a reference, 44% of the peptide was 
found after 5 h treatment, but nothing was detected after 24 h (Table 4). Mass 
spectrometry analysis of Esc(1-21) after 5 h treatment (Fig. 28C) confirmed 
the presence of two main peaks, corresponding to degradation products of 
1,743 Da (fragment 1-16, the most abundant one) and 1,160 Da (fragment 1-
11) obtained after cleavage of the peptide bonds between Ile16 and Ser17 and 
between Ile11 and Lys12, respectively (see table at the bottom of Fig. 28). 
Additional peaks corresponding to degradation products of 1,096 Da and 
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1,338 Da were detected after 24 h (Fig. 28E). Differently, in the case of 
Esc(1-21)-1c, one single peak at 2,185 Da corresponding to the calculated 
molecular mass of the unmodified peptide was detected within 5 h of 
enzymatic treatment (Fig. 28D). This is probably due to the presence of D-Ser 
at position 17 which prevents the enzyme from recognizing its main cleavage 
site. Only after 24 h, three additional peaks with 1,781 Da, 1,539 Da and 
1,041 Da corresponding to different secondary products were visible (Fig. 
28F). Fig. 29 shows the mass spectra profile and the corresponding 
degradation products of LL-37 after human elastase treatment. 
 
Table 4 Peptide amount after 5 and 24 h of incubation with human and P. aeruginosa 
elastase at 37 °C. 
a Peptide amounts were determined by the peak areas of the RP-HPLC relative to those of 
the control peptide (dissolved in buffer) at 0 min (set as 100%). 
 
 
Peptide 
designation 
Peptide amounta (%)  
Human elastase P. aeruginosa elastase 
5 h 24 h 5 h 24 h 
Esc(1-21) 0 0 0 0 
Esc(1-21)-1c 78 13 91 77 
LL-37 44 0 0 0 
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Fig. 28 Proteolytic activity of elastase from human neutrophils on both Esc(1-21) and Esc(1-
21)-1c. Mass spectrometry profile of the two peptides immediately after enzyme addition (A, 
B) and after 5 h (C, D) or 24 h (E, F) incubation with the enzyme are reported. Molecular 
masses for intact peptides and proteolytic fragments produced by elastase treatment are 
indicated. Insets within each panel show HPLC profile of the sample. The retention time of 
the intact peptide is also indicated (18 min). The tables show the mass spectra peaks and the 
corresponding cleavage fragments. Proteolytic sites of the enzyme on the two peptides are 
indicated by the arrows. D-amino acids are in italics and underlined. 
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Fig. 29 Proteolytic activity of elastase from human neutrophils on LL-37. HPLC (A-C) and 
mass spectrometry profiles (D-F) of the peptide immediately after enzyme addition (A, D) 
and after 5 h (B, E) or 24 h (C, F) incubation with the enzyme are reported. Molecular 
masses for intact peptides and proteolytic fragments produced by elastase treatment are 
indicated. Retention time of intact peptide is also indicated (23,9 min). Proteolytic sites of 
the enzyme on LL-37 are indicated by the arrows. 
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4.3.2 Peptides’ susceptibility to P. aeruginosa elastase 
When P. aeruginosa elastase was used, both LL-37 and Esc(1-21) were 
completely degraded within 5 h (Table 4), while in the case of Esc(1-21)-1c 
about 91% and 77% of non-degraded peptide was detected after 5 h and 24 h, 
respectively (33% after 48 h, data not shown). Interestingly, when the 
corresponding mass spectra were analyzed, peaks with different molecular 
masses than those found after treatment with human elastase were 
distinguished, indicating different cleavage sites by the two elastases either in 
the two esculentin isoforms (Fig. 30) or in LL-37 (Fig. 31). Indeed, the first 
principal digestion product obtained after 5 h treatment of Esc(1-21) with this 
enzyme had a molecular mass of 1,403 Da and corresponded to the 1-13 
fragment (Fig. 30C). This points out that the main cleavage site by 
Pseudomonas elastase in Esc(1-21) is between Asn13 and Leu14 (see table at 
the bottom of Fig. 30) while an additional secondary product corresponding 
to the fragment 1-10 was visible after 24 h (Fig. 30E). Note that the major 
peptide binding site of Pseudomonas elastase flanks the D-Leu14 in Esc(1-
21)-1c, thus preventing its proteolytic cleavage compared to the all-L peptide 
(Fig. 30D, F).  
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Fig. 30 Proteolytic activity of elastase from P. aeruginosa on both Esc(1-21) and Esc(1-21)-
1c. Mass spectrometry profile of each peptide immediately after enzyme addition (A, B) and 
after 5 h (C, D) or 24 h (E, F) incubation with the enzyme are reported. Molecular masses for 
intact peptides and proteolytic fragments produced by elastase treatment are indicated. Insets 
within each panel show HPLC profile of the sample. The retention time of the intact peptide 
is also indicated (18 min). The tables show the mass spectra peaks and the corresponding 
cleavage fragments. Proteolytic sites of the enzyme on the two peptides are indicated by the 
arrows. D-amino acids are in italics and underlined. 
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Fig. 31 Proteolytic activity of elastase from P. aeruginosa on LL-37. HPLC (A-C) and mass 
spectrometry profiles (D-F) of the peptide immediately after enzyme addition (A, D) and 
after 5 h (B, E) or 24 h (C, F) incubation with the enzyme are reported. Molecular masses for 
intact peptides and proteolytic fragments produced by elastase treatment are indicated. 
Retention time of intact peptide is also indicated (23,9 min). Proteolytic sites of the enzyme 
on LL-37 are indicated by the arrows. 
 
4.4 Antimicrobial properties 
To enlarge the knowledge on the effect of the two L- to D-amino acids 
substitution on the antimicrobial properties of the peptide, the killing activity 
of Esc(1-21) and its diastereomer either against the more dangerous 
phenotype of P. aeruginosa i.e. the biofilm form, or against intracellular 
Pseudomonas cells were analyzed and compared. 
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4.4.1 Activity of the peptides against P. aeruginosa biofilm 
Esc(1-21) and its diastereomer were tested for their ability to kill the biofilm 
form of P. aeruginosa strains associated with the persistent chronic infection 
and colonization of lungs in CF patients. Interestingly, the diastereomer 
Esc(1-21)-1c displayed an equal or higher anti-biofilm activity than the 
Esc(1-21) (Table 5). More specifically, it gave rise to ~95% reduction in the 
amount of viable biofilm cells of the CF isolates AA11 and TR1 at 12.5 μM 
compared to 25 μM found for Esc(1-21), while a concentration of 12.5 μM 
was needed for both peptides against P. aeruginosa ATCC 27853 and KK1 
(Table 5). 
 
Table 5 Anti-biofilm activity of Esc(1-21) isomers. 
Bacterial strains 
Anti-biofilm activitya (μM) 
Esc(1-21) Esc(1-21)-1c 
P. aeruginosa ATCC 27853 12.5 12.5 
P. aeruginosa AA11 25 12.5 
P. aeruginosa KK1 12.5 12.5 
P. aeruginosa TR1 25 12.5 
a Antibiofilm activity was defined as the lowest peptide concentration that is sufficient to 
cause 95% reduction in the amount of viable biofilm cells in 2 h. The results are the average 
of three independent experiments. 
 
4.4.2 Killing activity against P. aeruginosa internalized in 
bronchial epithelial cells  
It was reported that the clinical isolate of P. aeruginosa, KK1 strain, can 
invade bronchial cells in vitro (Lore et al. 2012). Therefore, the effect of the 
two peptides on wt-CFBE (Fig. 32A and B) and ΔF508-CFBE cells (Fig. 32C 
and D) after infection with KK1 was monitored. The number of intracellular 
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bacteria was expressed either as CFU per sample (Fig. 32A and C) or as 
percentage (Fig. 32B and D) with respect to the peptide untreated infected 
cells (control). According to the literature (Ko et al. 1997), P. aeruginosa 
usually targets particular CF epithelial cells rather than the whole population 
of cells. Note that the number of internalized bacteria (~3,500 CFU) in our 
control bronchial cells (Fig. 32A and C) well correlated to the previously 
described uptake of different P. aeruginosa strains by CF airway epithelial 
cells (Pier et al. 1996). 
In our experiment, the two peptides were used in Hanks’ buffer to better 
simulate a physiological environment without the presence of cell culture 
medium components. In wt-CFBE cells, at 5 µM the peptides caused about 
15 to 20% killing of intracellular bacteria within 1 h (Fig. 32B). However, the 
killing effect was more evident in ΔF508-CFBE cells (Fig. 32D); in fact, at 5 
µM Esc(1-21) and its diastereomer caused ~40% and 60% decrease in the 
number of intracellular bacteria, respectively, compared to untreated infected 
cells. Since the cytotoxicity of Esc(1-21)-1c in Hanks’ buffer was 
significantly lower than that of the all-L isomer (Table 6), the diastereomer 
could be used at higher concentrations without damaging host epithelial cells. 
As reported in Fig. 32, 10 µM and 15 µM Esc(1-21)-1c led to about 70% and 
90% reduction in the survival of intracellular bacteria in ΔF508-CFBE (Fig. 
32D), whereas only ~50% bacterial killing was observed in wt-CFBE cells 
after exposure to 15 µM Esc(1-21)-1c (Fig. 32B). Note that the higher 
toxicity of Esc(1-21) to bronchial cells when tested in Hanks’ buffer, 
compared to that in MEMg (Fig. 22), could be due to the absence of medium 
components that may affect its activity, resulting in lower cytotoxicity.  
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Fig. 32 Effect of Esc(1-21) and its diastereomer, Esc(1-21)-1c, on the intracellular killing of 
P. aeruginosa KK1 in wt-CFBE (A and B) and ΔF508-CFBE (C and D) cells. About 1 × 105 
cells were seeded in 24-well plates and grown to confluence. Afterwards, they were infected 
with the bacterium for 1 h; nonadherent extracellular bacteria were removed upon antibiotic 
treatment, and infected cells were left untreated or were treated for 1 h with the peptide at 
different concentrations, as indicated. Control samples (Ctrl) are peptide-untreated infected 
cells. The number of intracellular bacteria is expressed either as CFU per sample (A and C) 
or as a percentage with respect to the control (B and D). All data are the mean from four 
independent experiments ± SEM. The levels of statistical significance between peptide-
treated infected cells and control samples are P values of <0.05 (*), <0.001 (***) and 
<0.0001 (****). 
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Table 6 Peptides' effect on the viability of bronchial epithelial cells in Hank’s buffer. 
Peptide Concentration 
(µM) 
Metabolically-active cells (%) 
wt-CFBE ΔF508-CFBE 
Esc(1-21) 10  62 88 
15  43 71 
30  10 15 
Esc(1-21)-1c 10  97 99 
15  94 95 
30  88 92 
About 4 × 104 wt-CFBE (A) or ΔF508-CFBE (B) cells were plated in wells of a microtiter 
plate. After overnight incubation at 37 °C in a 5% CO2 atmosphere, the medium was 
removed and replaced with 100 µl Hank’s supplemented with the peptides at different 
concentrations. After 2 h, cell viability was determined by the MTT reduction to insoluble 
formazan. Cell viability is expressed as percentage with respect to the control (cells not 
treated with the peptide). All data are the mean of a representative single experiment, 
performed in triplicates. The SD at each point did not exceed 2.5%. 
 
4.4.3 Peptides’ distribution within bronchial cells 
The peptides’ distribution in wt-CFBE and ΔF508-CFBE cells was then 
investigated by using rhodamine-labeled peptides and confocal microscopy. 
Fig. 33A and B show that rho-Esc(1-21) was mainly aligned to the 
perinuclear region of the cell already after 30 min from its addition, as well as 
after 24 h. Importantly, to exclude that rhodamine facilitated the uptake of the 
peptide, the rhodamine dye not conjugated to the peptide was employed. In 
this case, no fluorescence was observed inside bronchial cells (Fig. 33C and 
D). Differently, in the case of rho-Esc(1-21)-1c, the fluorescence intensity 
appeared equally distributed within the cytosol and nucleus (Fig. 33E and F). 
These results were confirmed by the quantitative analysis of fluorescence 
intensity of the two peptides between the cytoplasm and nucleus in both types 
of cells. This indicated a greater distribution of the fluorescent Esc(1-21) in 
the cytoplasm rather than in the nucleus, after 30 min and 24 h from its 
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addition, compared to rho-Esc(1-21)-1c, which was almost evenly distributed 
all over the cells (Fig. 34). 
 
Fig. 33 Confocal laser-scanning microscopy images of wt-CFBE and ΔF508-CFBE cells 
treated with rho-Esc(1-21) (A and B), rhodamine alone (C and D), or rho-Esc(1-21)-1c (E 
and F) at different times. After treatment with the peptide (or rhodamine), cells were stained 
with DAPI for nucleus detection. DAPI fluorescence, rhodamine-labeled peptide (or 
rhodamine) signal, and the overlay of the two fluorescent probes are shown. All images are z 
sections taken from the mid-cell height. All bars represent 10 µm. 
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Fig. 34 Peptide distribution between cytoplasm and nucleus in wt-CFBE and ΔF508-CFBE 
cells. Each peptide was tested on a minimum of 35 cells. The ratio between the fluorescence 
intensity of rhodamine-labeled peptides in the cytoplasm versus the nucleus was calculated 
for each cell, and the mean ± SEM value was reported on the y-axis. If the ratio is equal to 1, 
this means that the peptide is evenly distributed all over the cell. When the ratio is higher 
than 1, the amount of fluorescent peptide is higher in the cytoplasm than the nucleus. The 
level of statistical significance between the calculated ratios of the two peptides at different 
time points is indicated as a P value of <0.001 (***). 
 
4.5 Wound healing activity in bronchial epithelial cells  
Since the healing of an infected tissue does not only require the elimination 
of microbial cells but also the recovery of tissue integrity, the peptides’ effect 
on the migratory activity of bronchial epithelial cells was investigated by 
means of an in vitro pseudo-wound healing assay. Even though wound 
healing is a complex event which cannot be easily reproduced in vitro, 
studies on the peptides ability in promoting cell migration are indicative of 
their propensity to accelerate healing of a compromised epithelium. This is an 
important advantage for the development of a new therapeutic agent to be 
used not only as antibiotic but also as a multifunctional mediator of the host 
immune system. 
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4.5.1 Wound-healing activity in the presence of peptides 
As shown in Fig. 35, both AMPs stimulated migration of wt-CFBE and 
ΔF508-CFBE cells by inducing ~100% coverage of the pseudo-wound field 
produced in the monolayer of bronchial cells by means of the Ibidi culture 
inserts (see Materials and Methods) within 20 h at an optimal concentration 
of 10 µM (Fig. 35A and B) or 1 µM (Fig. 35C and D) for Esc(1-21) or its 
diastereomer, respectively. As shown in Fig. 35 both peptides significantly 
stimulated migration of bronchial cells at a concentration range from 4 µM to 
10 µM and from 1 µM to 10 µM for wt-CFBE and ΔF508-CFBE, 
respectively. 
The results reported in Fig. 35 are supported by the representative 
micrographs showing wt-CFBE (Fig. 36A) and ΔF508-CFBE (Fig. 36B) 
pseudo-wound closure before (T0) and 20 h after treatment with each peptide 
at the optimal concentration (10 µM and 1µM for Esc(1-21) and Esc(1-21)-
1c, respectively) in comparison to the untreated control cells.  
To further validate that both peptides induced cell migration, fluorescence 
studies on wt-CFBE cells were performed by using phalloidin for 
cytoskeleton detection. Untreated control cells appeared rounded, linked 
together and organized in clusters (Fig. 37A), while typical morphological 
changes associated with a migratory phenotype, such as cytoplasmic 
protrusions developing into lamellipodia (Schiller et al. 2010; Mihai et al. 
2012; Shaykhiev et al. 2005), were detected in wt-CFBE cells upon treatment 
with each peptide (at the optimal concentration to induce cell migration) (Fig. 
37B and C).  
Noteworthy, according to what found in the literature (Trinh et al. 2012), the 
migration speed of the mutant ΔF508-CFBE resulted to be slower than that of 
wt-cells. This finding can be related to the defective function of CFTR which 
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has been shown to play a crucial role in maintaining lung function and wound 
repair (Trinh et al. 2012) and to cause a reduced lamellipodium area from the 
leading edge of airway epithelial cells (Schiller et al. 2010). 
 
 
Fig. 35 Effect of Esc(1-21) and Esc(1-21)-1c on the closure of a pseudo-wound field 
produced in a monolayer of wt-CFBE (A, C) and ΔF508-CFBE (B, D). Cells were seeded in 
each side of an Ibidi culture insert and grown to confluence; afterwards, they were treated or 
not with the peptide. Cells were photographed at the time of insert removal and examined for 
cell migration after 15, 20 and 24 h from peptide addition. The percentage of cell-covered 
area at each time point is reported on the y-axis. Peptide untreated cells were used as control 
(Ctrl). The data are the mean of four independent experiments ± SEM. The levels of 
statistical significance between Ctrl and treated samples are P values of <0.05 (*), <0.01 
(**), <0.001 (***), and <0.0001 (****).  
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Fig. 36 Micrographs showing representative results of pseudo-wound closure of wt-CFBE 
(A) and ΔF508-CFBE cells (B) before (T0) and 20 h after treatment with each peptide at the 
optimal concentration, i.e. 10 µM and 1 µM for Esc(1-21) and Esc(1-21)-1c, respectively, in 
comparison to the untreated control samples (Ctrl). 
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Fig. 37 Effects of Esc(1-21) and Esc(1-21)-1c on the morphology of wt-CFBE cells. After 
fixation in formaldehyde, cells were stained with DAPI (for nuclei detection) and phalloidin 
(for cytoskeletal detection). The untreated control cells (A) appeared organized in clusters; 
those treated with 10 μM Esc(1-21) (B) or 1 μM Esc(1-21)-1c (C) for 24 h showed 
lamellipodia protrusions indicated by white arrows. Bars are 10 μm long. 
 
4.5.2 Wound-healing activity in the presence of hydroxyurea 
To discriminate the contribution of cell migration and proliferation in the 
peptide-induced recovery of the integrity of wt-CFBE monolayers, the wound 
healing assay was performed by treating cells with the cell proliferation 
blocker hydroxyurea (Schiller et al. 2010). As shown in Fig. 38, proliferation 
of CFBE cells was not essential for the re-epithelialization process. Indeed, 
no statistically significant difference was found between the percentage of 
cell-covered area in samples treated with 250 µM hydroxyurea plus 10 µM 
Esc(1-21) or 1 µM Esc(1-21)-1c and those treated with the peptide alone, at 
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all time intervals. This suggested that the wound healing activity stimulated 
by both peptides was primarily dependent on the migration activity of CFBE 
cells. 
 
Fig 38 Effect of hydroxyurea on the closure of a pseudo-wound field produced in a 
monolayer of wt-CFBE cells. Cells were seeded in each side of an Ibidi culture insert and 
grown to confluence. Afterwards, the cells were treated with 250 μM hydroxyurea and 10 
μM Esc(1-21) or 1 μM Esc(1-21)-1c. Some samples were treated with the peptides or 
hydroxyurea alone. Cells incubated with MEMg were used as control (Ctrl). Cells were 
photographed at the time of insert removal and examined for cell migration after 15, 20, and 
24 h from peptide addition. The percentage of cell-covered area was calculated and reported 
on the y-axis. All data are the mean from four independent experiments ± SEM. No 
statistically significant difference was found between samples treated with hydroxyurea and 
peptide and those treated with the peptide alone, at all time intervals. 
 
4.5.3 Role of cell proliferation in the wound healing activity 
To confirm whether hydroxyurea and peptides treatment at the concentrations 
used for the wound healing assay affected or not the proliferation of wt-
CFBE cells, measurement of incorporated BrdU into newly synthesized DNA 
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of proliferating cells, was carried out (see Materials and Methods). The 
results were expressed as percentage with respect to cells incubated with 
MEMg (Ctrl). 
As expected, hydroxyurea inhibited cell proliferation either when used alone 
or in combination with each of the two peptides (Fig. 39) in comparison to 
the control. Otherwise, both peptides alone did not significantly affect cell 
proliferation compared to the control sample. Similar results were obtained 
for ΔF508-CFBE cells and therefore are not shown. These data highly 
contributed to support the notion that the wound healing activity promoted by 
Esc(1-21) and Esc(1-21)-1c was mainly due to the peptide-induced migration 
of bronchial epithelial cells rather than to their proliferation.  
 
  
Fig. 39 Effect of hydroxyurea on cell proliferation. About 2 × 104 wt-CFBE cells were 
seeded in each well of a microtiter plate. After overnight incubation at 37 °C and 5% CO2 
atmosphere, the medium was replaced with 100 µl fresh MEMg supplemented with 10 µM 
Esc(1-21), 1 µM Esc(1-21)-1c, 250 µM hydroxyurea or the combination peptide and 
hydroxyurea, for 24 h. Two hours after the start of the treatment, cells were pulsed with 
BrdU. The percentage of cell proliferation was normalized to that of cells growing in MEMg 
(100% cell proliferation; Ctrl). All the results are the mean of three independent experiments 
± SEM. The level of statistical significance between Ctrl and treated samples is P value of 
<0.0001 (****). 
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4.5.4 Mechanism of peptide-induced cell migration 
The involvement of an EGFR-mediated signaling pathway had been found to 
control the Esc peptides-induced migration of immortalized human 
keratinocytes (HaCaT cell line) [please refer to the work attached at the end 
of the manuscript: “The frog skin-derived antimicrobial peptide esculentin-
1a(1-21)NH2 promotes the migration of human HaCaT keratinocytes in an 
EGF receptor-dependent manner: a novel promoter of human skin wound 
healing?” By Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, 
Picardo M, Paus R, Mangoni ML]. Since EGFR is also expressed in the 
airways of healthy or CF human subjects (Kim et al. 2013) and plays a 
crucial role in the repair of damaged airway epithelium (Burgel and Nadel 
2004), studies aimed at elucidating whether migration of CFBE cells induced 
by the peptides was a process mediated by activation of EGFR, were carried 
out. To this purpose, cells were pretreated with 5 µM of the tyrosine inhibitor 
of EGFR, AG1478 (Gan et al. 2007), before adding each of the two peptides 
at their optimal concentrations in stimulating bronchial cell migration [10 µM 
and 1 µM for Esc(1-21) and Esc(1-21)-1c, respectively]. As shown in Fig. 40, 
the peptide-promoted migration of bronchial cells was significantly impaired 
by inhibiting EGFR-mediated signaling. This is indicated by the significantly 
lower percentages of cell-covered area in AG1478-pretreated samples at all 
time intervals (15 h, 20 h and 24 h) compared to those obtained in bronchial 
cells which were not pretreated with AG1478 before peptide addition. 
Overall, these findings clearly highlighted that the peptides-induced re-
epithelialization of bronchial epithelium implies EGFR activation.  
Furthermore, to assess whether activation of EGFR required 
metalloproteinases, which are known to cleave membrane-anchored EGFR 
ligands and to be involved in EGFR trans-activation (Tjabringa et al. 2003), 
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the effect of a broad-spectrum MMP inhibitor, GM6001 (Stoll et al. 2012; He 
et al. 2008), was analyzed on the peptide-induced cell migration.  
Analogously to what found for AG1478, pretreatment of bronchial cells with 
25 µM GM6001 counteracted the peptide-induced closure of the pseudo-
wound field produced in the cell monolayer (Fig. 40). This supports the 
contribution of metalloproteinase activity in the peptide-induced stimulation 
of bronchial cells migration. 
Similar results were obtained with the mutant ΔF508-CFBE cells and 
therefore are not shown. 
 
Fig. 40 Effect of AG1478 and GM6001 inhibitors on the peptide-mediated migration of wt-
CFBE cells. Before removing the Ibidi culture insert, cells were preincubated with 5 µM 
AG1478 or 25 µM GM6001 for 30 min and subsequently treated with 10 µM Esc(1-21) or 1 
µM Esc(1-21)-1c. Some samples were treated with the peptide or inhibitors alone at the same 
concentration and cells incubated with MEMg were used as a control (Ctrl). Samples were 
photographed at different time intervals as indicated and the percentage of cell-covered area 
was calculated and reported on the y-axis. The data are the mean from four independent 
experiments ± SEM. The levels of statistical significance between samples pretreated with 
AG1478 or GM6001 and Ctrl or between samples pretreated with AG1478 or GM6001 
before incubation with the peptide and those treated with the peptide alone at the 
corresponding time intervals are P values of <0.05 (*), <0.01 (**) and <0.0001 (****). 
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4.6 Effect of the peptides on the migration of adenocarcinoma human 
alveolar epithelial cells (A549)  
Similar to what found for CFBE, the two peptides were able to stimulate 
migration of A549 cells, promoting the closure of a gap area produced in a 
monolayer of these cells at optimal concentrations of 10 µM and 4 µM for 
Esc(1-21) and (1-21)-1c, respectively. Also in this case the cell migration 
activity induced by both peptides resulted to be dependent on EGFR-
signaling pathway [please refer to the work attached at the end of the 
manuscript: “D-Amino acids incorporation in the frog skin-derived peptide 
esculentin-1a(1-21)NH2 is beneficial for its multiple functions.” By Di Grazia 
A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, 
Mangoni ML]. 
4.6.1 Morphological studies 
Also in this case, fluorescence microscopy was used to further assess whether 
the peptide-induced cell migration was accompanied by morphological 
changes. As explained in Materials and Methods section, A549 cells were 
stained with Hoechst and phalloidin for nuclei and cytoskeleton detection, 
respectively. Fig. 41 shows that A549 control cells (panel A) and those 
treated with AG1478 (panel A’) appeared organized into clusters with a 
regular morphological shape, characteristic of epithelial cells with poor 
motility (Lauand et al. 2013). Differently, cells treated either with Esc(1-21) 
or Esc(1-21)-1c appeared elongated, with an altered organization of actin 
filaments and cytoplasmic protrusions, polarized and separated one from each 
other (Fig. 41 panels B and B’, respectively), which is consistent with an 
enhanced cell motility. However, these morphological changes were not 
identified in A549 cells treated with peptides after exposure to AG1478 (Fig. 
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41 panels C, C’), supporting the participation of EGFR in the esculentin-
elicited migration of alveolar epithelial cells. 
 
Fig. 41 Effects of Esc(1-21) and Esc(1-21)-1c on the morphology of A549 cells. After 
fixation in formaldehyde, cells were stained with Hoechst (for nuclei detection) and 
phalloidin (for cytoskeletal detection). The untreated control cells (panel A) as well as those 
treated with 0.2 μM AG1478 for 15 min (panel A’) appeared organized in clusters. The 
Esc(1-21) and Esc(1-21)-1c-treated cells (panels B and B’ respectively) appeared elongated 
with cytoplasmic protrusions. These alterations were not identified in A549 cells pretreated 
with AG1478 and subsequently exposed to Esc(1-21) and Esc(1-21)-1c (panels C and C’, 
respectively). Bars are 20 μm long.  
A
B
A'
B’
C C’
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4.6.2 Cell anchorage-independent growth 
To verify if peptides treatment of A549 cells promoted an anchoring-
independent cell growth, a soft agar assay for colony formation was carried 
out.  
A549 cells were treated for 24 h with 10 µM Esc(1-21) or 4 µM Esc(1-21)-1c 
in DMEMg supplemented with 2% FBS to reproduce the conditions used in 
the wound healing assays. Indeed, these two peptide concentrations were 
found to be optimal to stimulate A549 cell migration [please refer to the work 
attached at the end of the manuscript: “D-Amino acids incorporation in the 
frog skin-derived peptide esculentin-1a(1-21)NH2 is beneficial for its 
multiple functions.” By Di Grazia A, Cappiello F, Cohen H, Casciaro B, 
Luca V, Pini A, Di YP, Shai Y, Mangoni ML]. As shown in Fig. 42, 
treatment of cells with each peptide did not induce any increase in the 
number of single colonies in soft-agar. The results were expressed as 
percentage of colonies formation with respect to the peptide-untreated control 
sample (100% colonies). 
These findings indicated that the peptide-induced migration of A549 would 
not translate into cells invasiveness and/or metastasis.  
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Fig. 42 A549 cells, previously treated with 10 µM Esc(1-21) or 4 µM Esc(1-21)-1c in 
DMEMg supplemented with 2% FBS, were grown at a density of 15,000 cells/plate in soft 
agar medium. After 14 days, formed colonies were stained with 0.001% crystal violet and 
counted. Untreated A549 cells were used as control (100% colonies/plate). The data are the 
mean from three independent experiments ± SEM (A). Image of an A549 colony captured 
with a 4× objective using an inverted microscope (Olympus CKX41) and photographed with 
a Color View II digital camera. Bar is 80 μm long (B). 
 
4.7 Anti-inflammatory activity 
The LPS aggregates are recognized as pathogen-associated molecular 
patterns by specific receptors which are expressed on innate immune cells 
(e.g. monocytes and macrophages), promoting their activation. This is 
characterized by increased phagocytic activity and secretion of pro-
inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) 
(Woltmann et al. 1998; Cohen 2002; Lee and Yang 2013). 
Despite activation of the immune system is beneficial, its overstimulation 
characterized by increased production of various pro-inflammatory agents is 
recognized as a key factor for lung deterioration (Nathan and Ding 2010). In 
addition, high levels of TNF-α can lead to septic shock syndrome (Rittirsch et 
al. 2008). 
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Interestingly, beside displaying antimicrobial activity, several AMPs have 
been found to detoxify LPS and/or to reduce the expression of 
cyclooxygenase-2 (COX-2) which is an important enzyme controlling the 
production of several pro-inflammatory mediators (Rosenfeld et al. 2008; 
Fabisiak et al. 2016; Brunetti et al. 2016). Therefore, the discovery of 
alternative antimicrobials with the potential to both kill bacteria and to 
display an anti-inflammatory activity is extremely helpful. 
4.7.1 Neutralization of the toxic effect of P. aeruginosa 
lipopolysaccharide  
To further investigate additional host-defense properties, Esc(1-21) and its 
diastereomer were tested for their ability to inhibit the secretion of TNF‐α 
from murine macrophages after activation with LPS (10 ng/ml) from P. 
aeruginosa, as already observed for some human AMPs (Hancock et al. 
2012; Pulido et al. 2012). The results demonstrated a dose-dependent effect 
in the inhibition of TNF-α release; 80 and 90% inhibition at 10 and 20 μM 
Esc(1-21), respectively, compared to that of LPS alone (Fig. 43). In 
comparison, a weaker activity was detected with the diastereomer Esc(1-21)-
1c; 20 and 30% inhibition at 10 and 20 μM, respectively (Fig. 43).  
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Fig. 43 The effect of peptides on the secretion of TNF-α from murine macrophages. RAW 
264.7 macrophages stimulated with LPS (10 ng/ml) derived from P. aeruginosa 10 in the 
presence of 1, 5, 10 and 20 μM Esc(1-21) or Esc(1-21)-1c for 4 h at 37 °C and 5% CO2. The 
percentage of inhibition of TNF-α release was normalized to that of macrophages stimulated 
with LPS without peptides (0% inhibition). All the results are the mean of three independent 
experiments ± SEM. The level of statistical significance between samples treated with Esc(1-
21) and Esc(1-21)-1c is P value of <0.001 (***). 
 
To get insight into the molecular mechanism underlying the LPS-
detoxification activity of the two peptides and whether these latter competed 
with LPS for binding to the LPS receptor, macrophages were first treated 
with the peptides and then exposed to LPS. As shown in Table 7 an invariant 
secretion of TNF-α was observed compared to what found for the control 
sample (cells stimulated with LPS, 100% TNF-α secretion).  
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Table 7 Effect of each peptide on the secretion of TNF-α from murine macrophages RAW 
264.7 macrophages after 2 h treatment at 37 °C. 
 TNF-α secretion (%) 
Peptide concentration (µM) Esc(1-21) Esc(1-21)-1c 
1 96 92 
5 97 99 
10 92 98 
20 105 97 
Esc(1-21) or Esc(1-21)-1c at 1, 5, 10 and 20 μM were used. After 2 h incubation peptides 
were removed and the cells were stimulated with LPS (10 ng/ml) derived from P. aeruginosa 
10 for 5 h. The percentage of TNF-α secretion was normalized to that of macrophages 
stimulated with LPS without peptide (100% secretion). All the results are the mean of a 
representative single experiment, performed in triplicates. The SD at each point did not 
exceed 2.5%. 
 
These results suggested that the detoxification of LPS was presumably due to 
a physical interaction of the peptides with LPS. One possible mechanism of 
action in which AMPs neutralize LPS consists in the breakage of LPS 
aggregates into smaller-size particles (Rosenfeld et al. 2006a, b; Bhunia et al. 
2011). This would prevent LPS from binding to LPS binding protein (LBP) 
and therefore the activation of the host immune cells.  
4.7.2 Effect of the peptides on the structural organization of 
lipopolysaccharide  
Light scattering experiments were used to understand whether the peptides 
could alter the micelle morphology of LPS. Fig. 44 shows that LPS from 
Pseudomonas was poly-dispersed in solution with major size-populations 
having hydrodynamic radius centered at 355 nm. When LPS was incubated 
with Esc(1-21) a shift of the average size of LPS to a lower value centered at 
67.7 nm was observed, compared to the diastereomer Esc(1-21)-1c which 
induced a larger LPS mean diameter centered at 116, indicating weaker 
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potency to dissociate LPS aggregates. These experiments were performed in 
collaboration with the group of Prof. Shai (Department of Biological 
Chemistry, The Weizmann Institute of Science, Israel). 
 
 
Fig. 44 The effect of peptides on the structural organization of LPS micelles. Light scattering 
of LPS from P. aeruginosa 10 in water before and after incubation with Esc(1-21) or Esc(1-
21)-1c at equimolar concentration. 
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4.7.3 Effect of the peptides on the expression level of 
cyclooxigenase-2 in macrophages activated by P. aeruginosa 
lipopolysaccharide 
During an inflammatory process, large amounts of pro-inflammatory 
mediators are generated by the cyclooxygenase-2 (COX-2), which is induced 
in immune cells, such as macrophages, in response to infection, injury or 
other stresses (Kim et al. 2007; Kumar and Abraham 2017; Lee et al. 2017). 
Therefore, the production of COX-2 was evaluated in macrophages 
stimulated by LPS from Pseudomonas aeruginosa (20 ng/ml), with or 
without Esc(1-21) or Esc(1-21)-1c at different concentrations. The results 
obtained by western blot analysis are reported in Fig. 45. They show that LPS 
induced an increase of COX-2 expression, whereas Esc(1-21) (Fig. 45A and 
B) and its diastereomer (Fig. 45C and D) led to a significant reduction in the 
expression level of COX-2, in a dose-dependent manner. However, the 
inhibitory effect was less pronounced for the diastereomer Esc(1-21)-1c as 
indicated by the higher peptide concentrations needed to achieve the same 
results as those found for Esc(1-21). These data are in line with those 
observed for the inhibition of TNF-α secretion. 
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Fig. 45 Effect of Esc(1-21) (A and B) or Esc(1-21)-1c (C and D) on LPS-induced expression 
of COX-2 in murine RAW 264.7 cells. Cells were stimulated with: LPS from Pseudomonas 
aeruginosa (20 ng/ml), peptides or LPS and peptides as indicated for 4 h. Relative COX-2 
levels were analyzed by western blot, normalized to β-actin and quantified by densitometry 
by using ImageJ software. Data are presented as the mean ± SD of three independent 
experiments. The levels of statistical significance between samples treated with LPS and 
LPS+peptide are P values of <0.05 (*) and <0.01 (**). 
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5. Discussion 
Multidrug-resistant (MDR) bacterial infections represent a serious worldwide 
health hazard causing almost 50,000 deaths per year in Europe and in the US. 
Since this number is expected to grow up to tenfold by 2050 (Grundmann et 
al. 2011; O’Neill 2016), the discovery of novel antimicrobial agents is an 
urgent need. In this regard AMPs represent a promising alternative to the 
commonly used drugs. 
Among microorganisms that develop resistance to the available antibiotics 
there is the opportunistic Gram-negative bacterium P. aeruginosa. It is able 
to colonize multiple tissues and to cause persistent chronic or lethal 
infections, such as those associated with the respiratory tract of CF patients. 
In fact, P. aeruginosa can create sessile communities, defined biofilms, 
which are extremely difficult to eradicate (Mangoni et al. 2015; Larrosa et al. 
2012; Millar et al. 2009). 
With the aim to develop new anti-infective agents with a different 
mechanism of action, the biological properties of two AMPs, Esc(1-21) and 
Esc(1-21)-1c, were studied and compared.  
Esc(1-21) is a derivative of the frog skin AMP esculentin-1a. It has a broad 
spectrum of activity, especially against Gram-negative bacteria including 
both the planktonic and the sessile form of P. aeruginosa (Luca et al. 2013).  
Esc(1-21)-1c is a diastereomer of Esc(1-21) which was designed by replacing 
two L-amino acids with the corresponding D-enantiomers. These 
modifications had the purpose to overcome those unfavorable aspects for the 
therapeutic development of AMPs, that are the cytotoxicity and the 
susceptibility to proteolytic degradation (Hancock and Sahl 2006; Aoki and 
Ueda 2013). 
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Cell viability assays initially performed on eukaryotic cells showed that the 
diastereomer is significantly less toxic than Esc(1-21) towards both bronchial 
epithelial cells and murine macrophages. 
Structural studies, performed by CD analysis, showed that both peptides 
adopt an α-helix conformation in zwitterionic and anionic environments, e.g. 
DPC and SDS micelles, that mimic the neutral membrane of mammalian 
cells and the anionic bacterial membrane, respectively. However, compared 
to Esc(1-21), the presence of two D-enantiomers in the C-terminal region of 
the all-L peptide, significantly reduces its α-helical content, especially in 
zwitterionic lipids. These results are in line with the lower cytotoxicity of 
Esc(1-21)-1c compared to Esc(1-21); indeed, numerous studies based on 
several native AMPs have underlined the importance of an amphipathic α-
helical structure for mammalian cell lysis (Pouny et al. 1992; Gazit et al. 
1994; Strahilevitz et al. 1994). Moreover, the lower cytotoxicity of the 
diastereomer reflects in a weaker ability to destabilize zwitterionic 
membranes as demonstrated by the results of CxF leakage assay from neutral 
liposomes. This is also in agreement with previous studies (Carotenuto et al. 
2008; Mangoni et al. 2011) showing a deeper insertion of peptides with a 
higher helical content into the hydrophobic core of mammalian cell 
membranes.  
The data obtained by CD spectra analysis are also supported by solution 
NMR studies in DPC micelles: an α-helical structure is preserved along the 
entire amino acid sequence of Esc(1-21), while a highly flexible C-terminal 
arm is present in Esc(1-21)-1c. This is due to the presence of D-amino acids 
at 14th and 17th position, which break the integrity of the α-helix made of L-
amino acids, as also observed for other naturally occurring AMPs, e.g. 
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magainin, cytolysin and melittin (Shai and Oren 1996; Saravanan et al. 2010; 
Wieprecht et al. 1999). 
The lung environment of CF patients is rich in proteases, i.e., elastase from 
host neutrophils and also from P. aeruginosa. 
Neutrophils elastase degrades almost all extracellular matrix and key plasma 
proteins, upregulates pro-inflammatory cytokine expression and is required 
for maximal intracellular killing of Gram-negative bacteria by neutrophils 
(Kelly et al. 2008). P. aeruginosa elastase is one of the extracellular and cell-
associated virulence factors that contributes to tissue damage in 
Pseudomonas infections; it degrades elastin, collagen, several cytokines as 
well as several complement components (Mariencheck et al. 2003). 
Interestingly, the incorporation of two D-amino acids at specific positions in 
Esc(1-21) makes the peptide significantly more resistant to degradation by 
both human and bacterial elastases. Moreover, the diastereomer is also more 
resistant than the human cathelicidin LL-37, an antimicrobial peptide which 
is found in granules of polymorphonuclear leukocytes and keratinocytes and 
involved in mammalian innate immune defense against invasive bacterial 
infections (Zanetti 2004). 
This result can explain the better effectiveness of the diastereomer, compared 
to the all-L peptide, against the biofilm form of P. aeruginosa. Indeed, 
proteases are mainly produced by bacteria in their biofilm form. Thanks to its 
higher biostability, the diastereomer would have a prolonged residence time 
with a resulting higher antibacterial activity in comparison to Esc(1-21), 
which would be rapidly degraded. In addition, it is worthwhile noting that D-
amino acids have been reported to promote the disassembly of the 
extracellular matrix of biofilm cells (Romero et al. 2011; Segev-Zarko et al. 
2015). 
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The diastereomer was also found to be more efficient than the all-L peptide in 
killing Pseudomonas internalized in bronchial cells either with a functional or 
a mutated CFTR. Furthermore, this activity is comparable to that of 
ciprofloxacin (Chadwick and Mellersh 1987), one of the few conventional 
antibiotics (fluoroquinolones) able to penetrate the plasma membrane 
(Bonventre et al. 1967; Brayton et al. 2002) and that is currently used against 
P. aeruginosa despite its toxicity (Ilgin et al. 2015). 
As revealed by confocal microscopy analysis, rho-Esc(1-21) has a prevalent 
perinuclear distribution in bronchial cells, while rho-Esc(1-21)-1c appears 
equally distributed within the cytosol and nucleus. 
Therefore, it is likely that the clearance of intracellular Pseudomonas is 
mainly due to the interaction of the internalized peptides with the 
intracellular bacterial cells. The weaker efficacy of the all-L peptide Esc(1-
21) in killing intracellular bacteria compared to its diastereomer may be due 
either to its stereospecific binding to intracellular components or to its higher 
susceptibility to virulence factors, i.e. proteases released from the 
intracellular bacteria. However, it has to be underlined that rhodamine-
labelled peptides were used for confocal microscopy studies and that the 
fluorescence intensity cannot indicate if the peptide is intact, partially 
degraded or present in an inactive form. It cannot be excluded that additional 
mechanisms of host cell protection against microbial pathogens are also 
involved in the clearance of intracellular microorganisms.  
All these data contributed to justify the higher in vivo antipseudomonal 
activity of the diastereomer Esc(1-21)-1c compared to that of the all-L 
peptide and LL-37 in a murine model of acute lung infection upon 
intratracheal instillation (Chen et al. 2017). 
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Another relevant aspect to take into consideration for the development of 
new anti-infective agents is their ability to promote re-epithelialization of a 
compromised epithelium. Indeed, healing of an infected tissue does not only 
require elimination of microbial pathogens but also recovery of the tissue 
integrity along with its barrier function preventing pathogens penetration. It 
is known that a persistent lung infection by Pseudomonas (especially in CF 
patients) results in the development of lesions (Goldberg and Pier 2000). 
Therefore, the capacity of drugs to accelerate wound repair of the bronchial 
epithelium is extremely advantageous to restore lung functionality. This is 
very important mainly in CF patients where wound healing processes are 
significantly slow. 
Wound healing in animals is an essential process for the repair and 
restoration of tissues function after injury or infections. This quite complex 
event occurs in distinct yet overlapping phases that include inflammation, cell 
migration, cell proliferation, epithelialization, angiogenesis and tissue 
remodeling (Mangoni et al. 2016). Therefore, wound healing is very difficult 
to simulate in vitro because of the absence of different cell types, the 
interaction between them and the production of cellular debris that greatly 
affect the tissue repair process. However, the use of special silicone inserts 
(Ibidi) allows to create a pseudo-wound in the monolayer of epithelial cells 
with a well-defined width. This provides an optimal experimental condition 
for a quantitative and reproducible evaluation of cell migration. In addition, 
in contrast to the traditional “scratch” method, based on the creation of a 
pseudo-wound by using plastic tips, such inserts do not alter the plastic 
surface on which the cells adhere, thus avoiding a possible variation of the 
cell migration results. 
104 
 
As described for A549 cells [please refer to the work attached at the end of 
the manuscript: “D-Amino acids incorporation in the frog skin-derived 
peptide esculentin-1a(1-21)NH2 is beneficial for its multiple functions.” By 
Di Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai 
Y, Mangoni ML], the diastereomer is more effective in inducing re-
epithelialization of the wounded area, with a mechanism that implies an 
EGFR mediated signaling pathway.  
EGF receptors are located in ordered lipid domains called lipid rafts (Pike et 
al. 2005) whose alteration may inhibit ligands binding to EGFR and its 
activation. The lower wound healing efficacy of the more helical Esc(1-21) 
compared to its diastereomer may be a consequence of its stronger ability in 
perturbing zwitterionic phospholipid membranes. Nevertheless, the different 
wound-healing activity between the two peptides may also be related to their 
different binding affinity to target receptors, such as membrane-bound 
metalloproteases (Kim et al. 2013; Peschon et al. 1998). Note that our in vitro 
assays have indicated trans-activation of EGFR mediated by 
metalloproteinases in the peptide-induced migration of epithelial bronchial 
cells. This was previously demonstrated also for HaCaT cells [please refer to 
the work attached at the end of the manuscript: “The frog skin-derived 
antimicrobial peptide esculentin-1a(1-21)NH2 promotes the migration of 
human HaCaT keratinocytes in an EGF receptor-dependent manner: a novel 
promoter of human skin wound healing?” By Di Grazia A, Cappiello F, 
Imanishi A, Mastrofrancesco A, Picardo M, Paus R, Mangoni ML]. 
Furthermore, the bronchial cells migration may be controlled by alternative 
processes that imply, for example, CFTR (especially in mutant cells) 
(Hussain et al. 2014). 
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Importantly, in line with what lately observed for HaCaT cells and A549 
cells [please refer to the work attached at the end of the manuscript: “D-
Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1-
21)NH2 is beneficial for its multiple functions.” By Di Grazia A, Cappiello F, 
Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, Mangoni ML], the 
wound closure driven by both esculentin peptides does not appear to be 
affected by cell proliferation, but rather depends on the cell migration 
activity. Indeed, bronchial cells exposed to the cell-proliferation inhibitor 
hydroxyurea in combination with each peptide have the same migration 
behavior as that obtained when the peptides are used alone. 
These data are further corroborated by the typical morphological changes of 
migrating cells (Schiller et al. 2010; Mihai et al. 2012; Shaykhiev et al. 
2005), observed in both A549 and CFBE cells. Remarkably, we can rule out 
that the peptide-induced cell migration promotes an invasive behavior of the 
cells and/or their malignant transformation. Indeed, no anchoring-
independent cell growth is detected in A549 cells upon their exposure to the 
peptides. 
It is well known that antibiotic treatment of microbial infections is frequently 
associated with the release of bacterial cell wall components, such as LPS, in 
the case of Gram-negative bacteria, or lipoteichoic acid (LTA), in the case of 
Gram-positive bacteria. These molecules stimulate the innate immune cells 
(mainly mononuclear cells and macrophages), inducing the secretion of pro-
inflammatory cytokines (e.g., tumor necrosis factor alpha, TNF-α). High 
levels of TNF-α can lead to deterioration of lung tissue or, to sepsis in most 
serious cases (Miller et al. 2005; Hancock and Sahl 2006). 
Esc(1-21)-1c is able to inhibit the release of TNF-α from macrophages 
activated by P. aeruginosa LPS, albeit to a lesser extent compared to the all-L 
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peptide. This weaker anti-inflammatory activity of the diastereomer 
compared to Esc(1-21) might be an advantage when the host’s innate 
immune response to bacterial infection is at the beginning stage. 
As previously reported in the literature, in aqueous solution, LPS molecules 
aggregate into micelles, that represent the biologically active form of the 
endotoxin (Takayama et al. 1994; Rosenfeld and Shai 2006). LPS micelles 
interact with the LPS-binding protein (LBP) and then, the LPS–LBP complex 
binds to CD14, the primary receptor of LPS, mainly expressed in 
macrophages (Schumann et al. 1990). The LPS-CD14 complex interacts with 
the transmembrane protein Toll-like receptor-4 (TLR4) and activates the 
intracellular signaling cascade resulting in the production and secretion of 
pro-inflammatory cytokines (Rosenfeld et al. 2006b). 
One of the mechanism by which AMPs can neutralize the toxic effect of LPS 
is their ability to disrupt the lipopolysaccharide micelles into smaller sized 
particles (Rosenfeld et al. 2006a, b; Bhunia et al. 2011). This would prevent 
LPS from binding to the LPB, and then to CD14 and to the TLR4 by 
blocking, consequently, the activation of intracellular signaling pathway for 
cytokine synthesis (Rosenfeld et al. 2006a, b; Mangoni and Shai 2011). Light 
scattering analysis highlighted the formation of smaller-sized LPS micelles 
upon addition of the esculentin peptides, with a stronger effect in the 
presence of Esc(1-21). Note that peptides with a well-defined and stabilized 
structure in both LPS and cytoplasmic membrane and the capability to 
disassemble the structural organization of LPS micelles are known to have a 
potent LPS detoxification activity (Rosenfeld et al. 2008). Therefore, the 
higher α-helical content of Esc(1-21) in LPS and its stronger efficacy in 
disrupting LPS aggregates are consistent with its stronger anti-endotoxin 
activity compared to its diastereomer. It can be excluded that the peptides 
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compete with LPS for their binding to the LPS receptor on the membrane of 
immune cells. Indeed, when macrophages are stimulated with the peptides 
prior to addition of LPS, no effect on the LPS-neutralization activity is 
observed. 
Moreover, these peptides can contribute to down-regulate the acute 
inflammatory response induced during infection or injury, by also acting on 
COX-2 synthesis, an enzyme responsible for the production of inflammatory 
mediators in response to LPS stimulation (Brunetti et al. 2016). COX-2 
production was proved to be inhibited by Esc(1-21) and Esc(1-21)-1c when 
macrophages are treated with the peptides and LPS from P. aeruginosa. As 
already observed for TNF-α secretion, the diastereomer has a weaker 
inhibitory effect compared to Esc(1-21).  
Considering these properties, there is an increasing interest in AMPs, which 
show not only a bactericidal activity against pathogenic microorganisms, but 
also the ability to detoxify LPS and to stimulate re-epithelialization, unlike 
conventional antibiotics. 
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6. Conclusions and future perspectives 
In conclusion, our studies have shown multiple functions for both the frog 
skin-derived AMP, Esc(1-21), and its designed diastereomer, Esc(1-21)-1c. 
Only two L-to-D-amino acids substitutions in the C-terminal end of Esc(1-21) 
are sufficient to: 
i) significantly reduce its cytotoxic effect towards mammalian cells (e.g., 
bronchial epithelial cells and macrophages) in agreement with a lower α-
helical structure, as determined by circular dichroism spectroscopy and NMR 
studies;  
ii) increase its effectiveness against the biofilm form of P. aeruginosa (either 
reference or clinical isolates from CF patients), while maintaining a high 
activity against the free-living form of this pathogen; 
iii) more effectively kill Pseudomonas cells once internalized into CF 
bronchial cells; 
iv) improve the ability of the peptide to promote migration of bronchial 
epithelial cells and presumably its capacity to restore the integrity of the 
injured lung tissue; 
v) enhance the peptide’s biostability to human and P. aeruginosa elastases. 
These multiple beneficial properties, along with the ability to detoxify LPS 
and to inhibit COX-2 synthesis, albeit less than the wild-type peptide, make 
the diastereomer a better candidate for the generation of new antimicrobial 
drugs that not only eliminate microbial pathogens, but also have the 
potentiality to recover the tissue’s integrity.  
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Further experiments will be carried out to investigate other possible pathways 
involved in the peptide-induced wound healing process, that is an attractive 
feature not detected for conventional antibiotics. In parallel, in vivo efficacy 
studies in murine models of chronic Pseudomonas lung infections will be 
performed. 
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A B S T R A C T
Antimicrobial peptides (AMPs) represent new alternatives to cope with the increasing number of multi-drug
resistant microbial infections. Recently, a derivative of the frog-skin AMP esculentin-1a, Esc(1-21), was found to
rapidly kill both the planktonic and bioﬁlm forms of the Gram-negative bacterium Pseudomonas aeruginosa with a
membrane-perturbing activity as a plausible mode of action. Lately, its diastereomer Esc(1-21)-1c containing
two D-amino acids i.e. DLeu14 and DSer17 revealed to be less cytotoxic, more stable to proteolytic degradation
and more eﬃcient in eradicating Pseudomonas bioﬁlm. When tested in vitro against the free-living form of this
pathogen, it displayed potent bactericidal activity, but this was weaker than that of the all-L peptide. To in-
vestigate the reason accounting for this diﬀerence, mechanistic studies were performed on Pseudomonas
spheroplasts and anionic or zwitterionic membranes, mimicking the composition of microbial and mammalian
membranes, respectively. Furthermore, structural studies by means of optical and nuclear magnetic resonance
spectroscopies were carried out. Our results suggest that the diﬀerent extent in the bactericidal activity between
the two isomers is principally due to diﬀerences in their interaction with the bacterial cell wall components.
Indeed, the lower ability in binding and perturbing anionic phospholipid bilayers for Esc(1-21)-1c contributes
only in a small part to this diﬀerence, while the ﬁnal eﬀect of membrane thinning once the peptide is inserted
into the membrane is identical to that provoked by Esc(1-21). In addition, the presence of two D-amino acids is
suﬃcient to reduce the α-helical content of the peptide, in parallel with its lower cytotoxicity.
1. Introduction
Most living organisms produce gene-encoded antimicrobial peptides
(AMPs) as readily available weapons against a wide variety of microbial
pathogens [1–3]. The majority of these AMPs are cationic molecules at
neutral pH and they adopt an amphipathic α-helical structure in
membrane environments [4]. These two remarkable features are fun-
damental for their broad microbicidal activity, which generally relies
on the perturbation of the target cell membrane, thus limiting the in-
duction of resistance [1,5]. Their ability to recognize and distinguish
bacterial membranes from those of mammalian cells is based on an
initial electrostatic interaction between the positively charged residues
of the peptide and the negatively charged membrane phospholipids
[6,7]. The latter are much more abundant at the outside of microbial
cells when compared to the external leaﬂet of mammalian cell mem-
branes, which are mostly made of zwitterionic phosphatidylcholine and
sphingomyelin [5]. However, in the case of Gram-negative bacteria,
before reaching the cytoplasmic membrane (i.e. inner membrane),
bacteria need to cross the lipopolysaccharide (LPS)-outer layer in a self-
promoted uptake mechanism [8]. Subsequently, the phospholipid bi-
layer of the inner membrane is destabilized via pore formation or mi-
cellization, leading to cell death [9–11]. After membrane passage, inner
http://dx.doi.org/10.1016/j.bbamem.2017.09.009
Received 21 June 2017; Received in revised form 21 August 2017; Accepted 8 September 2017
⁎ Corresponding author at: Department of Biochemical Sciences, Sapienza University of Rome, Via degli Apuli, 9-00185 Rome, Italy.
1 The authors equally contributed to the work.
E-mail address: marialuisa.mangoni@uniroma1.it (M.L. Mangoni).
BBA - Biomembranes 1859 (2017) 2327–2339
Available online 12 September 2017
0005-2736/ © 2017 Elsevier B.V. All rights reserved.
MARK
targets may also exist for some of the peptides [12,13]. In contrast,
conventional antibiotics generally inhibit intracellular biological func-
tion(s) upon interaction with a single stereospeciﬁc target that can be
mutated [14,15], making it easier for the microbes to become resistant
to this class of drugs [16,17]. Due to the alarming worldwide emer-
gence of multi-drug resistant (MDR) pathogenic microorganisms [18]
and the concomitant decrease in the pharmaceutical industry research
pipeline for novel antibiotics, the search for new antimicrobial strate-
gies has become strictly necessary [19–21]. AMPs hold promise for the
development of new anti-infective compounds [22–25]. Interestingly, a
few years ago we discovered that a short-sized AMP, esculentin-1a(1-
21)NH2, Esc(1-21), derived from a natural AMP of amphibian origin
was endowed with: (i) a wide and potent spectrum of activity especially
against Gram-negative bacteria [26–28] and (ii) rapid killing kinetics
on planktonic and bioﬁlm cells of Pseudomonas aeruginosa. It also
showed a membrane-perturbing activity as a plausible mode of action
[29]. In addition, it was found to have additional non-antimicrobial
properties. Among those, the ability (i) to detoxify P. aeruginosa LPS
[30] and (ii) to induce re-epithelialization of a pseudo-“wound”; a
property which is not shown by any traditional antibiotic [30,31].
Furthermore, we recently demonstrated that a diastereomer of Esc
(1-21), named Esc(1-21)-1c, containing two D-amino acids i.e. DLeu14
and DSer17 had signiﬁcant lower cytotoxicity and higher biostability
than its all-L isomer [30]. In addition, it was more eﬃcient in promoting
clearance of P. aeruginosa internalized in bronchial cells as well as in
stimulating wound-healing in an in vitro bronchial epithelial cells model
[32]. However, when tested in vitro against the free living form of P.
aeruginosa strains, even if it displayed a potent killing activity this was
weaker than the parent Esc(1-21) [32].
With the aim to understand whether this discrepancy reﬂected a
diﬀerent ability of the peptides in damaging the cytoplasmic membrane
of bacterial cells or a diﬀerent interaction with the bacterial cell sur-
face, mechanistic studies have been performed on intact bacterial cells,
with bacteria devoid of their cell wall (i.e. spheroplasts) as well as
micelles mimicking the head group composition and/or surface charge
of membranes. In parallel, to verify whether the lower cytotoxicity of
the diastereomer in comparison to the all-L peptide reﬂected a weaker
ability in destabilizing zwitterionic membranes, the leakage of a
ﬂuorescent marker from neutral lipid vesicles was assessed in com-
parison to anionic vesicles. Furthermore, by using optical and nuclear
magnetic resonance spectroscopies, the secondary structure of the
peptides in membrane-mimicking environments has been investigated.
Our studies revealed that the weaker in vitro antimicrobial activity of
the two D-amino acid containing Esc(1-21)-1c in comparison with the
all-L Esc(1-21) is mainly associated to a diﬀerent interaction of the
peptide with microbial cell wall components and only partially due to a
weaker ability in binding and perturbing anionic membranes.
Furthermore, the presence of two D-amino acids was found to be suf-
ﬁcient to reduce the α-helical content of the peptide, in line with its
lower cytotoxicity.
2. Materials and methods
2.1. Materials
Synthetic Esc(1-21) and its diastereomer Esc(1-21)-1c (Scheme 1)
were purchased from Chematek Spa (Milan, Italy). Each peptide was
assembled by stepwise solid-phase synthesis using a standard F-moc
strategy and puriﬁed via reverse-phase high-performance liquid chro-
matography (RP-HPLC) to a purity of 98%, while the molecular mass
was veriﬁed by mass spectrometry. The following lipids: 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoethanolamine (POPE); 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol (POPG); 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), POPE-2H31 and cholesterol (Cho)
were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Sodium-
dodecylsulfate (SDS), dodecylphosphocholine (DPC) were obtained
from Cambridge Isotope Laboratories (Tewksbury, MA); carboxy-
ﬂuorescein (CF), water (HPLC grade), deuterium depleted water
(≤1 ppm), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) were from Sigma (St. Quentin Fallavier, France). Sytox
Green was from Molecular Probes (Invitrogen, Carlsbad, CA, USA).
2.2. Microorganisms
The following bacterial strains were used for the antimicrobial as-
says: the standard P. aeruginosa PAO1 [29] and the clinical isolate P.
aeruginosa AA43 from the strains collection of the cystic ﬁbrosis clinic
Medizinische Hochschule of Hannover, Germany [33].
2.3. Spheroplasts preparation
Spheroplasts of P. aeruginosa PAO1 were prepared by adapting the
procedure described in [34]. Brieﬂy, bacteria from a log-phase culture
were collected by centrifugation at 3000 ×g and washed in 0.01 M
phosphate buﬀer, pH 7.0 (PB). The cells were then harvested by cen-
trifugation and resuspended in half-volume of 0.5 M sucrose solution in
PB to induce plasmolysis. Lysozyme was added to the cell suspension at
a ﬁnal concentration of 50 μg/ml. After incubation at 37 °C for 90 min
with moderate shaking, the sample was diluted 1:1 with PB and ethy-
lenediaminetetraacetic acid (EDTA) was added to a ﬁnal concentration
of 10 mM. The cell suspension was incubated again at 37 °C for addi-
tional 60 min. Thereafter, transition of the rod-shaped bacteria into
spheres was determined by light microscopy. When ~80% of the cells
were spheroplasted (as visualized by phase-contrast microscopy), the
reaction was stopped by pelleting the cells at 500 ×g for 15 min. The
spheroplasts were then washed in 0.25 mM sucrose in PB (SPB2),
centrifuged at 500 ×g for 15 min, and resuspended in SPB2.
2.4. Antimicrobial activity
Aliquots of 100 μl of SPB2 containing spheroplasts derived from
1 × 107 intact bacteria were treated with Esc(1-21) and its diaster-
eomer for 30 min at 37 °C. Afterwards, spheroplasts viability was as-
sayed by the reduction of MTT to insoluble formazan. Brieﬂy, 100 μl of
1 mg/ml MTT were added to the bacterial suspension, transferred into a
96-wells microplate, which was incubated for 90 min at 37 °C. The re-
duced formazan was then solubilized by the addition of an equal vo-
lume of 10% (w/v) SDS, measured in a microplate reader (Inﬁne M 200,
Tecan) at 590 nm. All assays were performed in triplicate, and the ex-
periments were repeated three times.
2.5. Sytox green assay on intact bacterial cells
The ability of the peptide to alter the membrane permeability of
whole Pseudomonas cells was assessed by the Sytox Green (~660 Da)
assay. Approximately 1 × 106 cells in 100 μl of phosphate buﬀered
Scheme 1. Amino acid sequence of Esc(1-21) and Esc(1-21)-1c.
The D-amino acids at position 14 and 17 are shown in green and
in italics.
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saline (PBS) were mixed with 1 μM Sytox Green for 5 min in the dark.
After adding peptides at diﬀerent concentrations, the increase of
ﬂuorescence, due to the binding of the dye to intracellular DNA, was
measured at 37 °C in the microplate reader (Inﬁnite M200). The ex-
citation and emission wavelengths were 485 and 535 nm, respectively.
Cells not exposed to the peptides were used as control, whereas the
maximal membrane perturbation was obtained after treating bacteria
with the highest peptide concentration used (32 μM) followed by the
addition of 1 mM EDTA +0. 5% Triton X-100 (ﬁnal concentration) to
completely destabilize the LPS-outer membrane and to solubilize the
cytoplasmic membrane [35]. Samples were run in triplicate and the
experiments were performed three times.
2.6. Preparation of large unilamellar vesicles (LUVs)
Lipid ﬁlms of POPE/POPG and POPC/Cho were prepared by dis-
solving lipids (2 mg of POPE⁄POPG mixture, 7:3, mol/mol or 2 mg of
POPC/Cho, 1:1, mol/mol) in chloroform⁄methanol (2:1, v/v). The
solvents were then evaporated under reduced argon atmosphere until a
thin ﬁlm was formed. Complete evaporation was ensured by applying a
rotary vacuum pump for at least 2 h. The lipid ﬁlm was then hydrated
with a 10 mM phosphate buﬀer containing 140 mM NaCl and 0.1 mM
EDTA, pH 7.4 (buﬀer A), or with a CF solution at a self-quenching
concentration, i.e. 30 mM (for CF leakage experiments) in 10 mM
phosphate buﬀer containing 80 mM NaCl and 0.1 mM EDTA, brought to
pH 7.4 with NaOH. The liposome suspension was subjected to 10 freeze
and thaw cycles and extruded for 31 times through two stacked poly-
carbonate membranes with 100 nm pores to obtain LUVs. The free CF
(when present) was removed by gel ﬁltration, using a 40 cm Sephadex
G-50 at room temperature, equilibrated with buﬀer A. NaF was used in
place of NaCl for CD experiments, to avoid the high absorption by Cl-
ions in the far UV [36]. The ﬁnal lipid concentration was determined by
the Stewart phospholipid assay [37].
2.7. CF leakage assay
CF release from LUVs due to membrane permeation induced by the
peptide was monitored at 37 °C by the ﬂuorescence increase (ex-
citation = 488 nm; emission = 520 nm). A concentration of lipid ve-
sicles of 200 μM was used and CF leakage after peptide addition at
20 μM was monitored for 30 min. Complete dye release was obtained
using 0.1% Triton X-100, which causes total destruction of lipid vesicles
[38,39]. The percentage of CF leakage was calculated according to the
following formula [40]: leakage (%) = 100(F1− F0) / (Ft− F0),
where F0 represents the ﬂuorescence of intact vesicles, and F1 and Ft
denote the intensities of the ﬂuorescence achieved by peptide and
Triton X-100 treatment, respectively, at diﬀerent time points, as in-
dicated. The experiments were performed in duplicate and repeated
three times.
2.8. Circular dichroism spectroscopy
In order to investigate the change in secondary structure of Esc(1-
21) and Esc(1-21)-1c in SDS and DPC micelles, circular dichroism (CD)
experiments were performed using a Jasco J-815 spectrometer (Jasco
International Co., Ltd. Tokyo, Japan) with a Peltier cell holder and
temperature controller unit accessory. CD spectra were recorded for
both the peptides in water (25 μM) and in the presence of diﬀerent
concentrations of SDS (peptide 25 μM, detergent 40 mM), DPC (peptide
25 μM, detergent 10 mM) at 37 °C, or in liposomes of POPE/POPG 7:3
(mol/mol) (peptide 5 or 20 μM, lipids up to 1 mM), at 25 °C. Both
working concentrations of SDS and DPC micelles were above previously
published critical micellar concentrations (CMC) [41]. The far-UV
spectra were scanned over a range of 190–260 nm with 1 nm data in-
terval and averaging over 4 scans. Blank sample spectra were sub-
tracted from the raw data and the CD values were converted to per
residue molar ellipticity ([θ]) (deg cm2 dmol−1).
2.9. Solution-state NMR experiments
All solution-state NMR experiments were executed on a Bruker
Avance III 700 MHz spectrometer furnished with a CryoProbe at 310 K
and/or 335 K. Topspin 3.1 (Bruker Biospin, Rheinstetten, Germany)
and SPARKY 3.113 (UCSF) was used for processing and analysis of NMR
data [42]. Two-dimensional total correlation (TOCSY) and nuclear
Overhauser eﬀect (NOESY) spectra of Esc(1-21) and Esc(1-21)-1c alone
(1 mM) and in the presence of perdeuterated d25-SDS (200 mM) and
d38-DPC (125 mM) were performed in aqueous solution comprising
10% D2O (pH ~4.5). All spectra were acquired at 1024 and 512 com-
plex data points along t2 and t1 dimensions, respectively, where the
States-TPPI-mode was used for quadrature detection in the t1 dimension
[43]. The spectral width was 12 ppm, the oﬀset was adjusted at the
water resonance (4.703 ppm) and the relaxation delay was of 2.0 s.
TOCSY spectra were acquired using the standard pulse sequence of the
pulse sequence library of the Bruker spectrometer, having excitation
sculpting for water suppression and spin-lock mixing times of 80 ms
(using MLEV-17 mixing scheme), whereas NOESY experiments with 80,
100, 150 and 250 ms mixing time were performed. Sequence-speciﬁc
resonance assignment was accomplished based on 2D TOCSY and
NOESY spectra of peptides in DPC micelles by means of standard as-
signment procedures [44]. All 1H chemical shifts were referenced using
DSS (2,2-Dimethyl-2-silapentane-5-sulfonate sodium salt) as an internal
standard.
2.10. NMR derived structure calculation
The three-dimensional solution NMR structures of Esc(1-21) and Esc
(1-21)-1c in DPC micelles were determined using the CYANA 2.1 soft-
ware [45]. From NOESY spectra of Esc(1-21) and Esc(1-21)-1c in SDS
and DPC micelles, NOE cross peak intensities were converted to upper
bound distance limits of 3.0, 4.0, and 5.5 Å, corresponding to strong,
medium, and weak intensities, respectively. The lower limits for all
distance restraints were kept at 2.0 Å. In addition, the dihedral angle
constraints were estimated from PREDITOR by means of CαH chemical
shifts and were used for structure calculations with± 20° variation,
from the derived dihedral angle values [46]. Several rounds of structure
calculation were performed for iterative reﬁnement using the standard
protocol of CYANA 2.1, as described previously [47,48]. Finally, the
best 20 structures with lowest target function values were selected,
depending upon low RMSD and minimum violation of distance and
dihedral angle constraint. The stereochemical nature of the ﬁnal
structures was analyzed using PROCHECK-NMR validation suite [49].
To estimate the convergence of NMR-derived ensemble of structures,
NH order parameters (S2) [50] for both the peptides were calculated.
2.11. Preparation of peptide-loaded liposomes for solid-state NMR
spectroscopy
Multilamellar vesicles (MLVs) were prepared by co-solubilization of
lipids [POPE:POPE-2H31:POPG (2:1:1)] and peptides at the appropriate
lipid-to-peptide molar ratio in chloroform/methanol 2:1 (v/v) to ensure
homogenous mixing of the components, followed by solvent evapora-
tion under a stream of nitrogen gas, removal of solvent traces by lyo-
philisation from a water suspension and then rehydration at h = 0.9
[h = mass of water over the total mass of the system (phospholipids
and water)]. To improve sample homogeneity the liposomes were re-
peatedly vortexed for 40 s, frozen in liquid nitrogen for 30 s and heated
in a water bath at 40 °C for 10 min. After 1 to 3 freeze-thaw-vortex
cycles, Esc(1-21) and Esc(1-21)-1c embedded in liposomes were ob-
tained.
M.R. Loﬀredo et al. BBA - Biomembranes 1859 (2017) 2327–2339
2329
2.12. Solid-state NMR spectroscopy
2H quadrupole echo experiments [51,52] were acquired with a
spectral width of 100 kHz, a recycle delay of 1 s, 25 μs echo delay,
30 ms acquisition time, π/2 pulses of 3.4 μs, and between 50 k and 80 k
scans. All samples were investigated at temperatures at least 15 K above
the phase transition of the individual lipids of the mixture.
Oriented 2H spectra were obtained from the powder pattern by de-
Pakeing [53] thus the splitting can be measured more easily. The de-
Paking procedure was performed according to the fast Fourier trans-
form-based deconvolution algorithm [54] and ﬁrst spectral moments
were calculated using the NMR-Depaker software (available from the
Launchpad Web site: https://launchpad.net/nmr-friend).
Individual Ce2H bond order parameters (SCDi) were calculated from
quadrupolar splittings as described previously [52,55],
=S 4 3Δv ACD Q Q (1)
where AQ is 167 KHz.
2.13. Average acyl chain length measurement
Calculation of acyl chain length is performed according to Douliez
et al. [56–60] and can be performed by considering the average pro-
jection of each CeC bond along the bilayer normal. This is achieved by
connecting the SCD order parameter to the CeC bonds order parameters
(SCC), and to sum all the average lengths of the aliphatic chain CeC
bonds, projected on the normal to the bilayer. The average length of an
aliphatic chain with an even number of carbons is obtained by the
following expression:
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where 〈lCn ‐D〉 represents the contribution of the terminal methyl
Cne2H bond, and Smol is the molecular order parameter (taking into
account wobbling motions).
By taking n = 14 for DMPC and DMPE and n = 16 for POPC and
POPE; Smol = 1, 〈lCn ‐D〉 is estimated equal to 1.09 Å cos (35,35°)
= 0.89 Å, and the angle between the Cne2H bond and CnleCn being
111° the equation reduces to:
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The order parameter SCC can be obtained after considering a fast
axial rotation of the methyl group around the CnleCn bond; hence, SCC
is obtained from measured SCD using the recurring equation
SnCC+Sn+1CC=−2SnCD. The order parameter for the nth term can be
obtained from:
=
°
S 3cos (111 )‐1
2
SnCD
2
n
CC
(4)
The area per lipid A is determined according to de Planque et al.,
and Nagle [61,62]:
= +A 2[27.6Å (1.27(0.5 Sp))]2 (5)
where Sp is the average order parameter of the plateau region (carbons
2–6).
2.14. Statistical analysis
Quantitative data were expressed as the mean ± standard devia-
tion (SD). Statistical analysis was performed using Student's t-test with
the PRISM software (GraphPad, San Diego, CA). Diﬀerences were
considered to be statistically signiﬁcant for p < 0.05 and are indicated
in the legend to ﬁgures.
3. Results
3.1. Cytoplasmic membrane perturbation
The diastereomer Esc(1-21)-1c was previously found to display a
potent killing activity against the planktonic form of reference and
cystic ﬁbrosis strains of P. aeruginosa [30]. However, this activity was
less pronounced than that of the parent Esc(1-21), as proved by the
corresponding minimal bactericidal concentration (MBC) causing
99.9% reduction in the number of viable cells within 30 min, in PBS.
This was 4 μM versus 1 μM of Esc(1-21) when tested against a bacterial
cell density of 1 × 106 CFU/ml [30].
To assess whether this diﬀerence reﬂected a diﬀerent perturbation
of the cytoplasmic membrane of this pathogen by the two peptides, a
Sytox Green assay was carried out on two diﬀerent bacterial strains: the
reference P. aeruginosa PAO1 and the clinical isolate P. aeruginosa
AA43. Sytox Green is a membrane-impermeable probe whose ﬂuores-
cence intensity rapidly enhances upon binding to nucleic acids of bac-
terial cells with damaged cytoplasmic membrane; and its ﬂuorescent
signal is positively correlated to the level of membrane injury. Note that
a signiﬁcantly higher number of bacterial cells (i.e. 1 × 107 CFU/ml)
than that generally used for in vitro antimicrobial assays is needed, in
order to get a detectable signal [29]. As reported in Fig. 1 for P. aeru-
ginosa AA43, both peptides were able to destabilize the bacterial
membrane, but with a higher potency and faster kinetics for Esc(1-21)
(see also the dose-response relationship after 5 min from peptide ad-
dition in the Supplementary Fig. S1). While almost total membrane
perturbation was achieved by Esc(1-21) within 5 min (at the con-
centrations of 16 μM and 32 μM, Fig. 1 and Fig. S1) or 15 min (in the
concentration range from 2 μM to 8 μM, Fig. 1), a signiﬁcantly weaker
and slower eﬀect was recorded for Esc(1-21)-1c (Figs. 1 and S1). With
reference to the latter, ~40% of membrane damage was caused at the
highest peptide concentration of 32 μM within 5 min (Fig. S1). The
degree of membrane injury gradually diminished in a dose-dependent
manner and became negligible at 1 μM. Diﬀerently, ~40% of mem-
brane perturbation was registered at 1 μM of Esc(1-21) at the same time
point of 5 min (Fig. S1). Similar results were also found for the re-
ference PAO1 [29] and ATCC 27853 strains (data not shown). These
data indicate a signiﬁcant discrepancy between the two peptides in
perturbing the cytoplasmic membrane of intact bacterial cells (i.e.
much more than the 4 times ratio observed for the MBC values).
3.2. Activity on spheroplasts of P. aeruginosa
To investigate whether the bacterial cell wall was a barrier that
diﬀerently interferes with the activity of the two peptides, their eﬀect
on Pseudomonas cells lacking of cell wall (i.e. spheroplasts) was studied.
The reference strain of P. aeruginosa PAO1 was employed for this pur-
pose and the peptides' eﬀect on the viability of its spheroplasts
(1 × 108 cells/ml) was evaluated by the MTT assay, 30 min after pep-
tide addition at diﬀerent concentrations, with respect to untreated
control cells. As shown in Fig. 2, the percentage of metabolically-active
spheroplasts after incubation with the all-L peptide at 2 μM was about
70%, while it dropped down to ~2% at 10 μM, in a dose-dependent
manner. In comparison, the activity of the diastereomer on spheroplasts
was lower, but the diﬀerence was much smaller than what was ob-
served on intact cells: Esc(1-21)-1c was only ~1.5-fold less eﬀective,
with an LD50 of 4.4 ± 0.5 μM versus 2.9 ± 0.5 μM of Esc(1-21).
3.3. Peptides' eﬀect on LUVs of diﬀerent composition
To expand our knowledge on the membrane perturbing activities of
Esc(1-21) and Esc(1-21)-1c, the leakage of CF entrapped in the water
volume inside liposomes made of both anionic and zwitterionic phos-
pholipid bilayers was evaluated. A CF concentration of 30 mM was used
to induce self-association and the consequent quenching of the dye
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[63]. After peptide administration, the membrane destabilization leads
to probe release and dissociation with a resulting ﬂuorescence increase.
Both peptides were tested at a concentration of 20 μM on POPE/POPG
liposomes (7:3 mol:mol, 200 μM), which mimic the lipid composition of
the anionic membrane of Gram-negative bacteria. After addition to the
lipid vesicles, Esc(1-21) gave rise to a 2-fold higher membrane-per-
turbing activity than the diastereomer, within 30 min (Fig. 3 panel A)
and this was consistent with the results on spheroplasts.
When the two isomers were used on zwitterionic liposomes made of
POPC/cholesterol (1:1, mol:mol) to simulate the neutral membrane of
mammalian cells, a 5-fold lower leakage of entrapped CF was found for
the diastereomer in comparison with its all-L counterpart (Fig. 3 panel
B) in line with the lower cytotoxicity of Esc(1-21)-1c on mammalian
cells [30,32].
3.4. Structural studies by CD and NMR spectroscopy
In parallel, studies aimed at understanding the structural properties
of the two peptides were performed by CD and multidimensional so-
lution-state NMR spectroscopy, in the presence of micellar and lipo-
somal membrane mimetics.
3.4.1. CD
The secondary structure of Esc(1-21) and Esc(1-21)-1c in mem-
branes, and their aﬃnity for lipid bilayers, was initially characterized
by CD spectroscopy, in the presence of increasing concentrations of
POPE/POPG liposomes (Fig. 4). Their spectra presented a single nega-
tive minimum around 200 nm, a characteristic spectral signature for
random coil conformations. By contrast, after addition of increasing
concentrations of vesicles, the appearance of two negative minima at
208 nm and 222 nm was indicative of α-helical conformations of both
peptide isomers, although to a lesser extent in the case of Esc(1-21)-1c
(Fig. 4, panels A and B). The change in CD intensity at a ﬁxed wave-
length upon binding is directly proportional to the amount of complex
formed.
= + − ∙θθ L θ θ f[ ]([ ]) [ ] ([ ] [ ] ) (6)free bound free bound
Here, [θ]([L]), [θ]free and [θ]bound are the values of molar ellipticity
(in our case at 222 nm) observed at a given lipid concentration [L], in
the absence of liposomes, and in the completely bound state, respec-
tively, and fbound is the fraction of membrane-bound peptide [64].
In an ideal water-membrane partition equilibrium, fbound depends on
lipid concentration according to the following equation, where Kp is an
apparent partition constant [63].
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Combining these two equations, the expected lipid dependence of
the molar ellipticity is given by
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In our case, unfortunately, signiﬁcant binding (and increase in he-
licity) took place only at lipid concentrations in the 100 μM range
(Fig. 4 panels C and D), so that in the experimentally useful range of
lipid concentrations (limited to 1 mM by the necessity to avoid
Fig. 1. Kinetics of cytoplasmic membrane permeabilization of the planktonic form of P.
aeruginosa AA43. Cells (1 × 107 CFU/ml) were incubated with 1 μM Sytox Green in PBS.
Once basal ﬂuorescence reached a constant value, the peptide was added (arrow, t= 0) at
diﬀerent concentrations and changes in ﬂuorescence (λexc = 485 nm, λems = 535 nm)
were monitored for 60 min and plotted as the percentage of membrane perturbation re-
lative to that obtained after treating bacteria with the highest peptide concentration
(32 μM) and the addition of 1 mM EDTA +0.5% Triton-×100. Data points represent the
mean of triplicate samples from a single experiment, representative of three diﬀerent
experiments. Cells not exposed to the peptide were used as control (Ctrl).
Fig. 2. Eﬀect of diﬀerent concentrations of Esc(1-21), red line, and its diastereomer, blue
line, on the viability of spheroplasts of P. aeruginosa PAO1, 30 min after treatment at
37 °C. Cell viability was determined by the MTT reduction to insoluble formazan (see
Materials and Methods) and is expressed as percentage with respect to the control (cells
not treated with the peptide). Data represent the mean ± SD of three independent ex-
periments performed in triplicate. The level of statistical signiﬁcance between samples
treated with Esc(1-21) and Esc(1-21)-1c are indicated as follows *p < 0.05,
***p < 0.001.
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Fig. 3. CF release from POPE⁄POPG (panel A) and
POPC/chol (panel B) LUVs (ﬁnal lipid concentration
200 μM) within 30 min after addition of peptides
(20 μM) at 37 °C. The percentage of leakage was cal-
culated according to the formula:
100(F1− F0) ⁄ (Ft− F0) as explained in the
Materials and Methods. Data points are means ± SD
of three independent measurements performed in du-
plicate. The diﬀerence between the two peptides was
signiﬁcant (p < 0.05).
Fig. 4. Top row: Circular dichroism spectra of Esc(1-
21) (panel A) and Esc(1-21)-1c (panel B), measured in
the presence of increasing lipid concentrations (POPE/
POPG 7/3, mol/mol). Peptide concentration: 20 μM,
lipid concentrations: 1 μM, 2 μM, 5 μM, 10 μM, 20 μM,
50 μM, 100 μM, 200 μM, 500 μM and 1 mM. The CD
spectra are colored from blue to red, in order of in-
creasing concentrations and following the order of
colors in the visible spectrum. Middle row: Mean re-
sidue ellipticity ([θ]) at 222 nm as function of lipid
concentrations, [peptide] = 20 μM (panel C) and
[peptide] = 5 μM (panel D), Esc(1-21) in red and Esc
(1-21)-1c in blue. Bottom row: Circular dichroism
spectra of Esc(1-21) (panel E) and Esc(1-21)-1c (panel
F), measured in the presence of SDS (broken line) and
DPC (solid line) (25 μM peptide, 40 mM SDS or 10 mM
DPC).
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scattering artefacts [65]) a plateau was not observed. For this reason,
data ﬁtting with the above equation was aﬀected by a large uncertainty
on the values of [θ]bound, and thus of Kp. However, the data are suﬃ-
cient to indicate that the latter constant is of the same order of mag-
nitude for the two peptides (~1 mM), although its value is possibly
higher for Esc(1-21)-1c (blue lines).
In order to characterize the conformation of the two peptides when
associated to a membrane-mimicking environment, CD spectra were
measured in the presence of SDS (broken line) and DPC micelles (solid
line), mimicking the anionic and zwitterionic composition of the outer
leaﬂet of the cell membrane of bacteria and mammalian cells, respec-
tively (Fig. 4, panels E, F). In this case, the smaller size of the amphi-
philic aggregates reduced light scattering eﬀects, compared to studies
in the presence of vesicles. Therefore, surfactant concentrations much
higher than the Kp values estimated for POPE/POPG liposomes could be
employed, thus favouring peptide association to the micelles. In all
cases, the spectral intensities typical of alpha helices were observed,
although this was less pronounced in the case of Esc(1-21)-1c (Fig. 4
panel F), probably as a consequence of the presence of D-amino acids.
The spectra in SDS exhibited a 222 nm intensity that is more negative
than the 208 nm peaks. This ﬁnding is often considered indicative of
the formation of helical aggregates [66].
3.4.2. NMR studies of Esc(1-21) and Esc(1-21)-1c in SDS and DPC
micelles
The conformational transition from random coil to α-helical in the
presence of membrane-mimicking environments, as detected by CD
spectra, motivated us to explore the peptide structures at atomistic
detail by high-resolution solution state NMR spectroscopy. DPC and/or
SDS assemble as small size detergent micelles which, in contrast to large
liposomes, provide appropriate systems for the structural analysis of
AMPs in membrane mimetic environments by multidimensional NMR
spectroscopy, due to fast tumbling of the peptide-micellar complex in
solution [67,68].
Fig. 5 shows the amide proton region of the one-dimensional 1H
NMR spectra of Esc(1-21) and Esc(1-21)-1c in water and in the presence
of SDS and DPC micelles. In water, both peptides displayed little dis-
persion and broad signals in the amide proton region of the spectra
whereas in the presence of zwitterionic DPC micelles the spectra were
not only well dispersed but also well resolved. The diﬀerence in one-
dimensional proton spectral pattern demonstrated that micelles in-
duced conformational transformation of both peptides with well-de-
ﬁned secondary structure. Moreover, in the presence of DPC micelles
the spectra were better dispersed when compared to their association
with SDS micelles, which can be accounted as diﬀerential conforma-
tional stabilization in the diﬀerent micellar environment.
Unfortunately, due to poor spectral resolution, in SDS micelles for both
peptides extensive peak overlap in the ﬁngerprint region of two-di-
mensional 1He1H NOESY and TOCSY precludes further analysis of the
2D spectra.
With the help of two-dimensional 1He1H TOCSY and NOESY
spectra, sequential resonance assignment of Esc(1-21) and Esc(1-21)-1c
in DPC was performed. It is noteworthy that the NOESY spectra in DPC
micelles contained the adequate number of sequential and medium-
range NOE cross peaks in comparison to the spectra in aqueous solution
(Fig. S2 in SI). Therefore, the lack of diagnostic NOEs for both peptides
in aqueous solution conﬁrmed the CD spectral analysis where random
coil conformations were observed. Diﬀerently, in zwitterionic DPC
micelles the peptides adopted a more ordered conformation, as reported
below. Intense sequential CαH/HN (i to i + 1) NOEs were observed for
all residues of both peptides (Fig. 6A and B). In addition, several
medium range CαH/HN (i to i + 2/i + 3/i + 4) NOEs were observed
for Esc(1-21) throughout the peptide (Fig. S2 A and Fig. 6A). Further-
more, the presence of medium range NH/NH (i to i + 2) NOE contacts
reinforced the α-helical conformation of Esc(1-21). Overall the dis-
tribution of medium range CαH/HN (i to i + 3/i + 4) as well as NH/
NH (i to i + 2) backbone NOEs throughout the sequence established an
α-helical conformation in DPC micelles for Esc(1-21), in good ac-
cordance with the CD spectral analysis.
On the other hand, Esc(1-21)-1c in DPC micelles contained less di-
agnostic CαH/HN (i to i + 2/i + 3/i + 4) NOEs in comparison to Esc
(1-21) (Fig. S2 B). Most of the medium range NOEs (i to i + 2/i + 3/i
+ 4) were observed in the N-terminal G1-N13 region (Fig. 6B). This
was also in agreement with the trend in backbone NH/NH (i to i + 2)
NOE patterns which showed that most NOEs are in the N terminal re-
gion such as I2/F4, F3/K5, S4/L6, K5/A7 while the C-terminal stretch,
having D-amino acid mutations at 14th and 17th position contained very
few NOEs such as K12/L14, N13/L15 and I16/G18.
The discrepancy in NOE distribution for both peptides indicated that
the N-terminal portion was mostly well-organized in the parent peptide
while the C-terminal region of Esc(1-21)-1c was relatively unstructured
and ﬂexible in zwitterionic DPC micellar environments. This was sup-
ported by the trend in the ΔHα values for each residue of Esc(1-21) and
Esc(1-21)-1c where the chemical shift deviation of the alpha proton
resonances from the reported values of random coil resonances pro-
vided information about the secondary structure of the peptide [69].
Here, a helical segment is characteristic of negative chemical shift de-
viation of ΔHα for consecutive 4 residues while a positive chemical shift
deviation is a signature of the beta sheet structure. In our systems in
DPC micelles, all the CαH resonances throughout the sequence of Esc(1-
21) and Esc(1-21)-1c experienced a downﬁeld trend for the CαH che-
mical shifts (Fig. S3). This chemical shift deviation is a signature of the
Fig. 5. Amide proton region of 1H NMR spectra of 1 mM Esc(1-
21) (left column) and of 1 mM Esc(1-21)-1c (right column) in the
absence of detergent (A), and in the presence of (B) 200 mM
perdeuterated DPC or (C) 125 mM perdeuterated SDS. The NMR
experiments were performed using a Bruker Avance III 700 MHz
spectrometer at pH ~4.5 and at 37 °C.
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predominance of α-helical conformations in DPC micelles. Moreover, it
was noted that the overall average chemical shift deviation was little
higher in case of Esc(1-21) in comparison to Esc(1-21)-1c. The diﬀer-
ence in average chemical shift deviation in the L14-G21 region was
almost double for Esc(1-21) in comparison to Esc(1-21)-1c in line with
the previous observation from NOESY spectra of both peptides.
3.5. Structure calculations for Esc(1-21) and Esc(1-21)-1c in DPC micelles
The NOESY derived distance constraints in conjunction with an-
gular constrains, obtained from PREDITOR, were used to elucidate the
three-dimensional conformations of Esc(1-21) and Esc(1-21)-1c pep-
tides in DPC micellar solution. For structure calculations of Esc(1-21), a
total of 190 distance restraints including 38 intra-residue, 85 sequential
and 67 medium range constraints were used while in the case of Esc(1-
21)-1c 39 intra-residue, 82 sequential and 44 medium range constraints
(as a total of 165 NOEs) were available (Table 1). It is also evident that
the number of medium range NOE constraints (i to i + 2/i + 3/i + 4)
was much less for Esc(1-21)-1c compared to Esc(1-21), which is also
reﬂected in the RMSD from the ensemble of the 20 lowest energy
structures, as reported below. The Esc(1-21) conformations converged
to a helical structure extending from I2 to G21 with an average root
mean square deviation (RMSD) for the backbone atoms (N, Cα, and C′)
and the heavy atoms of 0.31 ± 0.13 and 0.67 ± 0.14 Å, respectively.
On the other hand, the ensemble of conformations of Esc(1-21)-1c was
not precise and diverged especially at the C-terminal residues N13-G18
as designated by RMSD values of 0.96 ± 0.20 and 1.28 ± 0.21 Å for
backbone and heavy atoms, respectively. From the Ramachandran plot,
it was seen that the backbone dihedral angles (Φ, Ψ) accumulate in the
most favoured regions for most of the residues of both Esc(1-21) and
Esc(1-21)-lc, respectively.
In DPC micelles, Esc(1-21) adopted mainly α-helical conformations
with a tilt at the N-terminal end (Fig. 7 A and B), whereas the central
region of the α-helix was straight and amphipathic due to the presence
of several polar residues such as K5, K9, K10, N13 and K20, across one
face of the helix. In contrast, the other face of the helix consists of the
hydrophobic residues I2, F3, L6, A7, I11, L14, L15, I16 and L19. In the
N-terminal region of Esc(1-21), I2, F3 and L6 were in close vicinity;
thereby facilitating CH3-π interaction among β-branched side chains
and the phenyl ring of the respective residues. Collectively, the am-
phipathicity of Esc(1-21) was conserved in its structure so that the
cumulative hydrophobic and hydrophilic interactions governed the
peptide stabilization in DPC micelles. The amphipathic character was
also obvious from a representation emphasizing the separation of hy-
drophobic and hydrophilic residues on opposite sides of the helix.
Fig. 6. Summary of NOE contacts of Esc(1-21) and
Esc(1-21)-1c peptides in the DPC micelles. Left panel:
Bar diagram demonstrating diﬀerent (sequential,
medium range, and long range) NOE contacts of Esc
(1–21) (A) and Esc(1–21)-lc (B) in deuterated DPC
micelles. The intensity of the NOESY peaks are de-
signated by the thickness of the bars which are as-
signed as strong, medium, and weak during structure
calculation. CαH/NH (i to i + 3) NOEs are marked by
blue bars and CαH/NH (i to i + 4) NOEs are marked
by red bars. Right panel: A histogram displaying the
number and type (intra, sequential, medium) of NOEs
of Esc(1-21) (C) and Esc(1-21)-lc (D) as a function of
residue number in complex with DPC micelles. The
NOESY experiments (mixing time 150 ms) were per-
formed using Bruker Avance III 700 MHz spectro-
meter with 1 mM peptide in aqueous solution
(pH ~4.5) at 37 °C.
Table 1
Summarizes the information for the 20 ﬁnal NMR structures of Esc(1-21) and Esc(1-21)-
1c in DPC micelles.
Distance restrains Esc(1-21) Esc(1-21)-lc
Intra-residue (i–j = 0) 38 39
Sequential (| i–j | = 1) 85 82
Medium-range (2≤ | i–j |≤ 4) 67 44
Long-range (|i–j |≥ 5) 0 0
Total 190 165
Angular restraints 40 40
Ф (phi) 20 20
Ѱ (psi) 20 20
Distance restraints from violations (≥0.3 Å) 0 1
Deviation from mean structure (Å) 0.31 ± 0.13 0.96 ± 0.20
Average back bone to mean structure (G1-N13) 0.08 ± 0.02
Average heavy atom to mean structure 0.67 ± 0.14 1.28 ± 0.21
Ramachandran plot analysis for ensemble
% Residues in the most favourable and
additionally allowed regions
(98.4 + 1.6)
= 100
(90.0 + 6.6)
= 96.6
% Residues in the generously allowed Region 0 3.4
% Residues in the disallowed region 0 0
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(Fig. 7C).
In contrast, Esc(1-21)-1c in DPC micelles exhibits a partial α-helical
conformation only at the N-terminal region between residues I2-N13,
with an average backbone RMSD of 0.08 ± 0.02 (Fig. 8). However, the
helix breaks after residue N13, likely due to the presence of two D-
amino acids DL14 and DS17 [70]. It is also worth mentioning that the
polar residues K5, K9 and K12 of Esc(1-21)-1c are located on one face of
the N-terminal helical region, while the non-polar residues I2, F3, L6,
A7 and I11 are on the opposite face of the helix, thereby maintaining an
amphipathic character. Therefore, in comparison to Esc(1-21), Esc(1-
21)-lc adopts a partial helical conformation only at the N-terminal re-
gion (G1-K12) while the C-terminal region (N13-G21) is unstructured
and adopts a ﬂexible conformation, which is well supported by the
trend in NeH order parameter (S2) for both peptides (Fig. S3). An order
parameter of ~0.8 designates a well-deﬁned backbone conformation,
while smaller values indicate disorder. Both peptides exhibited similar
trends in the order parameters of the (G1-K12) region, which are almost
overlapping. The high order parameters indicate formation of well-
deﬁned backbone conformations for both Esc(1-21) and Esc(1-21)-1c.
However, due to the incorporation of D-amino acids in the C-terminal
part of Esc(1-21)-1c, the order parameter ﬂuctuates in the (N13-G21)
segment which supports the existence of poorly deﬁned backbone
conformations (Fig. S4). Collectively, close inspection suggests that the
main diﬀerence between both structures are in the C-terminal region
L14-G21 (Fig. 9).
3.6. Membrane disorder induced by both Esc(1-21) and Esc(1-21)-1c
To gain insight into how membrane insertion of these amphiphilic
peptides changes the fatty acyl chain packing of phospholipid bilayers,
solid-state 2H NMR spectra of membranes encompassing 75 mol% of
POPE and 25 mol% of PG lipid were recorded. To assess how the lipid
chain mobility and the conformational distribution of the methylene
segments is inﬂuenced by Esc(1-21) or its diastereomer, the quad-
rupolar splittings of the 2H NMR spectra were recorded and converted
into fatty acyl chain order parameter proﬁles. The corresponding order
parameter proﬁles of POPE-d31 are shown in Fig. 10 and display the
characteristic signature of bilayer packing, with a plateau of |SCD| va-
lues extending towards the 6th carbon position. The plateau regions
exhibit a value of ca. 0.23 for the pure lipid system and of ca. 0.21 for
membrane embedded with Esc(1-21) or Esc(1-21)-1c. In both cases, the
chain order of the POPE palmitoyl was found to be signiﬁcantly reduced
when compared to the pure lipid sample (Fig. 10). As outlined in the
methods section, the 2H NMR order parameters can be converted into
the thickness of the acyl chain region of the bilayer (< Lchain >) and
into the area per lipid (A) assuming that these values reﬂect the dis-
tribution of the acyl chain conformation. Therefore, one obtains<
Lchain > = 13.4 ± 0.1 Å for the pure system and 13.1 ± 0.1 Å upon
addition of 2 mol% Esc(1-21) or Esc(1-21)-1c. Although the diﬀerence
Fig. 7. Three dimensional solution structures of Esc(1-
21) in DPC micelles (PDB ID 5XDJ). Superposition of
backbone atoms (N, Cα, C′) of the 20 lowest energy
conformations of Esc(1–21) (A). Cartoon representa-
tion of side chain orientation of a representative NMR
structure of Esc(1–21) showing diﬀerent residues (B).
Electrostatic potential surface of Esc(1–21) showing
the distribution of polar and non-polar residues (C).
The hydrophobic and positively charged amino acid
residues are indicated by green and blue, respectively,
while all other residues are in white. These images
were produced using the PyMOL software.
Fig. 8. Three dimensional solution structures of Esc(1-21)-1c in DPC micelles. Superposition of backbone atoms (N, Cα, C′) of the 20 lowest energy conformations of Esc(1-21)-1c (A).
Cartoon representation of side chain orientation of a representative NMR structure of Esc(1-21)-lc showing diﬀerent residues (B). Electrostatic potential surface of Esc(1–21)-1c showing
the distribution of polar and non-polar residues (C). The hydrophobic and positively charged amino acid residues are indicated by green and blue, respectively, while all other residues are
in white. These images were produced using the PyMOL and Chimera software.
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in average thickness may appear small, the membrane disordering ef-
fects in the direct vicinity of the peptides are probably more pro-
nounced and the decreases in order parameters are signiﬁcant.
4. Discussion
Recently, the short-sized AMP Esc(1-21) and especially its diaster-
eomer Esc(1-21)-1c have been identiﬁed as encouraging candidates for
the development of new anti-infective agents, because of their unique
properties [30,32]. The diastereomer showed a relevant bactericidal
activity against the planktonic form of the bacterial pathogen P. aeru-
ginosa, albeit ~4-fold lower than that of Esc(1-21). Here, to investigate
the reasons accounting for this diﬀerence, the bacterial membrane
perturbation was initially assessed by the Sytox Green assay on intact
bacterial cells. Similarly to the bactericidal activity, but with a more
pronounced diﬀerence between the two peptides, a stronger and faster
membrane permeabilization was recorded for Esc(1-21). Therefore, it
can be stated that the weaker in vitro antibacterial activity of Esc(1-21)-
1c on the planktonic phenotype of the Gram-negative bacterium P.
aeruginosa, as compared to Esc(1-21) is mainly associated to a weaker
ability in perturbing the bacterial membrane of this pathogen with
consequent cell death. In general, such a diﬀerence can have three
origins [71–73]: a) a diﬀerent peptide ability in crossing the LPS outer
layer and reaching the target bacterial membrane; b) a diﬀerent aﬃnity
for the anionic bacterial membrane; c) diﬀerential eﬀects once the
peptides are bound to phospholipid bilayers.
Interestingly, when the eﬀect of the two peptides was tested on cells
devoid of cell wall i.e. spheroplasts of Pseudomonas instead of whole
bacterial cells, only a slightly more (1.5-fold) pronounced microbicidal
activity was obtained for the wild-type Esc(1-21) with respect to the
diastereomer. Similarly, when the two isomers were analyzed on an-
ionic model membranes, the all-L Esc(1-21) was found to induce ~2-
fold higher leakage of vesicle contents in comparison to Esc(1-21)-1c.
Indeed, CD studies indicated that the aﬃnities of the two peptides for
these membranes were only slightly diﬀerent, while solid-state NMR
studies revealed a similar eﬀect of the two peptides on the membrane
order parameters. Based on these observations, we can exclude that
diﬀerences in the antibacterial activity between the two esculentin-
derived peptides are mainly due to signiﬁcant diﬀerences in their
membrane aﬃnity (hypothesis b) or to a diﬀerent ability to aﬀect the
phospholipid bilayer of the cytoplasmic membrane once inserted into it
(hypothesis c). By exclusion, we are led to conclude that the bacter-
icidal activity of the diastereomer against planktonic P. aeruginosa cells,
compared to the parent peptide, is signiﬁcantly impaired by a diﬀerent
interaction with the cell wall components, including the LPS outer
membrane, which is lacking in spheroplasts. This is in agreement with
Fig. 9. Overlaid structures of Esc(1-21) (red) and Esc
(1-21)-1c (green) in DPC micelles. The N-terminal
helical segment (I2-N13) is superimposed nicely with
a backbone RMS deviation of 0.482.
Fig. 10. 2H solid state NMR spectra (A) and the cor-
responding SCD order parameters proﬁles (B) of
POPE:POPE2H31:POPG (2:1:1) at T= 310 K, in the
absence (black line) and presence of 2 mol% Esc(1-21)
(red line) and 2 mol% Esc(1-21)-lc (blue line), re-
spectively, with an estimated uncertainty of± 1%.
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previous studies revealing that the relative binding aﬃnity of Esc(1-
21)-1c to P. aeruginosa LPS is ~8-fold lower in magnitude than Esc(1-
21) binding to LPS and that a minor perturbation of LPS structure is
caused by the diastereomer when compared to Esc(1-21) [48].
In this work we have also seen how replacement of two amino acids
with the corresponding D-enantiomers in the C-terminal region of Esc(1-
21) is suﬃcient to obtain a peptide, Esc(1-21)-1c, with a reduced α-
helical content along with a lower tendency in perturbing zwitterionic
model membranes. This is in line with its reduced eﬀect on mammalian
cells compared to the all-L peptide, as indicated by the corresponding
concentrations causing 50% cell death (> 256 μM in comparison to a
LD50 ranging from 64 μM to 150 μM for the all-L peptide) [30]).
According to the literature, the ease of adopting stable amphipathic
three-dimensional folds, which for many peptides is achieved by α-helix
formation is an essential factor for AMPs to cause cytotoxicity [74,75].
As demonstrated by solution NMR studies in DPC micelles which si-
mulate the neutral membrane of mammalian cells, an α-helical struc-
ture is preserved along the entire amino acid sequence of Esc(1-21),
while a highly ﬂexible C-terminal arm is present in Esc(1-21)-1c. This is
attributed to the presence of D-amino acids at 14th and 17th position,
which break the stereo chemical integrity of the sequence made of L-
amino acids. This corroborates well previous structural studies of
naturally occurring AMPs e.g. magainin, cytolysin and melittin
[76–78].
Interestingly, a remarkable structural diﬀerence was observed be-
tween the two peptides either in aggregates of LPS, the major compo-
nent of the outer-membrane of Gram-negative bacteria or in DPC mi-
celles mimicking the lipid composition of the mammalian cell
membrane (Fig. S5). The main diﬀerence is at the C-terminal region
(N13-G18) of Esc(1-21)-lc (Fig. S5 B and Table 1), whose higher ﬂex-
ibility (RMSD = 0.96 ± 0.20 Å) (Table 1) may interfere with the
peptide ability to destabilize bacterial and mammalian cell membranes
in comparison to the parent Esc(1-21) [32].
Importantly, even though the two amino acid substitutions cause a
somewhat weaker activity of the peptide against free-living cells of P.
aeruginosa [30], a higher potency was shown by Esc(1-21)-1c against
the more resistant form of P. aeruginosa, that is its bioﬁlm community
[30].
Note that the lower antimicrobial activity against the planktonic
state of Pseudomonas is not in contradiction with its stronger eﬀec-
tiveness in killing the more dangerous bioﬁlm phenotype [79]. Com-
pared to the all-L peptide, Esc(1-21)-1c is more resistant to proteases
which are mainly produced by cells within bioﬁlms and much less by
free living bacteria [80]. This may prolong the residence time of the
diastereomer and therefore its exposure to the bacterial cells, resulting
in a prolonged antimicrobial eﬃcacy in comparison with the all-L
peptide, which would be rapidly degraded. In addition, it has been
lately demonstrated that D-amino acids can promote the disassembly of
the extracellular matrix of bioﬁlm cells [81,82].
Finally, it is worthwhile recalling that the diastereomer showed a
reduced cytotoxicity and anti-inﬂammatory activity [30] than the all-L
peptide. This would represent an advantage for the host immune re-
sponse to bacterial infection at the initial stage.
5. Conclusions
In this work we demonstrated how the cell wall of the free living
form of P. aeruginosa plays a major role in determining diﬀerences in
the antibacterial activity between the two esculentin isomers. Most
likely, a weaker binding of the diastereomer Esc(1-21)-1c to LPS and
presumably slower translocation into the target bacterial membrane
account for its weaker activity in comparison to the all-L peptide. The
slightly lower ability in binding and perturbing anionic phospholipid
bilayers for Esc(1-21)-1c contributes only in a small part to this dif-
ference, while the ﬁnal eﬀect on membrane thinning once the peptide is
inserted into the membrane is identical to that provoked by Esc(1-21).
Moreover, we showed how two L- toD- amino acid substitutions in
Esc(1-21) led to a lower tendency in perturbing zwitterionic model
membranes in line with the lower cytotoxicity of the diastereomer.
In summary, even if Esc(1-21)-1c has a weaker bactericidal activity
than the all-L peptide against the planktonic form of Pseudomonas, this
still occurs at a low micromolar range [30] and it comes with a sig-
niﬁcant higher peptide biostability, higher wound-healing activity, less
pronounced cytotoxicity and anti-inﬂammatory property [30]. Overall,
these ﬁndings represent a valuable compromise for the development of
a safer antibacterial agent with an extended in vivo activity. This is
supported by our recent in vivo eﬃcacy studies on the two selected
peptide isoforms [83]. Finally, besides providing information on the
structural organization of the two esculentin-derived AMPs, our data
may assist in the design of new anti-infective agents with optimized
biological properties.
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Esculentin-1a-Derived Peptides Promote Clearance of Pseudomonas
aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients
and Lung Cell Migration: Biochemical Properties and a Plausible
Mode of Action
Floriana Cappiello,a Antonio Di Grazia,a Li-av Segev-Zarko,b Silvia Scali,c Loretta Ferrera,d Luis Galietta,d Alessandro Pini,c
Yechiel Shai,b Y. Peter Di,e Maria Luisa Mangonia
Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italya; Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israelb;
Department of Medical Biotechnology, University of Siena, Siena, Italyc; U.O.C. Genetica Medica, Giannina Gaslini Institute, Genoa, Italyd; Department of Environmental
and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USAe
Pseudomonas aeruginosa is the major microorganism colonizing the respiratory epithelium in cystic fibrosis (CF) sufferers. The
widespread use of available antibiotics has drastically reduced their efficacy, and antimicrobial peptides (AMPs) are a promising
alternative. Among them, the frog skin-derived AMPs, i.e., Esc(1-21) and its diastereomer, Esc(1-21)-1c, have recently shown
potent activity against free-living and sessile forms of P. aeruginosa. Importantly, this pathogen also escapes antibiotics treat-
ment by invading airway epithelial cells. Here, we demonstrate that both AMPs kill Pseudomonas once internalized into bron-
chial cells which express either the functional or theF508 mutant of the CF transmembrane conductance regulator. A higher
efficacy is displayed by Esc(1-21)-1c (90% killing at 15M in 1 h). We also show the peptides’ ability to stimulate migration of
these cells and restore the induction of cell migration that is inhibited by Pseudomonas lipopolysaccharide when used at concen-
trations mimicking lung infection. This property of AMPs was not investigated before. Our findings suggest new therapeutics
that not only eliminate bacteria but also can promote reepithelialization of the injured infected tissue. Confocal microscopy in-
dicated that both peptides are intracellularly localized with a different distribution. Biochemical analyses highlighted that
Esc(1-21)-1c is significantly more resistant than the all-L peptide to bacterial and human elastase, which is abundant in CF lungs.
Besides proposing a plausible mechanism underlying the properties of the two AMPs, we discuss the data with regard to differ-
ences between them and suggest Esc(1-21)-1c as a candidate for the development of a newmultifunctional drug against Pseu-
domonas respiratory infections.
Pseudomonas aeruginosa is an opportunistic Gram-negativebacterium characterized by an intrinsic high resistance to
commonly used antimicrobials (1, 2) and by its ability to form
sessile communities, named biofilms (3–5). In this scenario, P.
aeruginosa infections can easily take over and affectmultiple organ
systems, such as the respiratory tract, particularly in cystic fi-
brosis (CF) patients (6–8). The most common mutation asso-
ciated with the CF phenotype is phenylalanine deletion at po-
sition 508 (F508) in the CF transmembrane conductance
regulator (CFTR) gene (9), encoding an ABC transporter that
functions as a chloride channel in themembrane of epithelial cells
(10). As a result of this mutation, the secretion of chloride ions
outside the cell is inhibited, resulting in the generation of a dehy-
drated and sticky mucus layer coating the airway epithelia (11,
12). This helps the accumulation of trapped microbes, including
P. aeruginosa, with deterioration of lung tissue and impairment of
respiratory functions (13–15).
Importantly, P. aeruginosa colonization of host tissues is trig-
gered by an initial attachment of the bacterium to epithelial cells
(7, 16) via a variety of surface appendages (e.g., flagella and pili)
(17–19). This is then followed by cell internalization, presumably
mediated by binding of the bacterial lipopolysaccharide (LPS; i.e.,
the major component of the outer membrane in Gram-negative
bacteria) to the CFTR (20–24). Other mechanisms include, e.g.,
interaction with asialoganglioside 1 (25). Invasion of host cells is a
common process used by different microbial pathogens to facili-
tate escape from immune factors and/or to assist systemic diffu-
sion and infection (26, 27). Intracellular persistence of bacteria
that spread into the respiratory tract of CF patients may be one of
the reasons responsible for the chronic nature of P. aeruginosa
lung infections (17). It protects the bacteria from the host defense
mechanisms and from the killing action of conventional antibiot-
ics that hardly enter epithelial cells (28). Hence, the discovery of
new antibiotics with new modes of action is highly demanding,
and naturally occurring antimicrobial peptides (AMPs) repre-
sent potential alternatives (29, 30). AMPs are produced by all
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living organisms as the first barrier against invading microor-
ganisms (31), and the majority of them are characterized by
having a net positive charge at neutral pH and the tendency to
form an amphipathic structure in a hydrophobic environment
(32, 33).
Recently, we studied a derivative of the frog skin AMP esculen-
tin-1a, esculentin-1a(1-21)NH2 [Esc(1-21) GIFSKLAGKKIKNLL
ISGLKG-NH2] (34, 35), corresponding to the first 20 residues of
esculentin-1a, as well as its diastereomer, Esc(1-21)-1c, contain-
ing two D-amino acids at positions 14 and 17 (i.e., D-Leu and
D-Ser, respectively). The data revealed that the two peptides have
strong bactericidal activity against both the planktonic and bio-
film forms of P. aeruginosa, with the diastereomer being more
active than the wild-type peptide on the sessile form of this patho-
gen (36). Furthermore, the diastereomer is more stable in human
serum (36). However, there are no studies on the effect of these
peptides on infected lung epithelial cells, and only limited infor-
mation is available for other AMPs.
Importantly, the ability of a peptide to restore the integrity of
damaged infected tissue, for example, by acceleratingmigration of
epithelial cells in addition to potent antimicrobial activity, would
make it a more promising candidate for the development of a new
anti-infective agent. Another advantage is the ability to resist deg-
radation by proteases. Here, we report on the effect of the two
esculentin-derived AMPs on the viability of bronchial epithelial
cells expressing a functional CFTR or a mutant form of CFTR
(F508-CFTR). Furthermore, we investigated the peptides’ abil-
ity (i) to kill a clinical isolate of P. aeruginosa, once internalized in
the two bronchial cell lines, and (ii) to stimulate migration of
bronchial cells in the presence of concentrations of LPS that better
simulate an infection condition by means of a pseudo-wound-
healing assay. To the best of our knowledge, this is the first dem-
onstration of cell migration induced by AMPs in the presence of
LPS. In addition, we studied the peptides’ distribution within
bronchial cells and their stability to elastase from P. aeruginosa
and human neutrophils. The data are discussed with regard to the
different biochemical properties of the two peptides, and a plau-
siblemechanism for their antimicrobial andwound-healing prop-
erties is proposed.
MATERIALS AND METHODS
Materials. Minimal essential medium (MEM), heat-inactivated fetal
bovine serum (FBS), and penicillin-streptomycin were from Euroclone
(Milan, Italy); puromycin, gentamicin, 3(4,5-dimethylthiazol-2yl)2,5-di-
phenyltetrazolium bromide (MTT), Triton X-100, AG1478, 4=,6-di-
amidino-2-phenylindole (DAPI), rhodamine, Mowiol 4-88, LPS from
P. aeruginosa serotype 10 (purified by phenol extraction), and elastase
from human leukocytes were purchased from Sigma-Aldrich (St. Luis,
MO). Elastase from P. aeruginosa was fromMillipore Merck (Merck, Mi-
lan, Italy). All other chemicals were reagent grade.
Peptides synthesis. Synthetic Esc(1-21) and its diastereomer, Esc(1-
21)-1c, as well as rhodamine-labeled peptides [rho-Esc(1-21) and rho-
Esc(1-21)-1c], were purchased fromChematek Spa (Milan, Italy). Briefly,
each peptidewas assembled by stepwise solid-phase synthesis using a stan-
dard F-moc strategy and purified via reverse-phase high-performance liq-
uid chromatography (RP-HPLC) to a purity of 98%, while the molecular
mass was verified by mass spectrometry.
Cells and bacteria. The following cell cultures were employed: im-
mortalized human bronchial epithelial cells derived from a CF patient
(CFBE41o-) transduced with a lentiviral system to stably express F508-
CFTR (F508-CFBE) or functional CFTR (wt-CFBE) (37). Cells were
cultured inMEM supplementedwith 2mMglutamine (MEMg) plus 10%
FBS, antibiotics (0.1mg/ml of penicillin and streptomycin), and puromy-
cin (0.5 g/ml or 2 g/ml for wt-CFBE or F508-CFBE, respectively) at
37°C and 5% CO2 in 75-cm
2 flasks. The bacterial strain used was an
invasive clinical isolate from the early stage of chronic lung infection, P.
aeruginosa KK1, from the collection of the CF clinic Medizinische Hoch-
schule of Hannover, Germany (38, 39).
Peptides’ effect on the viability of airway epithelial cells.The effect of
both peptides on the viability of wt-CFBE or F508-CFBE cells was eval-
uated by the MTT colorimetric method (40). MTT is a tetrazolium salt
which is reduced to a colored formazan product by mitochondrial reduc-
tases inmetabolically active cells. Briefly, about 4 104 cells suspended in
MEMg supplemented with 2% FBS were seeded in wells of a 96-well
microtiter plate. After overnight incubation at 37°C in a 5% CO2 atmo-
sphere, the medium was removed and 100 l of fresh serum-free MEMg
orHanks’ buffer (136mMNaCl, 4.2mMNa2HPO4, 4.4mMKH2PO4, 5.4
mM KCl, 4.1 mM NaHCO3, pH 7.2, supplemented with 20 mM D-glu-
cose), with or without the peptide at different concentrations, was added
to each well. After 2 h or 24 h, as indicated, at 37°C in a 5% CO2 atmo-
sphere, themediumwas replaced with 100l of Hanks’ buffer containing
0.5mg/mlMTT. The plate was incubated at 37°C and 5%CO2 for 4 h, and
the formazan crystals were dissolved by adding 100l of acidified isopro-
panol according to reference 41. Absorption of each well was measured
using amicroplate reader (InfiniteM200; Tecan, Salzburg, Austria) at 570
nm.The percentage ofmetabolically active cells compared to control sam-
ples (cells not treated with peptide) was calculated according to the for-
mula (absorbancesample  absorbanceblank)/(absorbancecontrol  absor-
banceblank) 100, where the blank is given by samples without cells and
not treated with the peptide.
Cell infection and peptide’s effect on intracellular bacteria. About
100,000 bronchial cells in MEMg supplemented with 10% FBS were
seeded in 24-well plates and grown for 2 days at 37°C and 5% CO2. The
clinical isolate KK1 was grown in Luria-Bertani broth at 37°C with mild
shaking (125 rpm) tomid-log phase (optical density of 0.8 at 590 nm) and
subsequently harvested by centrifugation. The pellet was then resus-
pended inMEMg and properly syringed using a 21-gauge needle to avoid
clump formation before infecting cells. A multiplicity of infection (MOI)
of 100:1 (bacteria to cells) was used. Two hundred microliters of this
bacterial suspension, containing about 1 107 CFU, was coincubated for
1 h with wt-CFBE/F508-CFBE at 37°C and 5%CO2. After infection, the
medium was removed and the cells were washed three times with MEMg
and then incubated for 1 h with a gentamicin solution (200 g/ml in
MEMg) to remove extracellular bacteria. Afterwards, the medium was
aspirated and the infected cells were washed three times as described
above. Two hundred microliters of Hanks’ solution with or without the
peptide at different concentrations was added to each well, and the plate
was incubated for 1 h at 37°C and 5% CO2. After peptide treatment, cells
were washed with phosphate-buffered saline (PBS) and lysed with 300 l
of 0.1%TritonX-100 in PBS for 15min at 37°C and 5%CO2. Each sample
was then sonicated in a water bath for 5min to break up possible bacterial
clumps, and appropriate aliquots were plated on agar plates for counting
of CFU after 24 h at 37°C.
In vitro cell migration assay. The ability of single peptides or P.
aeruginosa LPS to stimulatemigration of CF cells was evaluated by amod-
ified scratch assay, as reported previously (36). Briefly, special cell culture
inserts for live cell analysis (Ibidi, Munich, Germany) were placed into
wells of a 12-well plate. About 35,000 cells suspended in MEMg supple-
mented with 10% FBS were seeded in each compartment of the culture
insert and incubated at 37°C and 5%CO2 for approximately 24 h to allow
cells to grow to confluence. Afterwards, inserts were removed to create a
cell-free area (pseudo-wound) of approximately 500 m; 1 ml MEMg
with or without the peptide or LPS at different concentrations was added
to each well. Plates were incubated as described above to allow cells to
migrate, and samples were visualized at different time intervals under an
inverted microscope (Olympus CKX41) at4 magnification and photo-
graphed with a Color View II digital camera. The percentage of cell-cov-
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ered area at each time was determined by the WIMASIS Image Analysis
program.
In another set of experiments, cell migration was evaluated in the
presence of both LPS and Esc(1-21) or Esc(1-21)-1c at the indicated con-
centration. Furthermore, the implication of epidermal growth factor re-
ceptor (EGFR) in peptide-induced cell migration was analyzed by pre-
treating cells for 30 min with 5 M tyrosine phosphorylation inhibitor
tyrphostin (AG1478) (42).
Fluorescence studies. About 2  105 bronchial cells in MEMg sup-
plemented with 10% FBS were seeded on 0.13- to 0.17-mm-thick cover-
slips (properly put into 35-mmdish plates) and incubated at 37°C and 5%
CO2. After 24 h, samples were washed with 1 ml PBS and treated with 4
M rhodamine-labeled peptide or rhodamine (for control samples) in
MEMg. After 30 min and 24 h of incubation at 37°C and 5% CO2, cells
were washed four times with PBS and fixed with 700 l of 4% formalde-
hyde for 15min at room temperature. Afterwards, theywere washed twice
with PBS and stainedwithDAPI (1g/ml) for 5min at room temperature
to visualize the nuclei. After three additional washes, the coverslips were
mounted on clean glass slides using Mowiol mounting medium and ob-
served under an Olympus FV1000 confocal microscope with a 60 ob-
jective lens (oil). Data analysis was done usingOlympus Fluoview (version
4.1) and Image J. Results are reported as the ratio between the fluores-
cence intensity of rhodamine-labeled peptides in the cytoplasm versus
that in the nucleus.
Peptides’ stability to proteases. Peptides were dissolved in 10 mM
Tris-HCl, pH 7.5, at a final concentration of 1 mg/ml; afterwards, 130 l
was incubated with 4 g of human or bacterial elastase (final enzyme
concentration equal to 1 M). At the indicated time intervals, 30-l ali-
quots were withdrawn, diluted with 770 l of 0.1% trifluoroacetic acid
(TFA)–water, and analyzed by RP-HPLC and mass spectrometry. Liquid
chromatography was performed on a Phenomenex Jupiter C18 analytical
column (300 Å, 5 m, 250 by 4.6 mm) in a 30-min gradient, using 0.1%
TFA in water as solvent A and methanol as solvent B. Mass spectrometry
analysis was performed with a Bruker Daltonic ultraflex matrix-assisted
laser desorption ionization tandem time-of-flight (MALDI-TOF/TOF)
mass spectrometer on withdrawn samples as well as on HPLC-eluted
peaks.
Statistical analyses. Quantitative data, collected from independent
experiments, were expressed as themeans standard errors of themeans
(SEM). Statistical analysis was performed using two-way analysis of vari-
ance (ANOVA) with PRISM software (GraphPad, San Diego, CA). Dif-
ferences were considered to be statistically significant for a P value
of0.05. The levels of statistical significance are indicated in the legends
to the figures.
RESULTS
Peptides’ effect on the viability of lung epithelial cells. In a
previous study (36), it was reported that both Esc(1-21) and its
diastereomer, Esc(1-21)-1c, are not toxic to A549 epithelial
cells up to 64M, and that the diastereomer is substantially less
toxic when used at higher concentrations (36). Although A549
cells possess morphological and biochemical properties of al-
veolar epithelial cells (type II pneumocytes) (17), they do not
express CFTR (43, 44). Therefore, we studied the effect of both
esculentin peptides on the viability of airway epithelial cells
stably expressing the most common CFTR mutation (F508)
FIG 1 Peptides’ effect on the viability of bronchial epithelial cells. About 4 104 wt-CFBE (A and C) or F508-CFBE (B and D) cells were plated in wells of a
microtiter plate. After overnight incubation at 37°C in a 5%CO2 atmosphere, themediumwas replacedwith 100l freshMEMg supplementedwith the peptides
at different concentrations. After 2 h or 24 h, cell viability was determined byMTT reduction to insoluble formazan. Cell viability is expressed as a percentagewith
respect to the control (cells not treated with the peptide). All data are the means from four independent experiments SEM. The levels of statistical significance
between the two peptides are P values of0.05 (*),0.01 (**), and P0.0001 (****).
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and the corresponding wild-type cell line expressing a func-
tional CFTR.
As indicated by the results of the viability assay performed in
the cell culturemedium,MEMg (Fig. 1), the twopeptideswere not
toxic to either type of epithelial cells at a concentration range
between 2 M and 64 M within 2 h. However, the wild-type
peptide turned out to be toxic at 128 M, causing approximately
25% and 70% reduction in the percentage of metabolically active
wt-CFBE andF508-CFBE cells, respectively (Fig. 1A andB). Fur-
thermore, after a long-term treatment (24 h), the cytotoxicity of
Esc(1-21) became more pronounced, inducing about 20 to 25%
reduction of metabolically active epithelial cells at 32 M and 64
M (Fig. 1C and D). A higher cytotoxicity was recorded at 128
M, with60% and 90% killing of wt-CFBE and F508-CFBE
cells, respectively. Importantly, the diastereomer did not in-
duce any reduction in the percentage of metabolically active
cells (Fig. 1).
Peptides’ activity on bronchial cells infected by the CF clini-
cal isolate KK1. We monitored the effect of the two peptides on
wt-CFBE (Fig. 2A and B) and F508-CFBE cells (Fig. 2C and D)
after infection with a clinical isolate of P. aeruginosa (KK1 strain).
This strain was already shown to invade bronchial cells in vitro
(38). According to the published literature (25), P. aeruginosa
tends to target particular CF epithelial cells rather than making a
concerted attack on the whole population of cells. Figure 2 shows
the number of intracellular bacteria that were calculated either as
CFU per sample (Fig. 2A and C) or as percentage (Fig. 2B and D)
with respect to the peptide-untreated infected cells (control).
Note that the number of internalized bacteria (3,500 CFU) in
our control bronchial cells (Fig. 2A and C) was well correlated
with the previously found uptake of different P. aeruginosa strains
by CF airway epithelial cells (21).
The data shown in Fig. 2B reveal that the two peptides, at 5M,
caused about 15 to 20% killing of intracellular bacteria 1 h after
treatment. This is when they were used on wt-CFBE cells in
Hanks’ buffer. This condition was used to better simulate a phys-
iological environment without the presence of cell culture me-
dium components. However, the killing effect was more evident
in F508-CFBE cells (Fig. 2D), where 5 M Esc(1-21) and its
diastereomer caused an40%and 60%decrease in the number of
intracellular bacteria, respectively, compared to untreated in-
fected cells. Due to the negligible cytotoxicity of the diastereomer
Esc(1-21)-1c compared to the all-L isomer in Hanks’ buffer (see
Fig. S1 in the supplemental material), it was possible to use Esc(1-
21)-1c at higher concentrations without damaging host epithelial
cells. Interestingly, 10 M and 15 M Esc(1-21)-1c gave rise to
about 70% and 90% reduction in the survival of intracellular
bacteria in F508-CFBE (Fig. 2D), whereas only 50% bacte-
FIG 2 Effect of Esc(1-21) and its diastereomer, Esc(1-21)-1c, on the intracellular killing of P. aeruginosa KK1 in wt-CFBE (A and B) and F508-CFBE (C
and D) cells. About 1  105 cells were seeded in 24-well plates and grown to confluence. Afterwards, they were infected with the bacterium for 1 h;
nonadherent extracellular bacteria were removed upon antibiotic treatment, and infected cells were left untreated or were treated for 1 h with the peptide
at different concentrations, as indicated. Control samples (Ctrl) are peptide-untreated infected cells. The number of intracellular bacteria is expressed
either as CFU per sample (A and C) or as a percentage with respect to the control (B and D). All data are the means from four independent experiments
SEM. The levels of statistical significance between peptide-treated infected cells and control samples are P values of0.05 (*),0.001 (***), and0.0001
(****).
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rial killing in wt-CFBE cells was obtained after exposure to 15
M Esc(1-21)-1c (Fig. 2B). Note that the toxicity of Esc(1-21)
to bronchial cells when tested in Hanks’ buffer, compared to
that in MEMg (Fig. 1), could be due to the absence of medium
components that may affect its activity, resulting in lower cy-
totoxicity (Fig. 1).
Wound-healing assay in the presence of peptides, LPS, or
their combination. Since airway epithelium and CFTR have
been shown to play a crucial role in maintaining lung function
and wound repair (45), we investigated the effect of the two
peptides on the migratory activity of the bronchial cells in the
cell culture mediumMEMg. Both AMPs were able to stimulate
migration of wt-CFBE and F508-CFBE cells, as indicated by
their ability to induce 100% coverage of the pseudo-wound
field produced in the cell monolayer (by means of special cell
culture inserts) within 20 h at optimal concentrations of 10M
for Esc(1-21) (Fig. 3A and B) and 1 M for its diastereomer
(Fig. 3C and D). A slower cell migration speed was observed for
the mutant F508-CFBE, in agreement with a previous study
(45) that showed how the defective function of CFTR caused a
reduced lamellipodium area from the leading edge of airway
epithelial cells (46).
It is well known that following bacterial death or division, LPS
(the major component of the outer membrane of Gram-negative
bacteria) is released from the bacterial cell wall (6, 47). Recently, as
described in reference 48, it was demonstrated that the presence of
nontoxic levels of P. aeruginosa LPS accelerates wound repair in
airway epithelial cells. We therefore analyzed the effect of dif-
ferent concentrations of P. aeruginosa LPS on the migratory
activity of both wt-CFBE and F508-CFBE. As illustrated in
Fig. 4A and B, within 20 h LPS promoted the closure of a
500-m-wide gap created in a monolayer of wt-CFBE or
F508-CFBE cells at an optimal dose of 1,000 ng/ml or in the
range of 1,000 to 10,000 ng/ml, respectively. Alternately, when
LPS was used at higher concentrations (i.e., 15,000 ng/ml)
that can be found in the sputum of CF patients with chronic P.
aeruginosa lung infection (49), the coverage of the wounded
area was significantly slackened (Fig. 4A and B). To verify
whether this LPS concentration was lethal to the cells, a viabil-
ity assay was carried out. However, no cell damage was ob-
served up to 20 g/ml LPS, as indicated by the percentage of
metabolically active cells, which was comparable to that of con-
trol samples (data not shown). This correlates with the negli-
gible toxicity already found for LPS on both normal human
bronchial epithelial cells (48) and A549 cells (50).
Interestingly, the induction of cell migration was clearly
restored (Fig. 4C to F) when the LPS dosage that blocks the
closure of the wounded field was used in combination with the
optimal wound-healing concentration of Esc(1-21)-1c (1M).
A similar effect was noted when the inhibitory concentration of
LPS was mixed with a concentration of Esc(1-21) lower than its
optimal dosage in promoting migration of wt-CFBE and
F508-CFBE cells (4 M and 1 M, respectively) (Fig. 4C
to F).
FIG 3 Effect of Esc(1-21) and Esc(1-21)-1c on the closure of a pseudo-wound field produced in a monolayer of wt-CFBE (A and C) and F508-CFBE (B
and D). Cells were seeded in each side of an Ibidi culture insert and grown to confluence; afterwards, they were left untreated or were treated with the
peptide. Cells were photographed at the time of insert removal and examined for cell migration after 15, 20, and 24 h from peptide addition. The
percentage of cell-covered area at each time point is reported on the y axis. Peptide-untreated cells were used as a control (Ctrl). The data are the means
from four independent experiments SEM. The levels of statistical significance between Ctrl and treated samples are P values of0.05 (*),0.01 (**),
0.001 (***), and 0.0001 (****).
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Mechanism of peptide-induced cell migration. The airways
of healthy or CF human subjects express EGFR (42), which is
involved in the repair of damaged airway epithelium (51).
Hence, we examined whether the peptide-promoted cell mi-
gration was a process mediated by the EGFR signaling pathway.
For that purpose, we pretreated wt-CFBE cells with 5 M
AG1478, a selective inhibitor of EGFR tyrosine kinase (52),
before adding each of the two peptides at their optimal concen-
FIG 4 Effect of P. aeruginosa LPS alone (A and B) or in combination with Esc(1-21)/Esc(1-21)-1c (C to F) on the closure of a pseudo-wound field produced
in a monolayer of wt-CFBE (A, C, and E) and F508-CFBE (B, D, and F). Cells were seeded in each side of an Ibidi culture insert and grown to confluence;
afterwards, they were left untreated or were treated with LPS or LPS plus peptide. Cells were photographed at the time of insert removal and examined for
cell migration after 15, 20, and 24 h from addition of LPS or LPS plus peptide. The percentage of cell-covered area at each time point is reported on the
y axis. The control (Ctrl) used was cells not treated with LPS or peptide. All data are the means from four independent experiments SEM. The levels of
statistical significance of samples versus Ctrl (A and B) or LPS-treated (C and D) cells are P values of 0.05 (*), 0.01 (**), 0.001 (***), and 0.0001
(****). Micrographs showing representative results of wt-CFBE (E) or F508-CFBE (F) before (T0) and 24 h after (T24) treatment with the combination
of LPS and peptide (at the indicated concentrations in panels C or D) compared to samples treated with LPS are reported. The black linemarks the cell-free
area in samples after 24 h.
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trations in stimulating cell migration [10 M and 1 M for
Esc(1-21) and Esc(1-21)-1c, respectively]. A clear inhibition of
pseudo-wound closure was observed, as was shown by the sig-
nificantly lower percentages of cell-covered area at all time
intervals (15 h, 20 h, and 24 h), with respect to the results found
when the bronchial cells were not preincubated with the inhib-
itor (Fig. 5). These results highlight the involvement of EGFR
in the peptide-induced migration of bronchial cells. Similar
results were obtained with the mutant F508-CFBE (data not
shown).
Peptide distribution within bronchial cells. In order to know
the peptides’ distribution in wt-CFBE and F508-CFBE cells, we
used confocal microscopy and rhodamine-labeled peptides. As
reported in Fig. 6A andB, rho-Esc(1-21) wasmainly aligned to the
perinuclear region of the cell already after 30 min from its addi-
tion, as well as after 24 h. To address the possibility that rhoda-
mine facilitated the uptake of the peptide, we also used the
rhodamine dye not conjugated to the peptide. However, rho-
damine was not observed in the bronchial cells, as revealed by
the lack of fluorescence inside them (Fig. 6C and D). In com-
parison, in the case of rho-Esc(1-21)-1c, the fluorescence in-
tensity appeared to be evenly distributed within the cytosol and
nucleus (Fig. 6E and F). These findings were corroborated by
the quantitative analysis of fluorescence intensity of the two
peptides between the cytoplasm and nucleus in both types of
cells (Fig. 7).
Peptides’ susceptibility to human andP. aeruginosa elastase.
One of the main drawbacks in using AMPs for treatment of P.
aeruginosa lung infection is their susceptibility to enzymatic deg-
radation (53, 54). In particular, the lung environment of CF pa-
tients is rich in proteases, i.e., elastase from host neutrophils and
also from P. aeruginosa (55–57). Therefore, the stability of the two
peptides in the presence of both enzymes was studied. When elas-
tase from human leukocytes was used, Esc(1-21) was completely
degraded within 5 h (Table 1; see also Fig. S2 in the supplemental
material). In contrast, the diastereomer was highly stable, with
78% and 13% of nondegraded peptide after 5 h and 24 h of incu-
bation, respectively (Table 1). Mass spectrometry analysis con-
firmed the presence of one main peak at 2,185 Da correspond-
ing to the calculated molecular mass of Esc(1-21)-1c (see Fig.
S2). In comparison, when the human cathelicidin AMP LL-37
was used as a reference, 44% of the peptide remained after 5 h
of treatment but nothing was found after 24 h (Table 1). When
P. aeruginosa elastase was used, both LL-37 and Esc(1-21) were
completely degraded within 5 h (Table 1), while in the case of
Esc(1-21)-1c about 91% and 77% of nondegraded peptide was
detected after 5 h and 24 h, respectively (33% after 48 h, data
not shown).
Interestingly, mass spectrometry analysis of the samples re-
vealed the presence of peaks with different molecular masses than
those found after treatment with human elastase (see Fig. S3 in the
supplemental material), indicating different cleavage sites by the
two elastases either in the two esculentin isoforms (see Fig. S2 and
S3) or in LL-37 (see Fig. S4 and S5). Importantly, the main cleav-
age sites by human and bacterial elastase in Esc(1-21) were be-
tween Ile16 and Ser17 or between Asn13 and Leu14, respectively.
Note that these two peptide bonds flank each of the two D-amino
acids present in Esc(1-21)-1c (i.e., D-Leu14 and D-Ser17), thus
preventing their proteolytic cleavage by both enzymes compared
to the all-L peptide.
DISCUSSION
The airway epithelial surface represents an important place where
the host breaks off signals from inhaled microbial pathogens and
activates defense mechanisms to combat infections, especially in
chronic diseases. However, administration of exogenous mole-
cules endowed with anti-infective and/or immunomodulatory
properties are highly needed to speed up the recovery process (58).
Nevertheless, the challenge of treatment of respiratory infections
has been compounded by the increasing resistance of pathogens to
the commonly used drugs. Thus, new candidates are urgently
needed, among which AMPs represent a promising alternative.
With respect to this, Esc(1-21) and primarily its diastereomer
Esc(1-21)-1c have several advantages that support their develop-
ment as new antipseudomonal agents (6). However, no studies
were reported on the ability of these two peptides to clear intra-
cellular Pseudomonas, and only very limited information is docu-
mented for other AMPs with reference to this matter. Further-
more, the ability of AMPs to stimulatemigration of lung epithelial
cells in the context of a bacterial infection (e.g., in the presence of
pathogen-associated molecular patterns, such as LPS) should be
investigated in an attempt to develop a new drug that also has the
ability to restore the normal architecture of the injured lung tissue.
To the best of our knowledge, this has not yet been investigated for
AMPs.
Here, we demonstrated the killing of intracellular Pseudomo-
nas in bronchial cells with functional or mutated CFTR upon 1 h
of exposure to the esculentin peptides. A significantly higher effi-
cacy is displayed by the diastereomer Esc(1-21)-1c.
Note that conventional antibiotics (e.g., penicillins, cepha-
losporins, and aminoglycosides) are not ideal choices for treat-
FIG 5 Effect of AG1478 inhibitor on the peptide-mediated migration of
wt-CFBE cells. Before removing the Ibidi culture insert, cells were prein-
cubated with 5 M AG1478 for 30 min and subsequently treated with 10
M Esc(1-21) or 1 M Esc(1-21)-1c. Some samples were treated with the
peptide alone at the same concentration or with 5 M AG1478. Cells in-
cubated withMEMg served as a control (Ctrl). Samples were photographed
at different time intervals as indicated, and the percentage of cell-covered
area was calculated and reported on the y axis. The data are the means from
four independent experiments SEM. The levels of statistical significance
between Ctrl and AG1478-treated samples or between samples pretreated
with AG1478 before incubation with the peptide and those treated with the
peptide alone at the corresponding time intervals are P values of0.05 (*)
and 0.0001 (****).
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ing invasive infections due to their inability to penetrate the
plasma membrane (59, 60). An exception is fluoroquinolones,
e.g., ciprofloxacin (61), which is currently used due to its
strong activity against Gram-negative bacteria in spite of its
toxicity (62) and the increasing number of bacteria that are
resistant to it (63). Remarkably, the diastereomer had activity
comparable to that of ciprofloxacin, which was found to cause
64%, 77%, and 98% killing of intracellular bacteria when
tested under our conditions on infected F508-CFBE at 1 M,
5 M, and 15 M, respectively (data not shown).
By means of rhodamine-labeled peptides and confocal mi-
croscopy analysis, we visualized an intracellular localization of
the two molecules in which Esc(1-21) has a prevalent perinu-
clear distribution. No vesicular pattern of fluorescence was ob-
served, excluding an endocytotic mechanism of peptide up-
take, which was shown in the case of Syn B peptides (64) and
LL-37 in A549 cells after 30 min of incubation (65). A plausible
explanation is that both esculentin isomers enter the cell by a
self-translocation process through peptide-inducedmembrane
lipid destabilization without affecting cell viability (66). In-
deed, when tested at noncytotoxic concentrations, the peptides
were able to perturb the membranes of both wt-CFBE and
F508-CFBE cells, as indicated by the increased fluorescence
intensity of the small-sized membrane-impermeable dye Sytox
green, upon peptides’ addition to the cells (data not shown).
This reflects the intracellular influx of Sytox green, presumably
due to a mild membrane destabilization caused by the peptides
during their translocation across the cytoplasmic/nuclear
membrane into the cytosol/nucleus, respectively. Overall, we
can assume that the clearance of intracellular Pseudomonas is
FIG 6 Confocal laser-scanning microscopy images of wt-CFBE and F508-CFBE cells treated with rho-Esc(1-21) (A and B), rhodamine alone (C and D), or
rho-Esc(1-21)-1c (E and F) at different times. After treatment with the peptide (or rhodamine), cells were stained with DAPI for nucleus detection. DAPI
fluorescence, rhodamine-labeled peptide (or rhodamine) signal, and the overlay of the two fluorescent probes are shown. All images are z sections taken from the
mid-cell height. All bars represent 10 m.
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due mainly to the interaction of the internalized peptides with
the bacterial cells. A possible reason for the weaker efficacy of
the all-L peptide Esc(1-21) in killing intracellular bacteria com-
pared to its diastereomer is related to a stereochemical binding
of Esc(1-21), but not Esc(1-21)-1c, to intracellular compo-
nents, making it less available. In addition, Esc(1-21) is ex-
pected to be more susceptible to virulence factors, i.e., pro-
teases released from intracellular P. aeruginosa. It is worth
mentioning that the fluorescence intensity cannot tell us if the
peptide is intact or partially degraded or whether it is present in
an inactive form. Furthermore, the intranuclear location of the
peptides suggest additional mechanisms to boost their antimi-
crobial potency, e.g., by directly/indirectly upregulating the
expression of genes involved in host cell protection from mi-
crobial pathogens.
Another important finding in this study is the pseudo-
wound-healing activity of the two peptides in both wt-CFBE
and F508-CFBE cells. As reported for A549 cells (36), the
diastereomer is more effective in inducing reepithelialization
of the wounded area, with a mechanism that implies an EGFR-
mediated signaling pathway. We think that the lower wound-
healing efficacy of the more helical Esc(1-21) compared to its
diastereomer is a consequence of a stronger alteration of the
phospholipid membrane region where EGF receptors are lo-
cated. This would impair the binding of ligands to EGFR with a
resulting weaker EGFR activation (36). However, the discrep-
ancy between the two peptides in the wound-healing activity
may also be related to a difference in the binding affinity of the
two AMPs to the target receptor (presumably EGFR or mem-
brane-boundmetalloproteases [42, 66]). Furthermore, we can-
not rule out the participation of alternative processes in con-
trolling migration of bronchial cells. One of them could imply
CFTR (especially in mutant cells) via a yet-to-be-discovered
mechanism.
Here, we also demonstrated for the first time that bronchial
cell migration stimulated by both esculentin isomers is main-
tained in the presence of high concentrations of LPS, presum-
ably found in CF sputum (49), and different plausible mecha-
nisms underlying such events are discussed below. LPS has
been found to regulate wound repair in airway epithelial cells
through a signaling pathway triggered by its binding to Toll-
like receptor 4 (TLR-4) (expressed on the airway epithelial
cells) and implicating activation of EGFR (48, 67). Note that
LPS binds TLR-4 in its monomeric form (68). However, in
aqueous environments, micellar assemblies of LPS are formed
above its critical micellar concentrations (14,000 ng/ml) (68,
69). This may hamper the binding of LPS to TLR-4, thus explain-
ing the inhibitory pseudo-wound-healing effect of LPS when used
at high concentrations (i.e.,15,000 ng/ml) (Fig. 4A and B). Note
also that there is a reestablishment of the migratory activity of
bronchial cells when LPS (at its inhibitory concentration) is com-
bined with Esc(1-21)-1c (at the optimal wound-healing dosage of
1 M) (Fig. 4C and D). This is presumably due to the diaste-
reomer-induced reepithelialization process regardless of the
presence of LPS. In contrast, a different mechanism would
likely account for the increased pseudo-wound-healing activity
of Esc(1-21) when combined with high concentrations of LPS
(Fig. 4C and D) compared to the results found when the pep-
tide is used alone at the same concentrations (Fig. 3A and B). As
previously reported, Esc(1-21) is more efficient than its diaste-
reomer in disrupting LPS micelles (36). Such LPS disaggrega-
tion might be sufficient to reset the availability of LPS mono-
mers for an optimal binding to TLR-4 and retrieval/
improvement of wound-healing activity.
Importantly, we also proved that the incorporation of two D-
amino acids at specific positions in Esc(1-21) makes the peptide
significantly more resistant to degradation by both human and
bacterial elastases.
In conclusion, we have shown that (i) a derivative of a frog
skin-derived AMP, and particularly its designed diastereomer,
rapidly kills Pseudomonas cells once internalized in CF bronchial
cells; (ii) the peptides accelerate bronchial cell migration under
conditions that better simulate lung infection in CF (e.g., in the
presence of LPS); and (iii) the diastereomer has an overall higher
efficacy than the all-L parent isoform. These findings are very im-
portant for the generation of new antimicrobial drugs that not
only eliminate microbial pathogens but also would recover the
tissue’s integrity.
In this specific case, the aforementioned properties of Esc(1-
21)-1c, together with its higher biostability to elastases and unde-
tectable cytotoxicity compared to wild-type Esc(1-21), support
further studies toward the development and usage of the former
peptide for local treatment of P. aeruginosa-induced lung infec-
tions.
FIG 7 Peptide distribution between cytoplasm and nucleus in wt-CFBE
and F508-CFBE cells. Each peptide was tested on a minimum of 35 cells.
The ratio between the fluorescence intensity of rhodamine-labeled pep-
tides in the cytoplasm versus the nucleus was calculated for each cell, and
the mean SEM value was reported on the y axis. If the ratio is equal to 1,
this means that the peptide is evenly distributed all over the cell. When the
ratio is higher than 1, the amount of fluorescent peptide is higher in the
cytoplasm than the nucleus. The level of statistical significance between
the calculated ratios of the two peptides at different time points is indicated as
a P value of0.001 (***).
TABLE 1 Peptide amount after 5 and 24 h of incubation with human
and P. aeruginosa elastase at 37°C
Peptide designation
Peptide remaininga (%) by elastase type
Human P. aeruginosa
5 h 24 h 5 h 24 h
Esc(1-21) 0 0 0 0
Esc(1-21)-1c 78 13 91 77
LL-37 44 0 0 0
a Peptide amounts were determined by the peak areas of the RP-HPLC relative to those
of the control peptide (dissolved in buffer) at 0 min (set as 100%).
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higher activity in promoting migration of lung epithelial cells, 
and presumably in healing damaged lung tissue, and (5) disag-
gregates and detoxifies the bacterial lipopolysaccharide (LPS), 
albeit less than the wild-type. Light scattering studies revealed 
a correlation between anti-LPS activity and the ability to dis-
aggregate the LPS. Besides shedding light on the multifunc-
tion properties of esculentin-1a(1-21)NH2, the d-amino acid 
containing isomer may serve as an attractive template for the 
development of new anti-Pseudomonal compounds with addi-
tional beneficial properties. Furthermore, together with other 
studies, incorporation of d-amino acids may serve as a general 
approach to optimize the future design of new AMPs.
Keywords Diastereomer · Wound healing · Anti-biofilm 
activity · Antimicrobial peptide · Esculentin-1
Abbreviations
AMP  Antimicrobial peptide
CD  Circular dichroism
CFU  Colony-forming units
DMEMg  Dulbecco’s modified Eagle’s medium supple-
mented with glutamine
FBS  Heat-inactivated fetal bovine serum
LB  Luria–Bertani broth
LPC  Lysophosphatidylcholine
LPS  Lipopolysaccharide
MTT  3(4,5-Dimethylthiazol-2yl)2,5-diphenyltetrazo-
lium bromide
PBS  Phosphate buffered saline
Introduction
During the past three decades, the widespread use of con-
ventional antibiotics has led to a drastic reduction in their 
Abstract Naturally occurring antimicrobial peptides 
(AMPs) represent promising future antibiotics. We have pre-
viously isolated esculentin-1a(1-21)NH2, a short peptide 
derived from the frog skin AMP esculentin-1a, with a potent 
anti-Pseudomonal activity. Here, we investigated additional 
functions of the peptide and properties responsible for these 
activities. For that purpose, we synthesized the peptide, as well 
as its structurally altered analog containing two d-amino acids. 
The peptides were then biophysically and biologically investi-
gated for their cytotoxicity and immunomodulating activities. 
The data revealed that compared to the wild-type, the diastere-
omer: (1) is significantly less toxic towards mammalian cells, 
in agreement with its lower α-helical structure, as determined 
by circular dichroism spectroscopy; (2) is more effective 
against the biofilm form of Pseudomonas aeruginosa (respon-
sible for lung infections in cystic fibrosis sufferers), while 
maintaining a high activity against the free-living form of 
this important pathogen; (3) is more stable in serum; (4) has a 
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therapeutic efficacy with over 70 % of hospital bacte-
rial infections being resistant to them (Chen et al. 2009; 
Grundmann et al. 2011; Kaye 2012). This has resulted in 
more difficult and costly treatments, longer hospitaliza-
tion, higher risk of complications and increase in death. 
Furthermore, the number of new antibiotics approved by 
the FDA has steadily declined every year since 1980 and 
most therapeutics in clinical development are derivatives 
of existing medicines (Lohner and Staudegger 2001). 
Hence, the discovery of new classes of antimicrobial 
agents with a new mode of action is a major challenge. 
Cationic antimicrobial peptides (AMPs) are ancient ele-
ments of the innate immune defense of all living organisms 
(Boman 1995; Mangoni 2011; Yeung et al. 2011; Bevins 
2013; Kai-Larsen et al. 2014; Mansour et al. 2014) with 
common properties, e.g., a net positive charge at neutral 
pH and an amphipathic character in a hydrophobic envi-
ronment (Epand and Vogel 1999; Shai 2002). They hold 
promise for the generation of new drugs (Hancock and 
Sahl 2006; Dempsey et al. 2010; Alba et al. 2012; Guralp 
et al. 2013; Haney and Hancock 2013) and are consid-
ered as future compounds against both acute and chronic 
microbial infections (Brown and Hancock 2006; Cruz 
et al. 2014). Of particular interest are those caused by the 
multidrug-resistant biofilm-forming gram-negative bacte-
rium Pseudomonas aeruginosa in the lungs of cystic fibro-
sis (CF) sufferers (Drenkard and Ausubel 2002; Bjarn-
sholt et al. 2009; Millar et al. 2009; Macia et al. 2014). 
In these patients, the lack of Cl− secretion promotes air-
ways drying and mucus plugging, predisposing the lungs 
to microbial colonization, deterioration of lung tissue and 
impairment of respiratory functions (Moreau-Marquis 
et al. 2008). Since the mechanism of killing by the major-
ity of AMPs includes an irreversible membrane injury, it 
makes it difficult for the bacteria to develop resistance 
against them (Shai 2002; Mangoni 2006; Mangoni et al. 
2007), although some AMPs have been reported to induce 
limited resistance (Peschel et al. 1999). Noteworthy, anti-
biotic treatment of gram-negative bacteria is accompanied 
with the release of bacterial cell wall components, such as 
the lipopolysaccharide (LPS), also named endotoxin. LPS 
activates immune cells (Rietschel et al. 1994), leading to 
the secretion of pro-inflammatory cytokines e.g., tumor 
necrosis factor-alpha (TNF-α) whose high levels can dam-
age lung functionality and cause septic shock syndrome, 
in the most serious cases (Poltorak et al. 1998; Cohen 
2002). Regarding this, several AMPs have already shown 
additional properties, including the capability to neutral-
ize the toxic effect of LPS (Hancock et al. 2012; Pulido 
et al. 2012). This makes them important modulators of 
both adaptive and innate immunity, and distinguishes them 
from traditional antibiotics (Hancock and Sahl 2006; Fjell 
et al. 2012; Hancock et al. 2012; Semple and Dorin 2012).
Recent studies demonstrated that esculentin-1a(1-21)
NH2 [Esc(1-21)] derived from the N-terminal region of 
the 46 residues frog skin AMP esculentin-1a (Gamberi 
et al. 2007; Islas-Rodriguez et al. 2009) is endowed with 
antimicrobial activity at high ionic concentrations, which 
is a crucial aspect due to the high-salt environment exist-
ing at the apical side of CF epithelial cells. In addition, 
in vivo experiments revealed that Esc(1-21) prolongs sur-
vival of murine models of P. aeruginosa-induced sepsis or 
lung infection, upon intravenous or intra-tracheal admin-
istration, respectively (Luca et al. 2013). Despite this and 
other studies showing an in vivo antimicrobial activity of 
AMPs (Giacometti et al. 2006; Pini et al. 2010; Uccel-
letti et al. 2010; Xiong et al. 2011; Luca et al. 2014; Jung 
Kim et al. 2014; Kolar et al. 2015), inherent limitations for 
the development of these molecules as new anti-infective 
therapeutics include: (1) cytotoxicity outside their natu-
ral environment, which can strongly dampen the in vivo 
antimicrobial efficacy of AMPs, and (2) problems with 
stability, bioavailability and delivery systems. With refer-
ence to the latter, studies on the effect of the incorporation 
of d-amino acids into AMPs were mainly focused on the 
antimicrobial activity of the peptides, their reduced cyto-
toxicity and their increased stability to circulating enzymes 
(Hamamoto et al. 2002; Papo et al. 2002). However, before 
AMPs can be clinically used, evaluation of other beneficial 
properties (e.g., anti-inflammatory, wound healing) should 
be also investigated. Here, we report on the synthesis and 
properties of a diastereomer of Esc(1-21), named Esc-1a(1-
21)-1cNH2 [Esc(1-21)-1c], containing two d-amino acids, 
and compared its multiple functions with those of the wild-
type Esc(1-21). The results are discussed in line with the 
advanced properties of the diastereomer as a potential non-
toxic wound healing promoter in addition to its antimicro-
bial activity.
Materials and methods
Materials
Trypsin–EDTA was purchased from Invitrogen (Life-
Technologies Europe, Monza, Italy); 3(4,5-dimethylthia-
zol-2yl)2,5-diphenyltetrazolium bromide (MTT), Triton 
X-100, AG1478, mitomycin C, Hoechst 33258, LPS from 
P. aeruginosa serotype 10, lysophosphatidylcholine (LPC, 
(1-0-palmitoyl-sn-glycero-3-phosphocholine) were all 
from Sigma–Aldrich (St. Luis, MO). Dulbecco’s modi-
fied Eagle’s medium (DMEM); non-essential amino acids 
(NEAA); sodium pyruvate (100 mM); heat-inactivated fetal 
bovine serum (FBS); glutamine; penicillin/streptomycin 
were from Euroclone (Milan, Italy). All other chemicals 
were reagent grade.
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Peptides synthesis
Synthetic Esc(1-21) and the diastereomer Esc(1-21)-1c 
were purchased from Selleck Chemicals (Houston, TX, 
USA). Briefly, the peptides were assembled by step-wise 
solid-phase synthesis by a standard F-moc strategy and 
purified by RP-HPLC on a semipreparative C18-bonded 
silica column (Kromasyl, 5 μm, 100 Å, 25 cm × 4.6 mm) 
using a gradient of acetonitrile in 0.1 % aqueous trifluoro-
acetic acid at a flow rate of 1.0 ml/min, according to what 
reported in (Luca et al. 2013). Analytical RP-HPLC indi-
cated a purity >98 %. The molecular mass was verified by 
using MALDI-TOF Voyager DE (Applied Biosystems) as 
previously described (Islas-Rodriguez et al. 2009).
Peptide stability
A total of 125 μl of a 0.92 mM solution of peptide was 
incubated at 37 °C with 20 and 60 μl human serum. Sam-
ples were collected from healthy volunteers after 5 and 
24 h of incubation, precipitated with 200 μl methanol, and 
centrifuged for 2 min at 10,000×g. The crude solution was 
then analyzed by HPLC and mass spectrometry. HPLC 
was performed with a Vydac C18 column, and the crude 
solution was diluted 5 times with 0.1 % trifluoroacetic acid 
before injection, and monitored at 280 nm.
Microorganisms
The strains of P. aeruginosa used for the antimicrobial 
assays were: the standard non mucoid ATCC 27853 (Li 
et al. 2001), and the following ones from collection of the 
CF clinic Medizinische Hochschule of Hannover, Ger-
many: the mucoid AA11 and the non-mucoid TR1 and 
KK1 (Bragonzi et al. 2009).
Cell culture
The murine Raw 264.7 macrophage cell line and the human 
type II alveolar epithelial cell line A549 (from the Ameri-
can Type Culture Collection, Manassas, Va) were employed 
(Akram et al. 2013). Cells were cultured in DMEM sup-
plemented with 10 % FBS, glutamine (2 mM), and antibi-
otics (0.1 mg/ml of penicillin and streptomycin) at 37 °C 
and 5 % CO2 in 25-cm
2 flasks. In the case of macrophages, 
NEAA and sodium pyruvate were also added to the culture 
medium.
Antimicrobial activity
Bacteria were grown in Luria-Bertani (LB) broth at 37 °C 
till a mid-log phase which was aseptically monitored by 
absorbance at 590 nm (A590nm = 0.8) with an UV-1700 
Pharma Spec spectrophotometer (Shimadzu, Tokyo, Japan). 
Afterwards, bacterial cells were centrifuged at 1400×g 
for 10 min and resuspended in phosphate buffered saline 
(PBS).
About 1 × 105 colony-forming units (CFU) in 100 μl 
PBS were incubated at 37 °C with Esc(1-21) or Esc(1-
21)-1c in serial twofold dilutions. Aliquots of 10 μl were 
withdrawn at different time intervals, diluted in LB and 
spread onto LB-agar plates. After overnight incubation at 
37 °C, the number of CFU was counted. Controls were 
run without peptide and in the presence of peptide solvent 
(Luca et al. 2013).
Bactericidal activity was defined as the peptide concen-
tration necessary to cause a reduction in the number of via-
ble bacteria of ≥3 log10 CFU/ml.
Antibiofilm activity
Biofilm formation was performed by adapting the proce-
dure described in (Ceri et al. 2001; Falciani et al. 2012), 
using the Calgary Biofilm Device (Innovotech, Innovo-
tech Inc. Edmonton, Canada). Briefly, 96-well plates, each 
well containing 150 μl of the bacterial inoculum (1 × 107 
CFU/ml) in LB medium were sealed with 96 peg-lids on 
which biofilm cells can build up. Afterwards, plates were 
placed in an humidified orbital incubator at 35 °C for 20 h 
under agitation at 125 rpm. Once biofilms were allowed 
to form, the pegs were rinsed twice with PBS to remove 
planktonic cells. Each peg-lid was then transferred to a 
“challenge 96-well microtiter plate”, each well contain-
ing 200 μl of a twofold serial dilution of peptide in PBS. 
The “challenge plate” was incubated at 37 °C for 2 h. Pep-
tide activity was evaluated by determining the amount of 
viable biofilm cells by measuring the reduction of MTT to 
its insoluble formazan. Briefly, after peptide treatment, the 
pegs-lid was washed with PBS and used to close another 
96-well microtiter plate, each well containing 200 μl of 
Hank’s buffer (136 mM NaCl; 4.2 mM Na2HPO4; 4.4 mM 
KH2PO4; 5.4 mM KCl; 4.1 mM NaHCO3, pH 7.2, supple-
mented with 20 mM d-glucose) containing 1 mg/ml MTT. 
The plate was incubated at 37 °C for 4 h. Afterwards, 50 μl 
of 25 % sodium dodecyl sulfate were added to each well 
to dissolve formazan crystals. Bacterial viability was deter-
mined by absorbance measurements at 595 nm and calcu-
lated with respect to control cells (bacteria not treated with 
the peptide) (Mangoni et al. 2005). The percentage of via-
ble cells was calculated according to the equation:
where the blank is given by samples without cells and not 
treated with the peptide.
Absorbancesample − Absorbanceblank
Absorbancecontrol − Absorbanceblank
× 100
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Peptides’ effect on cell viability
The effect of both peptides on the viability of mamma-
lian macrophages and lung epithelial cells was determined 
by the MTT assay according to (Di Grazia et al. 2014). 
Lung epithelial cells in DMEM supplemented with 2 mM 
glutamine (DMEMg) and 2 % FBS or macrophages in 
DMEMg containing NEAA, sodium pyruvate and 2 % 
FBS were plated in triplicate wells of a microtiter plate, 
at 4 × 104 cells/well. After overnight incubation at 37 °C 
in a 5 % CO2 atmosphere, the medium was replaced with 
100 μl fresh serum-free medium supplemented with each 
peptide at different concentrations. The plate was incubated 
for 24 h at 37 °C in a 5 % CO2 atmosphere. Afterwards, 
the medium was removed and replaced with Hank’s buffer 
containing 0.5 mg/ml MTT. After 4 h incubation at 37 °C, 
the formazan crystals were dissolved by adding 100 μl of 
acidified isopropanol according to (Grieco et al. 2013), 
and viability was determined by absorbance measure-
ments at 570 nm using a microplate reader (Infinite M200; 
Tecan, Salzburg, Austria). Cell viability was calculated 
with respect to the control (cells not treated with peptide). 
The percentage of viable cells was calculated as described 
above. LD50, is the lethal peptide dose causing 50 % reduc-
tion in the number of viable cells.
Cell migration assay
The ability of both peptides to stimulate migration of lung 
epithelial cells was studied as follows: A549 cells (4 × 104) 
suspended in DMEMg and supplemented with 10 % FBS 
were seeded on each side of an Ibidi culture insert for 
wound healing assay (Ibidi, Munich, Germany). Inserts 
were placed into 35-mm dish plates and incubated over-
night at 37 °C and 5 % CO2 to allow cells grow to conflu-
ence. Afterwards, inserts were removed to create a cell-free 
area (pseudo-“wound”) of approximately 500 μm; 1 ml 
DMEMg supplemented with 2 % FBS and containing or 
not the peptide at different concentrations was added. Cells 
were allowed to migrate in an appropriate incubator. At 0, 
15, 20 and 24 h, fields of the injured area were visualized 
microscopically under an inverted microscope (Olympus 
CKX41) at 4× magnification and photographed with a 
Color View II digital camera. The percentage of cell-cov-
ered area at each time was determined by WIMASIS Image 
Analysis program. Pseudo-“wound” closure assays were 
also conducted after cells pretreatment with the cell prolif-
eration inhibitor mitomycin C (5 μM) for 90 min (Chieng-
Yane et al. 2011; Wang et al. 2012). Furthermore, the 
involvement of epidermal growth factor receptor (EGFR) 
in peptide-induced cell migration was analyzed by pretreat-
ing cells for 15 min with 0.2 μM AG1478 inhibitor (Toku-
maru et al. 2005; Hoq et al. 2011).
Fluorescence studies
Lung epithelial cells (1.5 × 105) were seeded on coverslips 
(properly put into 35 mm dishes) in DMEMg supplemented 
with 10 % FBS, at 37 °C and 5 % CO2. After overnight 
incubation, cells were washed with PBS and pretreated or 
not with 0.2 μM AG1478 before adding 10 μM Esc(1-
21) or 4 μM Esc(1-21)-1c in DMEMg supplemented with 
2 % FBS. For comparison, cells incubated with 0.2 μM 
AG1478 without any peptide treatment were also included. 
Cells neither treated with the peptide nor with the inhibi-
tor served as control. After 24 h incubation at 37 °C and 
5 % CO2, cells were washed with PBS and fixed with 3.7 % 
formaldehyde for 10 min at 4 °C. Afterwards, they were 
washed with PBS, permeabilized with 0.1 % Triton X-100 
in PBS for 10 min at room temperature, washed again and 
stained with phalloidin-fluorescein isothiocyanate (40 μM 
in PBS) for 30 min at room temperature to visualize the 
cytoskeleton. The nuclei were stained by adding 50 µl of 
Hoechst 33258 (2 µg/ml) for 10 min at room temperature. 
The coverslips were mounted on slides using buffered glyc-
erol, observed under the fluorescent microscope KOZO 
OPTICS XJF800 at 20× magnification and photographed 
with a Color View II digital camera.
Evaluation of Esc(1‑21) isomers on the TNF‑α release 
from Raw 264.7 macrophages
Macrophages were cultured overnight in 96-well plates 
(1 × 105 cells/well) in DMEMg supplemented with 
sodium pyruvate, NEAA and 10 % FBS. The medium was 
then removed and replaced with fresh medium containing 
10 ng/ml LPS in the presence of 1, 5, 10 and 20 μM pep-
tide. Samples were incubated at 37 °C for 4 h. The medium 
was then collected and TNF-α concentration was evaluated 
using a mouse TNF-α enzyme-linked immunosorbent assay 
kit according to the manufacturer’s protocol (eBioscience, 
Affymetrix, San Diego, CA, USA). Cells that were stimu-
lated with LPS alone and untreated cells served as controls. 
All experiments were done in triplicates.
Circular dichroism (CD) spectroscopy
CD measurements were performed on an Aviv 202 spec-
tropolarimeter (Applied Photophysics spectropolarim-
eter, United Kingdom). The spectra were scanned using 
a thermostatic quartz cuvette with a path length of 1 mm. 
All measurements were done at 25 °C. The average time 
recording of each spectrum was 20 s in 1 nm steps in the 
wavelength range of 190–260 nm. The peptides were 
scanned at a concentration of 50 µM in 5 mM Hepes, 
50 µM of purified P. aeruginosa LPS and 10 mg/ml LPC. 
Average MW of LPS used for calculations is 4 kD.
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LPS micelles measurements by using dynamic light 
scattering (DLS)
DLS is a well-known technique used to measure the 
Brownian motion (diffusion) and the size distribution of 
particles in solution. Here, we used the DLS machine (802 
DLS manufactured by Viscotek) to determine the size of 
LPS micelles in solution. To estimate the average size of 
the LPS particles, the measurements were done in wave-
length of 830 nm, the detection was performed at 90°, tem-
perature between 22 and 25 °C (the refractive index was 
measured, respectively) and analyzed by the Software of 
OMNISIZE (Viscotek). LPS measurement was performed 
before and after peptides addition. LPS:peptide molar ratio 
was 1:1 and the solvent was filtered water.
Statistical analyses
Data were collected from three independent experiments. 
Quantitative data are expressed as the mean ± SEM. Sta-
tistical analysis was performed using two-way analysis of 
variance (ANOVA), with PRISM software (GraphPad, San 
Diego, CA). Differences were considered to be statistically 
significant for p < 0.05. The levels of statistical significance 
are indicated in the legend to figures.
Results
Design of Esc(1‑21)‑1c
Previous studies using CD spectroscopy showed that 
Esc(1-21) adopts an α-helical structure in phosphati-
dylethanolamine/phosphatidylglycerol (7:3, v:v) vesi-
cles mimicking the lipid composition of the cytoplas-
mic membrane of gram-negative bacteria (Epand et al. 
2006, 2007). Similar results were found for the shorter 
analog, Esc-1b(1-18)NH2 (Gly-Ile-Phe-Ser-Lys-Leu-Ala-
Gly-Lys–Lys-Leu-Lys-Asn-Leu-Leu-Ile-Ser-Gly-NH2) 
(Marcellini et al. 2009; Manzo et al. 2012), which is less 
active against gram-negative bacteria, e.g., P. aeruginosa, 
and differs from Esc(1-21) by a single amino acid at posi-
tion 11, and lacks the 3 residues tail Leu-Lys-Gly-NH2 at 
its carboxyl end.
In order to choose a rational position for incorporating 
d-amino acids in Esc(1-21), we took advantage of the avail-
able structural data on the shorter Esc-1b(1-18)NH2. Solu-
tion-state NMR experiments in the presence of anisotropic 
membrane models, i.e., the negatively charged sodium 
dodecylsulfate/dodecylphosphocholine detergent micelles, 
revealed that Esc-1b(1-18)NH2 consists of two helical seg-
ments separated by a kink at Gly8 (Manzo et al. 2014). In 
addition, it was suggested that the cationic residues located 
at the N-terminal half of this peptide are important not 
only for peptide–bacteria binding but also for facilitating a 
deeper insertion of Esc-1b(1-18)NH2 between the detergent 
headgroups. Furthermore, in the presence of zwitterionic 
micelles, which mimic the electrically-neutral membrane 
of mammalian cells only the C-terminal fragment was 
expected to fold in a helical conformation (Manzo et al. 
2014). Therefore, with the aim of optimizing the biostabil-
ity of Esc(1-21) without affecting its antimicrobial activity, 
we synthesized a diastereomer of Esc(1-21), named Esc(1-
21)-1c, by replacing two l-amino acids in the C-terminal 
portion, i.e. L-Leu14 and L-Ser17, with the correspond-
ing d-amino acid enantiomers (Table 1). These changes 
were also expected to decrease the toxicity of the pep-
tide towards mammalian cells, by disturbing the expected 
C-terminal α-helix which is important for cytotoxicity (see 
“Discussion”).
The diastereomer Esc(1‑21)‑1c is more stable than the 
all‑l Esc(1‑21) in human serum
The stability of both Esc(1-21) and its diastereomer in 
biological fluids were examined in the presence of 10 
or 30 % fresh human serum after 5 and 24 h incubation 
at 37 °C. The data revealed that the isomer containing 
Table 1  Peptide amount after 5 h and 24 h incubation with human fresh serum at 37 °C
a  d-Amino acids are in italics and bold
b  Peptide amounts were determined by the peak areas of the RP-HPLC relative to those of the control peptide (dissolved in PBS) at 0 min (set 
as 100 %)
Peptide designation Peptide sequencea Peptide amount (%)b
5 h 24 h
10 % Serum 30 % Serum 10 % Serum 30 % Serum
Esc-1a(1-21)NH2 Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu- 
Leu-Ile-Ser-Gly-Leu-Lys-Gly-NH2
44.4 20.95 22.19 11.5
Esc-1a(1-21)-1cNH2 Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu- 
Leu-Ile-Ser-Gly-Leu-Lys-Gly-NH2
63.34 30.12 45.61 25.46
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d-amino acids, after 24 h, was less degraded compared to 
the wild-type: ~46 and 25 % of peptide in 10 and 30 % 
serum, respectively (Table 1). In comparison, the non-
degraded amount of the wild-type Esc(1-21) after 24 h 
incubation was only ~22 and 11.5 %, in 10 and 30 % 
serum, respectively. Mass spectrometry analysis of the 
samples confirmed the presence of two main peaks, one 
at 2186 Da, corresponding to the calculated molecular 
mass of unmodified Esc(1-21)/Esc(1-21)-1c, and one 
at 495 Da corresponding to the secondary product (data 
not shown). Note that the majority of naturally occurring 
AMPs have very short (1-2 h) half-life, mainly because 
they are degraded by circulating proteases (Noto et al. 
2008; Knappe et al. 2010; Nguyen et al. 2010; Falciani 
et al. 2012).
Esc(1‑21)‑1c is more active than Esc(1‑21) against  
P. aeruginosa biofilms
The antibacterial activity of the two esculentin deriva-
tives against the planktonic form of several strains of 
P. aeruginosa (either reference or clinical isolates from 
CF patients) was determined in phosphate buffered 
saline (Table 2). The data indicated that both isomers, 
at low concentrations, had potent microbicidal activity. 
The wild-type, at 1 μM, reduced ≥3 log10 the number 
of viable bacterial cells within 30 min, compared to the 
corresponding control (untreated cells). The diastereomer 
had the same efficacy at a concentration of 4 μM against 
all the examined bacteria (Table 2). Since P. aeruginosa 
biofilm growing is associated with the persistent chronic 
infection and colonization of lungs in CF patients, the two 
peptides were also tested for their ability to kill the ses-
sile form of P. aeruginosa strains. As shown in Table 3, 
Esc(1-21)-1c displayed a higher anti-biofilm activity than 
the all-l peptide on both the clinical CF isolates AA11 
and TR1, giving rise to 95 % reduction in the amount of 
viable biofilm cells at 12.5 μM compared to 25 μM found 
for Esc(1-21).
The diastereomer is significantly less toxic than the 
all‑l peptide against mammalian cells
Esc(1-21) and its diastereomer were analyzed for their 
effect on the viability of human type II alveolar epithe-
lial cell line (A549 cells) by the MTT assay. They did not 
significantly reduce the percentage of viable cells at con-
centrations up to 64 μM (Fig. 1a). The LD50 values of the 
Table 2  Anti-Pseudomonal activity of Esc(1-21) isomers
a  Bactericidal activity was defined as the lowest peptide concentra-
tion that is sufficient to reduce the number of planktonic viable bac-
teria by ≥3 log10 CFUs/mL in 30 min. The results are the average of 
four independent experiments
Bacterial strains Bactericidal activitya (μM)
Esc(1-21) Esc(1-21)-1c
P. aeruginosa ATCC 27853 1 4
P. aeruginosa AA11 1 4
P. aeruginosa KK1 1 4
P. aeruginosa TR1 1 4
Table 3  Anti-biofilm activity of Esc(1-21) isomers
a  Antibiofilm activity was defined as the lowest peptide concentra-
tion that is sufficient to cause 95 % reduction in the amount of viable 
biofilm cells in 2 h. The results are the average of three independent 
experiments
Bacterial strains Anti-biofilm activitya (μM)
Esc(1-21) Esc(1-21)-1c
P. aeruginosa ATCC 27853 12.5 12.5
P. aeruginosa AA11 25 12.5
P. aeruginosa KK1 12.5 12.5
P. aeruginosa TR1 25 12.5
Fig. 1  Peptides’ effect on the viability of A549 cells and Raw 264.7 
macrophages. A549 cells (a) or macrophages (b) were plated in wells 
of a microtiter plate, at 4 × 104 cells/well in the corresponding cul-
ture medium (see “Materials and methods”). After overnight incuba-
tion at 37 °C in a 5 % CO2 atmosphere, the medium was replaced 
with 100 μl fresh medium supplemented with the peptides at differ-
ent concentrations. After 24 h of peptide treatment, cell viability was 
determined by the MTT reduction to insoluble formazan. Cell viabil-
ity is expressed as percentage with respect to the control (cells not 
treated with the peptide). Data points represent the mean of triplicate 
samples ± SEM. The level of statistical significance between sam-
ples treated with Esc(1-21) and Esc(1-21)-1c are indicated as follows 
*p < 0.05, **p < 0.01, ***p < 0.001
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peptides were 150 μM and >256 μM for the wild-type and 
the diastereomer Esc(1-21)-1c, respectively. This difference 
was even more pronounced against macrophages, since 
Esc(1-21) had an LD50 of ~64 μM and the diastereomer 
higher than 256 μM (Fig. 1b).
The diastereomeric peptide is more efficient 
in promoting migration of human lung epithelial cells
It is known that colonization of lung epithelia by Pseu-
domonas leads to tissue damage with impairment of lung 
functions (Baltimore et al. 1989). Taking into account that 
type II pulmonary epithelial cells are responsible for epithe-
lial reparation upon injury (Chuquimia et al. 2013), we studied 
the peptides’ capability to promote migration of A549 cells in 
an in vitro pseudo-“wound” healing assay, by means of spe-
cial cell-culture inserts. Both peptides were able to stimulate 
the closure of a gap produced in a monolayer of A549 cells. 
The wild-type peptide induced ~98 % coverage of the pseudo-
“wound” field within 24 h at a concentration of 10 μM 
(Fig. 2a). In comparison, the diastereomer Esc(1-21)-1c led to 
the complete gap closure at 4 μM within 20 h (Fig. 2b).
We further investigated whether the peptide-induced 
cell migration involved an EGFR-mediated signaling 
Fig. 2  Effect of Esc(1-21) (panel a) and its diastereomer Esc(1-
21)-1c (panel b) on the closure of a pseudo-“wound” field produced 
in a monolayer of lung epithelial cells. A549 cells were seeded in 
each side of an ibidi culture insert and grown to confluence. After-
wards, they were treated or not with the peptide at different concen-
trations, as indicated. Cells were photographed at the time of insert 
removal (0 h) and examined for cell migration after 15, 20 and 24 h 
from peptide addition. The percentage of cell-covered area at each 
time point is reported on the y-axis. Control (Ctrl) are cells not 
treated with the peptide. All data are the mean of at least three inde-
pendent experiments ± SEM. The levels of statistical significance 
between Ctrl and treated samples are indicated as follows *p < 0.05, 
**p < 0.01. Micrographs show representative results of pseudo-
“wound” closure induced after 24 h peptide treatment at different 
concentrations with respect to the Ctrl sample
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pathway, as already found for Esc(1-21) on the immortal-
ized human keratinocytes (HaCaT cells) (Di Grazia et al. 
2015). Figure 3 shows that pre-incubation of cells with 
AG1478, a specifically selective inhibitor of EGFR tyros-
ine kinase (Osherov and Levitzki 1994; Levitzki and Gazit 
1995; Tokumaru et al. 2005; Hoq et al. 2011) resulted in 
the inhibition of the peptide-induced closure of the pseudo-
“wounds”. The percentages of cell-covered area in samples 
treated with the d-amino acids peptide alone were signifi-
cantly higher than those found when cells were pretreated 
with AG1478 (Fig. 3), at all time intervals (p < 0.05, < 0.01 
and < 0.05 after 15, 20 and 24 h, respectively). In the case 
of Esc(1-21), a significant difference was found only after 
20- and 24-h treatment (p < 0.05) (Fig. 3). All together, 
these results clearly emphasize the better efficacy of the 
diastereomer in promoting the repair of the “wounded” 
cells monolayer compared to the all-l peptide (for which a 
higher concentration and a longer time was needed) and the 
involvement of EGFR in the peptide-induced migration of 
epithelial cells.
Next, to assess whether the peptide-induced cell migra-
tion was accompanied by morphological changes of A549 
cells, we used fluorescence microscopy. Both untreated 
(control) and peptide-treated cells were stained with phal-
loidin and Hoechst for cytoskeletal and nuclei detection, 
respectively. Control A549 cells (Fig. 4a) as wells as those 
treated with 0.2 µM AG1478 (Fig. 4a’) appeared organized 
into clusters with a regular morphological shape. Differ-
ently, cells treated either with Esc(1-21) or Esc(1-21)-1c 
appeared elongated, polarized and separated one from each 
other (Fig. 4b, b’, respectively), which is consistent with an 
enhanced cell motility. However, these changes were not 
identified when the two peptides were added to A549 cells 
after AG1478 pretreatment (Fig. 4c, c’). These data support 
the participation of EGFR in the esculentin-elicited migra-
tion of alveolar epithelial cells (Fig. 3).
Moreover, to discriminate the contribution of cell migra-
tion and proliferation in the peptide-induced recovery of 
the integrity of A549 monolayers, the pseudo-“wound” 
healing assay was performed by pretreating cells with the 
cell proliferation blocker mitomycin C (Chieng-Yane et al. 
2011; Wang et al. 2012). As can be seen in Fig. 5, cell pro-
liferation was not essential for the re-epithelialization pro-
cess, as pretreatment with mitomycin C did not bias the 
cell migration pattern stimulated by both peptides. Overall, 
besides the finding of more rapid and efficient re-epithe-
lialization activity of Esc(1-21)-1c compared to the wild-
type Esc(1-21), our data indicate that the pseudo-“wound” 
healing activity primarily depends on the peptide-induced 
migratory activity of A549 cells.
Both esculentin derivatives neutralize LPS and prevent 
TNF‑α secretion from LPS‑activated macrophages
To get insight into additional host-defense properties, we 
tested Esc(1-21) and its diastereomer for their ability to 
inhibit the secretion of the pro-inflammatory cytokine 
TNF‐α from murine macrophages after stimulation with 
LPS (10 ng/ml) from P. aeruginosa. The results demon-
strated a dose-dependent effect in the inhibition of TNF-α 
release; 80 and 90 % inhibition at 10 and 20 μM Esc(1-
21), respectively, compared to that of LPS alone (Fig. 6). In 
comparison, a weaker activity was detected with the dias-
tereomer Esc(1-21)-1c; 20 and 30 % inhibition at 10 and 
20 μM, respectively (Fig. 6).
Esc(1‑21)‑1c has less helical content than the all‑l 
peptide in different lipid environments
The secondary structure of the peptides was determined 
by using CD spectroscopy in several environments: Hepes 
buffer, LPC, which mimics the zwitterionic nature of the 
plasma membrane of eukaryotic cells, or LPS (Fig. 7). Both 
peptides formed β-sheet structure in 5 mM Hepes (aqueous 
solution), but changed their conformation in LPC and LPS. 
Whereas Esc(1-21) adopted predominantly α-helix in both 
LPC and LPS environments, the CD spectra of the dias-
tereomer indicated a loss of most of the α-helical structure. 
Fig. 3  Effect of AG1478 inhibitor on the peptide-mediated closure 
of a pseudo-“wound” field produced in a monolayer of A549 cells. 
After removal of the ibidi culture insert, A549 cells were pre-incu-
bated with 0.2 μM AG1478 for 15 min and subsequently treated with 
10 μM Esc(1-21) or 4 μM Esc(1-21)-1c. Some samples were treated 
with the peptide alone. Cells incubated with medium served as con-
trol (Ctrl). Samples were photographed at different time intervals, as 
indicated in the legend to Fig 2, and the percentage of cell-covered 
area was calculated and reported on the y-axis. All data are the mean 
of at least three independent experiments ± SEM. The levels of sta-
tistical significance between samples pre-treated with AG1478 and 
subsequently incubated with the peptide and those treated with the 
peptide alone at the corresponding time intervals are indicated as fol-
lows *p < 0.05, **p < 0.01
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This could be the result of the incorporation of d-amino 
acids that (1) break an α-helical structure, and (2) induce 
an opposite CD spectra, because CD is chirality dependent.
Esculentin derivatives disassemble LPS aggregates
Light scattering experiments were used to figure out whether 
the peptides could alter the micelle morphology of LPS 
(above its critical micelle concentration). The data revealed 
that LPS from Pseudomonas is poly-dispersed in solution 
with major size-populations having hydrodynamic radius 
centered at 355 nm (Fig. 8). Incubation of LPS with Esc(1-
21) caused a shift of the average size of LPS to a lower value 
centered at 67.7 nm, compared to the diastereomer Esc(1-
21)-1c which induced a larger LPS mean diameter centered at 
116, indicating weaker potency to dissociate LPS aggregates.
Discussion
Previously, we identified a short-length peptide, Esc-
1a(1-21)NH2, derived from the frog skin AMP esculentin-
1a, with promising in vitro and in vivo anti-Pseudomonal 
activities (Luca et al. 2013). Here, we focused on the 
immunomodulating properties of this peptide and the effect 
of incorporation of d-amino acids on both its antimicrobial 
Fig. 4  Effects of Esc(1-21) and Esc(1-21)-1c on the morphology of 
A549 cells. After fixation in formaldehyde, cells were stained with 
Hoechst (for nuclei detection) and phalloidin (for cytoskeletal detec-
tion). The untreated control cells (a) as well as those treated with 
0.2 µM AG1478 for 15 min (a’) appeared organized in clusters. The 
Esc(1-21) and Esc(1-21)-1c-treated cells (b and b’ respectively) 
appeared elongated with a change in their shape and cytoplasmic pro-
trusions. These alterations were not identified in A549 cells pretreated 
with AG1478 and subsequently exposed to Esc(1-21) and Esc(1-
21)-1c (c and c’, respectively). Bars are 20 µm long
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and non-antimicrobial activities. Functionally, the d-amino 
acids containing diastereomer Esc(1-21)-1c retains potent 
activity against the planktonic form of P. aeruginosa and 
it is more efficient than the all-l peptide against the sessile 
form of this bacterium, which is very difficult to eradicate. 
Furthermore, the diastereomer is significantly less toxic 
than Esc(1-21) towards both mammalian macrophages and 
alveolar epithelial cells. In addition, it is endowed with a 
higher stability in serum and with a higher activity in pro-
moting migration of lung epithelial cells in an in vitro re-
epithelialization assay. This suggests better propensity of 
the diastereomer Esc(1-21)-1c to heal damaged lung tissue. 
The enhanced stability in serum and lower toxicity to epi-
thelial cells likely justify the diastereomer Esc(1-21)-1c to 
be a better candidate in future clinical application.
Mode-of-action studies pointed out that as found for 
Esc(1-21) on HaCaT cells, migration of alveolar epithe-
lial cells induced by both isomers is prevented by AG1478, 
corroborating the involvement of EGFR in the signaling 
pathway controlling such an event. Similar results were 
also described for the frog skin AMPs temporins A and B 
(Di Grazia et al. 2014) and the cathelicidin LL-37 towards 
keratinocytes (Tokumaru et al. 2005) or corneal epi-
thelial cells (Huang et al. 2007). It is known that plasma 
membrane-associated tyrosine kinase receptors, including 
EGFR, are localized in ordered lipid domain called lipid 
rafts (Pike et al. 2005) whose alteration may inhibit ligands 
binding to EGFR and its activation. Due to insertion of 
α-helical peptides in zwitterionic phospholipid bilay-
ers (see below), the difference in wound healing activity 
between Esc(1-21) and Esc(1-21)-1c may be explained on 
the basis of a more pronounced change in the plasma mem-
brane phospholipid organization and a resulting weaker 
activation of EGFR by the more helical Esc(1-21) com-
pared to its diastereomer.
Importantly, in line with what we lately observed for 
Esc(1-21) on HaCaT cells (Di Grazia et al. 2015), the gap 
closure driven by both esculentin isoforms does not appear 
to be affected by cell proliferation, but rather depends on 
the cell migration activity. Indeed, cells exposed to mito-
mycin C before peptide treatment gave the same results as 
those obtained when the peptide was used alone (Fig. 5).
Esc(1-21)-1c has also the capability to inhibit the 
release of the pro-inflammatory cytokine TNF-α from mac-
rophages activated by P. aeruginosa LPS, albeit to a lesser 
extent compared to the all-l parental peptide.
To define whether the secondary structure of the two 
peptides contributes to their different behavior in the tox-
icity studies and LPS detoxification activity, CD spectros-
copy was carried out. We found that Esc(1-21) but not its 
diastereomer, folds into a predominantly α-helical structure 
in the presence of LPC. These results are consistent with 
the higher cytotoxicity of the wild-type Esc(1-21) com-
pared to Esc(1-21)-1c. Indeed, numerous studies conducted 
with various native AMPs emphasized the importance of an 
amphiphatic α-helical structure for mammalian cell lysis 
(Pouny et al. 1992; Gazit et al. 1994; Strahilevitz et al. 
1994).
Fig. 5  Effect of mitomycin C on the peptide-mediated closure of a 
pseudo-“wound” field produced in a monolayer of A549 cells. After 
removal of the ibidi culture insert, A549 cells were pre-incubated 
with 5 μM mitomycin (Mito C) for 90 min and subsequently treated 
with 10 μM Esc(1-21) or 4 μM Esc(1-21)-1c. Some samples were 
treated with the peptide alone. Cells incubated with medium served as 
control (Ctrl). Samples were photographed at different time intervals, 
as indicated in the legend to Fig. 2, and the percentage of cell-covered 
area was calculated and reported on the y-axis. All data are the mean 
of three independent experiments ± SEM. No statistically significant 
difference was found between samples pretreated with Mito C and 
subsequently incubated with the peptide and those treated with the 
peptide alone, at all time intervals
Fig. 6  The effect of peptides on the secretion of TNF-α from murine 
macrophages. RAW 264.7 macrophages were stimulated with LPS 
(10 ng/ml) derived from P. aeruginosa 10 in the presence of 1, 5, 
10 and 20 μM Esc(1-21) or Esc(1-21)-1c for 4 h at 37 °C and 5 % 
CO2. The percentage of inhibition of TNF-α release was normalized 
to that of macrophages stimulated with LPS without peptides (0 % 
inhibition). All the results are the mean of three independent experi-
ments ± SEM. The level of statistical significance between sam-
ples treated with Esc(1-21) and Esc(1-21)-1c is indicated as follows 
***p < 0.001
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This is likely assisted by a deeper insertion of peptides 
with a higher helical content into the hydrophobic core of 
mammalian cell membranes (Carotenuto et al. 2008; Man-
goni et al. 2011). Furthermore, our findings are in line with 
previous reports showing that incorporation of d-amino 
acids into native AMPs, such as the cytolytic peptides 
pardaxin (Shai and Oren 1996) and melittin (Oren and Shai 
1997) or synthetic peptides causes (1) abrogation of their 
toxic effect on mammalian cells while retaining antibac-
terial activity and ability to permeate anionic membranes 
(Oren et al. 1997), and (2) increases the resistance of dias-
tereomers to serum inactivation (Oren et al. 1997).
Remarkably, LPS covers more than 90 % of the outer 
membrane in gram-negative bacteria and forms an imper-
meable barrier preventing the passage of both hydrophobic 
and hydrophilic molecules (Bhunia et al. 2011; Ghosh et al. 
2014). Nevertheless, beside protecting bacteria from their 
surroundings, LPS can also act as an effector molecule by 
activating the host’s immune response against invading 
microbial pathogens. Indeed, upon being shed from bacteria 
as a result of their death or cell division, it forms micelles, 
which are the active form of the endotoxin (Takayama et al. 
1994; Rosenfeld and Shai 2006). However, when LPS is 
transferred to CD14, e.g., the primary receptor of LPS, 
which is mainly expressed on macrophages (Schumann 
et al. 1990), it disaggregates (Tobias and Ulevitch 1993). 
The LPS-CD14 complex then interacts with the transmem-
brane protein Toll-like receptor-4 (TLR4) and initiates the 
intracellular signaling cascade controlling the expression of 
cytokines, i.e., TNF-α (Rosenfeld et al. 2006b). The pos-
sible mechanism of action in which AMPs neutralize LPS 
by breaking its large micelles into smaller ones has been 
Fig. 7  The effect of LPS and LPC on the structure of Esc(1-21) or Esc(1-21)-1c. Circular dichroism spectra of 50 µM peptide in 5 mM Hepes 
(dotted line), 50 µM of purified P. aeruginosa LPS (grey line) or 10 mg/ml LPC (black line)
Fig. 8  The effect of peptides 
on the structural organization of 
LPS micelles. Light scatter-
ing of LPS from P. aeruginosa 
10 in water before and after 
incubation with Esc(1-21) or 
Esc(1-21)-1c at equimolar 
concentration
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proposed by others as well (Rosenfeld et al. 2006a, b; Bhu-
nia et al. 2011). The disaggregated form of LPS can then 
interfere with its binding to the LPS-binding protein. As a 
consequence, TLR4 will not be activated and the synthe-
sis of TNF-α will be prevented (Rosenfeld et al. 2006a, 
b; Mangoni and Shai 2011). Our light scattering analysis 
highlights the formation of smaller-sized LPS micelles 
upon addition of the peptides, with a stronger effect in the 
presence of the all-l Esc(1-21).
Note that peptides characterized by having a well-
defined and stabilized structure in both LPS and cyto-
plasmic membrane and by the capability to disassemble 
the structural organization of LPS micelles are known to 
have a potent LPS detoxification activity (Rosenfeld et al. 
2008). Therefore, the higher α-helical content of Esc(1-21) 
in LPS and its stronger efficacy in disrupting LPS aggre-
gates compared to its diastereomer are consistent with its 
stronger anti-endotoxin activity (Fig. 6). Importantly, by 
suppressing the secretion of pro-inflammatory cytokines 
from activated immune cells, these peptides would contrib-
ute to a down-regulation of acute inflammatory responses 
elicited during infection or injury; an advanced benefit of 
an antimicrobial agent in vivo. The mild anti-inflammatory 
activity of the diastereomer compared to the wild-type pep-
tide might be an advantage when the host’s innate immune 
response to bacterial infection is at the beginning stage.
Conclusions
In conclusion, we have demonstrated multiple func-
tions for both the wild-type peptide and its diastereomer. 
Importantly, only two l-to-d-amino acids substitutions in 
the C-terminal end of Esc(1-21) are sufficient to: (1) sig-
nificantly reduce its cytotoxic effect towards mammalian 
cells (e.g., alveolar epithelial cells and macrophages); (2) 
increase its effectiveness against the biofilm form of P. 
aeruginosa, while maintaining a high activity against the 
free-living form of this important pathogen; (3) enhance 
the peptide’s biostability; and (4) improve the ability of 
the peptide to promote migration of lung epithelial cells 
and presumably its capacity to restore the integrity of the 
injured lung tissue. To the best of our knowledge, this is the 
first report showing multiple beneficial effects of d-amino 
acids incorporation into an AMP. These multiple benefi-
cial properties make the diastereomer a better candidate for 
future medical preparations against P. aeruginosa-induced 
infections, particularly in CF patients, while offering 
important findings to assist and optimize the future design 
of new AMPs exhibiting multiple functions.
Acknowledgments The authors thank Silvia Scali (University of 
Siena, Italy) for the help in the peptides stability studies as well as 
Dr. Alessandra Bragonzi (San Raffaele Institute, Milan, Italy) and 
Professor Burkhard Tummler (Klinische Forschergruppe, OE 6710, 
Medizinische Hochschule Hannover, Hannover, Germany) for the P. 
aeruginosa clinical isolates. This work was supported by grants from 
Sapienza Università di Roma and the Italian Foundation for Cystic 
Fibrosis (Project FFC#11/2014 adopted by FFC Delegations from 
Siena, Sondrio Valchiavenna, Cerea Il Sorriso di Jenny and Pavia). 
The Ordine Nazionale dei Biologi is acknowledged for the fellowship 
provided to V.L. Y. Shai is incumbents of The Harold S. and Harriet 
B. Brady Professorial Chair in Cancer Research. Part of the content of 
this work is object of a US patent application N. 14/506,383.
Conflict of interest The authors declare that they have no conflict 
of interest.
References
Akram KM, Samad S, Spiteri MA, Forsyth NR (2013) Mesenchymal 
stem cells promote alveolar epithelial cell wound repair in vitro 
through distinct migratory and paracrine mechanisms. Respir 
Res 14:9
Alba A, Lopez-Abarrategui C, Otero-Gonzalez AJ (2012) Host 
defense peptides: an alternative as antiinfective and immu-
nomodulatory therapeutics. Biopolymers 98:251–267
Baltimore RS, Christie CD, Smith GJ (1989) Immunohistopathologic 
localization of Pseudomonas aeruginosa in lungs from patients 
with cystic fibrosis. Implications for the pathogenesis of progres-
sive lung deterioration. Am Rev Respir Dis 140:1650–1661
Bevins CL (2013) Innate immune functions of alpha-defensins in the 
small intestine. Dig Dis 31:299–304
Bhunia A, Saravanan R, Mohanram H, Mangoni ML, Bhattacharjya 
S (2011) NMR structures and interactions of temporin-1Tl and 
temporin-1Tb with lipopolysaccharide micelles: mechanistic 
insights into outer membrane permeabilization and synergistic 
activity. J Biol Chem 286:24394–24406
Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, 
Andersen CB, Pressler T, Givskov M, Hoiby N (2009) Pseu-
domonas aeruginosa biofilms in the respiratory tract of cystic 
fibrosis patients. Pediatr Pulmonol 44:547–558
Boman HG (1995) Peptide antibiotics and their role in innate immu-
nity. Annu Rev Immunol 13:61–92
Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, 
Di Serio C, Doring G, Tummler B (2009) Pseudomonas aerugi-
nosa microevolution during cystic fibrosis lung infection estab-
lishes clones with adapted virulence. Am J Respir Crit Care Med 
180:138–145
Brown KL, Hancock RE (2006) Cationic host defense (antimicrobial) 
peptides. Curr Opin Immunol 18:24–30
Carotenuto A, Malfi S, Saviello MR, Campiglia P, Gomez-Monterrey 
I, Mangoni ML, Gaddi LM, Novellino E, Grieco P (2008) A dif-
ferent molecular mechanism underlying antimicrobial and hemo-
lytic actions of temporins A and L. J Med Chem 51:2354–2362
Ceri H, Olson M, Morck D, Storey D, Read R, Buret A, Olson B 
(2001) The MBEC assay system: multiple equivalent biofilms 
for antibiotic and biocide susceptibility testing. Methods Enzy-
mol 337:377–385
Chen LF, Chopra T, Kaye KS (2009) Pathogens resistant to antibacte-
rial agents. Infect Dis Clin North Am 23:817–845 vii
Chieng-Yane P, Bocquet A, Letienne R, Bourbon T, Sablayrolles S, 
Perez M, Hatem SN, Lompre AM, Le Grand B, David-Dufilho M 
(2011) Protease-activated receptor-1 antagonist F 16618 reduces 
arterial restenosis by down-regulation of tumor necrosis factor 
alpha and matrix metalloproteinase 7 expression, migration, and 
2517Effect of d-amino acid incorporation on anti-biofilm and immunomodulating activities
1 3
proliferation of vascular smooth muscle cells. J Pharmacol Exp 
Ther 336:643–651
Chuquimia OD, Petursdottir DH, Periolo N, Fernandez C (2013) 
Alveolar epithelial cells are critical in protection of the respira-
tory tract by secretion of factors able to modulate the activity of 
pulmonary macrophages and directly control bacterial growth. 
Infect Immun 81:381–389
Cohen J (2002) The immunopathogenesis of sepsis. Nature 
420:885–891
Cruz J, Ortiz C, Guzman F, Fernandez-Lafuente R, Torres R (2014) 
Antimicrobial peptides: promising compounds against patho-
genic microorganisms. Curr Med Chem 21:2299–2321
Dempsey CE, Hawrani A, Howe RA, Walsh TR (2010) Amphipathic 
antimicrobial peptides—from biophysics to therapeutics? Pro-
tein Pept Lett 17:1334–1344
Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, Picardo M, 
Paus R, Mangoni ML (2015) The frog skin-derived antimicro-
bial peptide esculentin-1a(1-21)NH2 promotes the migration of 
human HaCaT keratinocytes in an EGF receptor-dependent man-
ner: a novel promoter of human skin wound healing? PLoS One 
10:e0128663
Di Grazia A, Luca V, Segev-Zarko LA, Shai Y, Mangoni ML (2014) 
Temporins A and B stimulate migration of HaCaT keratinocytes 
and kill intracellular Staphylococcus aureus. Antimicrob Agents 
Chemother 58:2520–2527
Drenkard E, Ausubel FM (2002) Pseudomonas biofilm formation and 
antibiotic resistance are linked to phenotypic variation. Nature 
416:740–743
Epand RF, Savage PB, Epand RM (2007) Bacterial lipid composi-
tion and the antimicrobial efficacy of cationic steroid compounds 
(Ceragenins). Biochim Biophys Acta 1768:2500–2509
Epand RF, Schmitt MA, Gellman SH, Epand RM (2006) Role of 
membrane lipids in the mechanism of bacterial species selective 
toxicity by two alpha/beta-antimicrobial peptides. Biochim Bio-
phys Acta 1758:1343–1350
Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and 
their mechanisms of action. Biochim Biophys Acta 1462:11–28
Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, Lelli 
B, Bindi S, Scali S, Di Giulio A, Rossolini GM, Mangoni ML, 
Bracci L, Pini A (2012) Isomerization of an antimicrobial Pep-
tide broadens antimicrobial spectrum to gram-positive bacterial 
pathogens. PLoS One 7:e46259
Fjell CD, Hiss JA, Hancock RE, Schneider G (2012) Designing anti-
microbial peptides: form follows function. Nat Rev Drug Discov 
11:37–51
Gamberi T, Cavalieri D, Magherini F, Mangoni ML, De Filippo C, 
Borro M, Gentile G, Simmaco M, Modesti A (2007) An inte-
grated analysis of the effects of Esculentin 1-21 on Saccharomy-
ces cerevisiae. Biochim Biophys Acta 1774:688–700
Gazit E, Lee WJ, Brey PT, Shai Y (1994) Mode of action of the anti-
bacterial cecropin B2: a spectrofluorometric study. Biochemistry 
33:10681–10692
Ghosh A, Datta A, Jana J, Kar RK, Chatterjee C, Chatterjee S, Bhunia A 
(2014) Sequence context induced antimicrobial activity: insight into 
lipopolysaccharide permeabilization. Mol Biosyst 10:1596–1612
Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, Orlando F, Sil-
vestri C, Bozzi A, Di Giulio A, Luzi C, Mangoni ML, Barra D, 
Saba V, Scalise G, Rinaldi AC (2006) Interaction of antimicro-
bial peptide temporin L with lipopolysaccharide in vitro and in 
experimental rat models of septic shock caused by gram-negative 
bacteria. Antimicrob Agents Chemother 50:2478–2486
Grieco P, Carotenuto A, Auriemma L, Limatola A, Di Maro S, Mer-
lino F, Mangoni ML, Luca V, Di Grazia A, Gatti S, Campiglia 
P, Gomez-Monterrey I, Novellino E, Catania A (2013) Novel 
alpha-MSH peptide analogues with broad spectrum antimicro-
bial activity. PLoS One 8:e61614
Grundmann H, Klugman KP, Walsh T, Ramon-Pardo P, Sigauque B, 
Khan W, Laxminarayan R, Heddini A, Stelling J (2011) A frame-
work for global surveillance of antibiotic resistance. Drug Resist 
Updat 14:79–87
Guralp SA, Murgha YE, Rouillard JM, Gulari E (2013) From design 
to screening: a new antimicrobial peptide discovery pipeline. 
PLoS One 8:e59305
Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K (2002) Anti-
microbial activity and stability to proteolysis of small linear cati-
onic peptides with D-amino acid substitutions. Microbiol Immu-
nol 46:741–749
Hancock RE, Nijnik A, Philpott DJ (2012) Modulating immunity as a 
therapy for bacterial infections. Nat Rev Microbiol 10:243–254
Hancock RE, Sahl HG (2006) Antimicrobial and host-defense pep-
tides as new anti-infective therapeutic strategies. Nat Biotechnol 
24:1551–1557
Haney EF, Hancock RB (2013) Peptide design for antimicrobial and 
immunomodulatory applications. Biopolymers 100(572):583
Hoq MI, Niyonsaba F, Ushio H, Aung G, Okumura K, Ogawa H 
(2011) Human catestatin enhances migration and prolifera-
tion of normal human epidermal keratinocytes. J Dermatol Sci 
64:108–118
Huang LC, Redfern RL, Narayanan S, Reins RY, McDermott AM 
(2007) In vitro activity of human beta-defensin 2 against Pseu-
domonas aeruginosa in the presence of tear fluid. Antimicrob 
Agents Chemother 51:3853–3860
Islas-Rodriguez AE, Marcellini L, Orioni B, Barra D, Stella L, Man-
goni ML (2009) Esculentin 1-21: a linear antimicrobial peptide 
from frog skin with inhibitory effect on bovine mastitis-causing 
bacteria. J Pept Sci 15:607–614
Jung Kim D, Lee YW, Park MK, Shin JR, Lim KJ, Cho JH, Kim SC 
(2014) Efficacy of the designer antimicrobial peptide SHAP1 in 
wound healing and wound infection. Amino Acids 46:2333–2343
Kai-Larsen Y, Gudmundsson GH, Agerberth B (2014) A review of 
the innate immune defence of the human foetus and newborn, 
with the emphasis on antimicrobial peptides. Acta Paediatr 
103:1000–1008
Kaye KS (2012) Antimicrobial de-escalation strategies in hospitalized 
patients with pneumonia, intra- abdominal infections, and bacte-
remia. J Hosp Med 7(Suppl 1):S13–S21
Knappe D, Henklein P, Hoffmann R, Hilpert K (2010) Easy strategy 
to protect antimicrobial peptides from fast degradation in serum. 
Antimicrob Agents Chemother 54:4003–4005
Kolar SS, Luca V, Baidouri H, Mannino G, McDermott AM, Mangoni 
ML (2015) Esculentin-1a(1-21)NH: a frog skin-derived peptide 
for microbial keratitis. Cell Mol Life Sci 72:617–627
Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to 
drug development. Science 267:1782–1788
Li J, Turnidge J, Milne R, Nation RL, Coulthard K (2001) In vitro 
pharmacodynamic properties of colistin and colistin methanesul-
fonate against Pseudomonas aeruginosa isolates from patients 
with cystic fibrosis. Antimicrob Agents Chemother 45:781–785
Lohner K, Staudegger E (2001) Are we on the threshold of the post-
antibiotic era? In: Lohner K (ed) Development of novel antimi-
crobial agents: emerging strategies. Horizon Scientific Press, 
Wymondham, pp 1–15
Luca V, Stringaro A, Colone M, Pini A, Mangoni ML (2013) Escu-
lentin(1-21), an amphibian skin membrane-active peptide with 
potent activity on both planktonic and biofilm cells of the bac-
terial pathogen Pseudomonas aeruginosa. Cell Mol Life Sci 
70:2773–2786
Luca V, Olivi M, Di Grazia A, Palleschi C, Uccelletti D, Man-
goni ML (2014) Anti-Candida activity of 1-18 fragment of the 
frog skin peptide esculentin-1b: in vitro and in vivo studies in 
a Caenorhabditis elegans infection model. Cell Mol Life Sci 
71:2535–2546
2518 A. Di Grazia et al.
1 3
Macia MD, Rojo-Molinero E, Oliver A (2014) Antimicrobial suscep-
tibility testing in biofilm growing bacteria. Clin Microbiol Infect 
20:981–990
Mangoni ML (2006) Temporins, anti-infective peptides with expand-
ing properties. Cell Mol Life Sci 63:1060–1069
Mangoni ML (2011) Host-defense peptides: from biology to thera-
peutic strategies. Cell Mol Life Sci 68:2157–2159
Mangoni ML, Carotenuto A, Auriemma L, Saviello MR, Campiglia 
P, Gomez-Monterrey I, Malfi S, Marcellini L, Barra D, Novel-
lino E, Grieco P (2011) Structure-activity relationship, confor-
mational and biological studies of temporin L analogues. J Med 
Chem 54:1298–1307
Mangoni ML, Marcellini HG, Simmaco M (2007) Biological charac-
terization and modes of action of temporins and bombinins H, 
multiple forms of short and mildly cationic anti-microbial pep-
tides from amphibian skin. J Pept Sci 13:603–613
Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas 
L (2005) Temporins, small antimicrobial peptides with leishman-
icidal activity. J Biol Chem 280:984–990
Mangoni ML, Shai Y (2011) Short native antimicrobial peptides 
and engineered ultrashort lipopeptides: similarities and differ-
ences in cell specificities and modes of action. Cell Mol Life Sci 
68:2267–2280
Mansour SC, Pena OM, Hancock RE (2014) Host defense peptides: 
front-line immunomodulators. Trends Immunol 35:443–450
Manzo G, Casu M, Rinaldi AC, Montaldo NP, Luganini A, Gribaudo 
G, Scorciapino MA (2014) Folded structure and insertion depth 
of the frog-skin antimicrobial Peptide esculentin-1b(1-18) in the 
presence of differently charged membrane-mimicking micelles. J 
Nat Prod 77:2410–2417
Manzo G, Sanna R, Casu M, Mignogna G, Mangoni ML, Rinaldi AC, 
Scorciapino MA (2012) Toward an improved structural model of 
the frog-skin antimicrobial peptide esculentin-1b(1-18). Biopol-
ymers 97:873–881
Marcellini L, Borro M, Gentile G, Rinaldi AC, Stella L, Aimola P, 
Barra D, Mangoni ML (2009) Esculentin-1b(1-18)–a membrane-
active antimicrobial peptide that synergizes with antibiotics and 
modifies the expression level of a limited number of proteins in 
Escherichia coli. FEBS J 276:5647–5664
Millar FA, Simmonds NJ, Hodson ME (2009) Trends in pathogens 
colonising the respiratory tract of adult patients with cystic fibro-
sis, 1985–2005. J Cyst Fibros 8:386–391
Moreau-Marquis S, Stanton BA, O’Toole GA (2008) Pseudomonas 
aeruginosa biofilm formation in the cystic fibrosis airway. Pulm 
Pharmacol Ther 21:595–599
Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SA, Vogel HJ (2010) 
Serum stabilities of short tryptophan- and arginine-rich antimi-
crobial peptide analogs. PLoS One 5:e12684
Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, Wade 
JD, Szabo D, Kocsis B, Nagy K, Rozgonyi F, Otvos L Jr (2008) 
Alternative stabilities of a proline-rich antibacterial peptide 
in vitro and in vivo. Protein Sci 17:1249–1255
Oren Z, Hong J, Shai Y (1997) A repertoire of novel antibacterial 
diastereomeric peptides with selective cytolytic activity. J Biol 
Chem 272:14643–14649
Oren Z, Shai Y (1997) Selective lysis of bacteria but not mammalian 
cells by diastereomers of melittin: structure-function study. Bio-
chemistry 36:1826–1835
Osherov N, Levitzki A (1994) Epidermal-growth-factor-depend-
ent activation of the src-family kinases. Eur J Biochem 
225:1047–1053
Papo N, Oren Z, Pag U, Sahl HG, Shai Y (2002) The consequence of 
sequence alteration of an amphipathic alpha-helical antimicrobial 
peptide and its diastereomers. J Biol Chem 277:33913–33921
Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F (1999) 
Inactivation of the dlt operon in Staphylococcus aureus confers 
sensitivity to defensins, protegrins, and other antimicrobial pep-
tides. J Biol Chem 274:8405–8410
Pike LJ, Han X, Gross RW (2005) Epidermal growth factor recep-
tors are localized to lipid rafts that contain a balance of inner 
and outer leaflet lipids: a shotgun lipidomics study. J Biol Chem 
280:26796–26804
Pini A, Falciani C, Mantengoli E, Bindi S, Brunetti J, Iozzi S, Ros-
solini GM, Bracci L (2010) A novel tetrabranched antimicrobial 
peptide that neutralizes bacterial lipopolysaccharide and prevents 
septic shock in vivo. FASEB J 24:1015–1022
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell 
D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-
Castagnoli P, Layton B, Beutler B (1998) Defective LPS sign-
aling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 
gene. Science 282:2085–2088
Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y (1992) Interaction of 
antimicrobial dermaseptin and its fluorescently labeled analogues 
with phospholipid membranes. Biochemistry 31:12416–12423
Pulido D, Nogues MV, Boix E, Torrent M (2012) Lipopolysaccharide 
neutralization by antimicrobial peptides: a gambit in the innate 
host defense strategy. J Innate Immun 4:327–336
Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow 
H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F et al (1994) 
Bacterial endotoxin: molecular relationships of structure to 
activity and function. Faseb J 8:217–225
Rosenfeld Y, Barra D, Simmaco M, Shai Y, Mangoni ML (2006a) A 
synergism between temporins toward gram-negative bacteria 
overcomes resistance imposed by the lipopolysaccharide protec-
tive layer. J Biol Chem 281:28565–28574
Rosenfeld Y, Papo N, Shai Y (2006b) Endotoxin (lipopolysaccha-
ride) neutralization by innate immunity host-defense peptides. 
Peptide properties and plausible modes of action. J Biol Chem 
281:1636–1643
Rosenfeld Y, Sahl HG, Shai Y (2008) Parameters involved in antimi-
crobial and endotoxin detoxification activities of antimicrobial 
peptides. Biochemistry 47:6468–6478
Rosenfeld Y, Shai Y (2006) Lipopolysaccharide (Endotoxin)-host 
defense antibacterial peptides interactions: role in bacterial 
resistance and prevention of sepsis. Biochim Biophys Acta 
1758:1513–1522
Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, 
Mathison JC, Tobias PS, Ulevitch RJ (1990) Structure and 
function of lipopolysaccharide binding protein. Science 
249:1429–1431
Semple F, Dorin JR (2012) beta-Defensins: multifunctional modu-
lators of infection, inflammation and more? J Innate Immun 
4:337–348
Shai Y (2002) Mode of action of membrane active antimicrobial pep-
tides. Biopolymers 66:236–248
Shai Y, Oren Z (1996) Diastereoisomers of cytolysins, a novel class of 
potent antibacterial peptides. J Biol Chem 271:7305–7308
Strahilevitz J, Mor A, Nicolas P, Shai Y (1994) Spectrum of anti-
microbial activity and assembly of dermaseptin-b and its 
precursor form in phospholipid membranes. Biochemistry 
33:10951–10960
Takayama K, Mitchell DH, Din ZZ, Mukerjee P, Li C, Coleman DL 
(1994) Monomeric Re lipopolysaccharide from Escherichia coli 
is more active than the aggregated form in the Limulus amebo-
cyte lysate assay and in inducing Egr-1 mRNA in murine perito-
neal macrophages. J Biol Chem 269:2241–2244
Tobias PS, Ulevitch RJ (1993) Lipopolysaccharide binding protein 
and CD14 in LPS dependent macrophage activation. Immunobi-
ology 187:227–232
Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, 
Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, 
Higashiyama S, Yoshimura A, Sugai M, Hashimoto K (2005) 
2519Effect of d-amino acid incorporation on anti-biofilm and immunomodulating activities
1 3
Induction of keratinocyte migration via transactivation of the 
epidermal growth factor receptor by the antimicrobial peptide 
LL-37. J Immunol 175:4662–4668
Uccelletti D, Zanni E, Marcellini L, Palleschi C, Barra D, Mangoni 
ML (2010) Anti-Pseudomonas activity of frog skin antimicro-
bial peptides in a Caenorhabditis elegans infection model: a 
plausible mode of action in vitro and in vivo. Antimicrob Agents 
Chemother 54:3853–3860
Wang YW, Ren JH, Xia K, Wang SH, Yin TF, Xie DH, Li LH (2012) 
Effect of mitomycin on normal dermal fibroblast and HaCat cell: 
an in vitro study. J Zhejiang Univ Sci B 13:997–1005
Xiong YQ, Hady WA, Deslandes A, Rey A, Fraisse L, Kristensen 
HH, Yeaman MR, Bayer AS (2011) Efficacy of NZ2114, a novel 
plectasin-derived cationic antimicrobial peptide antibiotic, in 
experimental endocarditis due to methicillin-resistant Staphylo-
coccus aureus. Antimicrob Agents Chemother 55:5325–5330
Yeung AT, Gellatly SL, Hancock RE (2011) Multifunctional cationic 
host defence peptides and their clinical applications. Cell Mol 
Life Sci 68:2161–2176
RESEARCH ARTICLE
The Frog Skin-Derived Antimicrobial Peptide
Esculentin-1a(1-21)NH2 Promotes the
Migration of Human HaCaT Keratinocytes in
an EGF Receptor-Dependent Manner: A Novel
Promoter of Human Skin Wound Healing?
Antonio Di Grazia1, Floriana Cappiello1, Akiko Imanishi2, Arianna Mastrofrancesco3,
Mauro Picardo3, Ralf Paus2,4, Maria Luisa Mangoni1*
1 Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University
of Rome, Rome, Italy, 2 Centre for Dermatology Research, Institute of Inflammation and Repair, University of
Manchester, Manchester, United Kingdom, 3 Laboratory of Cutaneous Physiopathology and Integrated
Center of Metabolomics Research, San Gallicano Dermatologic Institute, Rome, Italy, 4 Department of
Dermatology, University of Münster, Münster, Germany
* marialuisa.mangoni@uniroma1.it
Abstract
One of the many functions of skin is to protect the organism against a wide range of patho-
gens. Antimicrobial peptides (AMPs) produced by the skin epithelium provide an effective
chemical shield against microbial pathogens. However, whereas antibacterial/antifungal ac-
tivities of AMPs have been extensively characterized, much less is known regarding their
wound healing-modulatory properties. By using an in vitro re-epithelialisation assay employ-
ing special cell-culture inserts, we detected that a derivative of the frog-skin AMP esculen-
tin-1a, named esculentin-1a(1-21)NH2, significantly stimulates migration of immortalized
human keratinocytes (HaCaT cells) over a wide range of peptide concentrations (0.025–
4 μM), and this notably more efficiently than human cathelicidin (LL-37). This activity is pre-
served in primary human epidermal keratinocytes. By using appropriate inhibitors and an
enzyme-linked immunosorbent assay we found that the peptide-induced cell migration in-
volves activation of the epidermal growth factor receptor and STAT3 protein. These results
suggest that esculentin-1a(1-21)NH2 now deserves to be tested in standard wound healing
assays as a novel candidate promoter of skin re-epithelialisation. The established ability of
esculentin-1a(1-21)NH2 to kill microbes without harming mammalian cells, namely its high
anti-Pseudomonal activity, makes this AMP a particularly attractive candidate wound heal-
ing promoter, especially in the management of chronic, often Pseudomonas-infected,
skin ulcers.
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Introduction
Gene-encoded antimicrobial peptides (AMPs) are produced by all living unicellular and multi-
cellular organisms; they serve key roles in innate immune defences and possess a wide spec-
trum of activities against bacteria, fungi and viruses [1–3]. Despite their enormous structural
diversity, most AMPs share a net positive charge at neutral pH, a high content of hydrophobic
residues and an amphipathic character [4,5]. In animals, they are predominantly expressed in
the skin and the mucosal surfaces (e.g. the mouth, the eyes, the genito-urinary tract and the
gut) where they form a chemical barrier between host tissues and the environment [6–8]. In
addition, they are also produced by circulating immune cells such as leukocytes [9,10].
The skin is the environmentally most exposed organ and provides first-line defence against
penetrating infectious microorganisms. In mammals, including humans, epidermal keratino-
cytes produce AMPs (e.g., the cathelicidin LL-37 and the beta-defensins hBD2 and hBD3)
which are stored along with lipids within secretory granules called lamellar bodies [11–17]. Fol-
lowing skin wounding, infection and inflammation, keratinocyte lamellar bodies release their
content of hydrophobic products and AMPs into intercellular spaces forming a chemical barri-
er against water loss and microbial attack [18–20]. Furthermore, infiltrating immune cells such
as neutrophils and natural killer cells also contribute to the pool of AMPs in the skin [21–23].
Apart from their direct antimicrobial activity, mammalian AMPs display additional protec-
tive functions which have led to their classification as "host-defence peptides" [24]. These func-
tions include the capability to stimulate the host immune system while suppressing the
inflammatory response, as well as the ability to promote tissue repair through stimulation of
epithelial cell migration [25–28].
In this respect, frog skin-derived peptides, including AMPs, may be of particular interest
[29]. As a stratified squamous epithelium, the epidermis of adult frogs is histologically quite
similar to that of humans [30]. Amphibian skin has a tissue repair and a defence system that
enables wound healing without scarring [31] and contains a huge arsenal of pharmacological
agents, including multiple neuropeptides and AMPs [32]. The AMPs are mainly stored within
granules of the dermal glands controlled by the sympathetic nervous system and are secreted
in response to stress or physical injury by a holocrine-type mechanism [33–35]. All frog species
synthesize a unique set of AMPs, constituting families of 2–100 closely related members
[36,37]. Over the past two decades, in vitro and in vivo experiments have demonstrated that
frog-skin AMPs play a crucial role in maintaining the equilibrium of the natural microbial
flora and that their synthesis is induced by microorganisms [38–40].
Recently, we have focused on the short variant of the frog-skin AMP esculentin-1a, esculen-
tin-1a(1-21)NH2 [Esc(1-21), GIFSKLAGKKIKNLLISGLKG-NH2]. This consists of the first 20
amino acids of esculentin-1a (isolated from the skin of Pelophylax lessonae/ridibundus, former-
ly known as Rana esculenta) plus a glycinamide residue at its C-terminus [34,41–43]. This pep-
tide possesses a wide spectrum of antimicrobial activity with demonstrated efficacy against
both planktonic and biofilm forms of the Gram-negative bacterium Pseudomonas aeruginosa.
P. aeruginosa is clinically important as a major pathogenic microorganism that causes various
types of infections, such as those associated with the lungs, ocular surface, middle ear and skin
wounds [44,45]. Mode of action studies have shown that membrane-perturbing activity is the
major mechanism responsible for the killing action of Esc(1-21) on both phenotypes of this
pathogen, thus limiting the induction of microbial resistance [46]. Resistance to cationic pep-
tides whose mechanism of action is based on non-specific interaction with the anionic phos-
pholipids of the bacterial membrane is considered difficult since it would involve drastic
changes of the membrane lipid composition and potentially compromising the pathogen’s sur-
vival [46]. Note that compared to the extensively studied human skin AMP, LL-37 [47–50], the
Esculentin-1a(1-21)NH2 Stimulates Migration of Keratinocytes
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frog-skin AMP derived Esc(1-21) peptide may be clinically more attractive, for example due to
the ability to preserve antimicrobial activity in biological fluids [51], and to its documented fast
killing activity against a major human pathogen associated with chronic skin ulcers, P. aerugi-
nosa [46,52]. However, it is as yet unknown whether Esc(1-21) has any wound healing-
promoting properties.
As a first screening step towards exploring whether Esc(1-21) peptide is able to promote re-
epithelialisation in the human system, we studied its ability to stimulate, in vitro, the migratory
activity of human immortalized and primary epidermal keratinocytes in a modified scratch
assay, and compared the results with those of LL-37. In order to establish whether a stereospe-
cific mechanism based on the interaction with a chiral target was involved, the all-D-enantio-
mer of Esc(1-21) (containing all amino acid residues in the D configuration) was used.
Furthermore, as already found for LL-37 [53], the involvement of the epidermal growth factor
receptor (EGFR) and STAT3 protein in the peptide-induced signaling pathway controlling mi-
gration of HaCaT cells was also investigated.
Materials and Methods
Materials
Hoechst 33258, 3(4,5-dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide (MTT), AG1478,
mitomycin C; phalloidin-fluorescein isothiocyanate, LL-37 were from Sigma-Aldrich (St. Luis,
MO); GM6001 was from Calbiochem (Merk Millipore, Germany).
Frog skin peptides
Synthetic all-L and all-D Esc(1-21) peptides as well as the rhodamine-labeled all-L Esc(1-21) were
purchased from Selleck Chemicals (Houston, TX, USA). Briefly, each peptide was assembled by
step-wise solid-phase synthesis using a standard F-moc strategy and purified by RP-HPLC on a
semipreparative C18-bonded silica column (Kromasyl, 5 μm, 100 Å, 25 cm × 4.6 mm) using a
gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid (from 25 to 100% in 30 min) at a flow
rate of 1.0 ml/min. The product was obtained by lyophilization of the appropriate fraction. Ana-
lytical RP-HPLC indicated a purity>98%. The molecular mass was verified by using MALDI--
TOF Voyager DE (Applied Biosystems, Carlsbad, CA, USA) as previously described [54].
Cell culture
The extensively characterized human immortalized keratinocyte cell line, HaCaT (ATCC,
USA) [55] was used in most assays. Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), glutamine (4 mM)
and 0.05 mg/ml gentamycin, at 37°C and 5% CO2, in 25-cm
2 flasks.
Cultures of primary human epidermal keratinocytes (NHKs), derived from neonatal fore-
skins (at passage 4) were maintained in Medium 154 (Invitrogen, Life Sciences, Milan, Italy)
supplemented with Human Keratinocyte Growth Supplement (HKGS, Invitrogen) plus antibi-
otics (100 μg/ml penicillin/streptomycin), 4 mM glutamine and Ca2+ (0.07 mM) in a humidi-
fied atmosphere containing 5% CO2 at 37°C, as previously described [56]. All treatments were
performed in the same medium without HKGS to avoid any interference with the
peptide's activity.
Cell toxicity assay
The toxic effect of the investigated peptides on HaCaT cells was evaluated using the MTT col-
orimetric method [57]. MTT is a tetrazolium salt which is reduced to a formazan product by
Esculentin-1a(1-21)NH2 Stimulates Migration of Keratinocytes
PLOS ONE | DOI:10.1371/journal.pone.0128663 June 12, 2015 3 / 20
mitochondrial reductases giving a purple color. The intensity of the color is directly propor-
tional to the number of metabolically-active cells. Keratinocytes were plated in triplicate wells
of a microtiter plate, at 4 x 104 cells/well in DMEM supplemented with 4 mM glutamine
(DMEMg) and 2% FBS without antibiotic. After overnight incubation at 37°C and 5% CO2 at-
mosphere, the medium was replaced with 100 μl fresh serum-free DMEMg containing the pep-
tides at different concentrations. The plate was incubated for 2h or 24h at 37°C and 5% CO2
atmosphere. Then, DMEMg was removed and replaced with Hank’s buffer (136 mMNaCl; 4.2
mMNa2HPO4; 4.4 mM KH2PO4; 5.4 mM KCl; 4.1 mM NaHCO3, pH 7.2, supplemented with
20 mMD-glucose) containing 0.5 mg/ml MTT. After 4 h incubation, the formazan crystals
were dissolved by adding 100 μl of acidified isopropanol according to [57], and absorbance of
each well was measured at 570 nm using a microplate reader (Infinite M200; Tecan, Salzburg,
Austria).
In vitro cell migration assay
The peptides' ability to stimulate migration of epithelial cells, in vitro, was studied according to
a modified scratch assay, as described in [58–60]. Briefly, HaCaT cells (40,000) suspended in
DMEMg supplemented with 10% FBS were seeded on each side of an ibidi culture insert for
live cell analysis (Ibidi, Munich, Germany). Inserts were placed into wells of a 12-wells plate
and incubated at 37°C and 5% CO2 to allow cells grow to confluence. Afterwards, inserts were
removed with sterile tweezers to create a cell-free area (pseudo-"wound") of approximately
500 μm, whose re-epithelialisation by migrating HaCaT keratinocytes was quantitatively as-
sessed; 1 ml serum-free DMEMg supplemented or not with the peptide at different concentra-
tions was added. Cells were allowed to migrate in an appropriate incubator.
In the case of NHKs, 35,000 cells suspended in supplemented Medium 154 were seeded on
each side of the ibidi culture insert. After overnight incubation at 37°C and 5% CO2 the medi-
um was replaced with fresh medium without HKGS for 6 h. Afterwards, inserts were removed
as described above and 1 ml of medium supplemented or not with the peptide at different con-
centrations was added. Primary keratinocytes were allowed to migrate in an appropriate incu-
bator, as for HaCaT cells. All experiments were run three times in triplicates.
At different time intervals, fields of the pseudo-"wound" area were visualized under an in-
verted microscope (Olympus CKX41) at x 4 magnification and photographed with a Color
View II digital camera. The percentage of cell-covered area at each time was determined by
WIMASIS Image Analysis program. The migration speed was evaluated according to
WIMASIS' instructions.
Pseudo-“wound” closure assays with HaCaT cells were also conducted by pre-treating these
cells with 3 μMmitomycin C [60,61], 25 μMGM6001 [62,63] or 0.2 μMAG1478 inhibitor
[53,64] in order to assess the contribution of cell proliferation, metalloproteinase activity or
EGFR signaling in the peptide-induced migration of keratinocytes.
Enzyme-linked immunosorbent assay (ELISA)
Phosphorylation of STAT-3 by all-L Esc(1-21) was analyzed by an ELISA assay according to
the manufacturer's protocol (Phospho Tyr 705-Stat3 ELISA, RayBiotech, Norcross, GA, USA).
Briefly, subconfluent HaCaT keratinocytes (about 1x 106 cells in a 6-cm dish plate) were treat-
ed or not with 0.25 μM peptide in DMEMg for 20 min. Afterwards, cells were lysed with lysis
buffer supplemented with proteases and phosphatases inhibitors. Samples were centrifuged
at 12,600 g and the supernatants were added to wells of a microtiter plate coated with anti-
STAT3 antibody. After 2.5 h incubation at room temperature, the supernatant was discarded,
the wells were washed and biotinylated anti-STAT3 (Tyr 705) antibody was added to each well,
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for 1h at room temperature, to detect only phosphorylated STAT3 (Tyr 705). After washing
away unbound antibody, horseradish peroxidase conjugated streptavidin was added to each
well for 1h. The wells were washed again and a substrate (3,3’,5,5’-tetramethylbenzidine) solu-
tion was added. Color developed in proportion to the amount of bound phosphorylated
STAT3 (Tyr 705). The reaction was stopped after 30 min incubation and the intensity of the
color was measured with a microplate reader (Infinite M200; Tecan, Salzburg, Austria) at
450 nm.
Fluorescence microscopy
HaCaT cells (40,000) were seeded on coverslips for 24h in DMEMg supplemented with 10%
FBS, at 37°C and 5% CO2. After 24h, cells were washed with phosphate buffered saline (PBS)
and treated with rhodamine-labeled Esc(1-21) (4 μM in serum-free DMEMg) at 37°C and 5%
CO2. After different time intervals (30 min and 24h), samples were washed with PBS and fixed
with 3.7% formaldehyde for 10 min at +4°C. Afterwards, they were washed with PBS and
stained with 2 μg/ml Hoechst 33258 for 10 min at room temperature [65]. The coverslips were
placed on a glass slide with buffered glycerol and visualized under a fluorescence microscope
(Keyence Biozero-8000 Microscope; Keyence Corporation, Osaka, Japan). Hoechst and rhoda-
mine-labeled Esc(1-21) were visualized using laser wavelength of 360 and 560 nm respectively.
All images were taken using objective lens of 60X and zoom.
Statistical analyses
Data were collected and pooled from three independent experiments. Quantitative data are ex-
pressed as the mean ± SEM. Statistical analysis was performed using Student's t test or two-way
analysis of variance (ANOVA) with PRISM software (GraphPad, San Diego, CA). Differences
were considered to be statistically significant for a p value< 0.05.
Results
Esc(1-21) enantiomers do not exhibit significant toxicity towards HaCaT
keratinocytes
In order to assess, first, the toxicity of Esc(1-21) enantiomers, the number of metabolically-ac-
tive HaCaT cells after a short (2h) and long (24h) treatment interval was studied. Neither pep-
tide showed any marked reduction in the number of metabolically-active keratinocytes after a
2h incubation at concentrations of 2 to 64 μM, and the difference between the two was not sta-
tistically significant (Fig 1A). In contrast, after a 24h interval, only the all-L peptide showed
slight toxicity at 32 μM and 64 μM (Fig 1B), causing approximately a 20% reduction in the per-
centage of metabolically-active cells compared to the all-D Esc(1-21) (p<0.001). Note that LL-
37 led to complete inhibition of HaCaT cells metabolism at 200 μg/ml (~44 μM) [66]. This
shows that only the all-L Esc(1-21) has limited toxicity towards HaCaT cells, but that this is sig-
nificantly lower than that reported for LL-37 [66].
All-L Esc(1-21), but not its all-D enantiomer, stimulates HaCaT cell
migration
To evaluate, next, the ability of different concentrations of both isomers to promote cell migra-
tion, an in vitro cell migration assay was performed by means of special plastic inserts and a
modified scratch assay design [55] to create a 500 μmwide gap within a monolayer of HaCaT
cells. The all-L peptide promoted complete coverage of the pseudo-"wound" field in about
9–12h with a bell-shaped dose-response curve (Fig 2A). The optimal concentration allowing
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gap closure was 0.25 μM (Fig 2A and 2B). In contrast, no statistically significant difference in
the cell-covered area was measured between the all-D Esc(1-21)-treated samples and the vehi-
cle (medium)-treated control group (Fig 2B and 2C). That the all-D enantiomer did not signifi-
cantly promote re-epithelialisation of the pseudo-"wound" area in vitro suggests
stereospecificity of the mechanism of all-L Esc(1-21)-induced keratinocyte migration.
All-L Esc(1-21) also stimulates “wound” re-epithelialisation by primary
human epidermal keratinocytes in vitro
As the biological properties of cell lines differ from those of primary cells, the pseudo-"wound"
healing activity of all-L Esc(1-21) was also tested on monolayers of primary human epidermal
keratinocytes. Importantly, the peptide was found to promote re-epithelialisation of the
"wound" gap area within 24h at a concentration range between 4 μM and 10 μM (Fig 3A). The
most effective peptide dosage (10 μM) completely restored integrity of the NHK monolayer
within 20 h (Fig 3B).
LL-37 stimulates HaCaT cell migration at a narrower concentration
range and less efficiently than all-L Esc(1-21)
In order to compare all-L Esc(1-21) with the most extensively investigated human skin AMP,
the cells' migratory activity caused by LL-37 was subsequently analyzed (Fig 4A). LL-37 is a
well-known human AMP with a demonstrated wound healing effect [67] and ability to pro-
mote the migration of several different mammalian cell types, including keratinocytes [68] and
corneal epithelial cells [69]. However, LL-37 activities have not previously been evaluated
under the present experimental conditions, i.e. using the culture insert scratch assay modifica-
tion employed here [55].
In agreement with a published report [53], LL-37 was able to stimulate the closure of the
pseudo-"wound" field within 12h at an optimal concentration of 0.25 μM (Fig 4A and 4B).
Fig 1. Effect of all-L and all-D Esc(1-21) peptides at different concentrations on the number of
metabolically-active HaCaT cells after a short (A) or long (B) term treatment. Cells were plated in wells
of a microtiter plate, at 4x104 cells/well. After overnight incubation at 37°C in a 5% CO2 atmosphere, the
medium was replaced with 100 μl fresh medium supplemented with the peptides at different concentrations.
After 2h (A) or 24h (B) of peptide treatment, cell viability was determined by the MTT reduction to insoluble
formazan (see Materials and Methods for additional information). Cell viability is expressed as percentage
with respect to the vehicle-treated control cells. Data points represent the mean of triplicate samples ± SEM.
The level of statistical significance between all-L and all-D peptides is indicated as follows: ***, p<0.001.
doi:10.1371/journal.pone.0128663.g001
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Importantly, however, the percentage of the re-epithelialized area calculated at different time
intervals following peptide addition was higher for all-L Esc(1-21) (Fig 2A), with a front speed
migration equal to 20 μm/h, compared to 17 μm/h estimated for LL-37. No statistically signifi-
cant difference was obtained between vehicle-treated samples and those incubated with LL-37
at concentrations lower than 0.25 μM (Fig 4A). Furthermore, the cell migration activity was
completely inhibited by LL-37 at concentrations of 1 μM and above (Fig 4B). Therefore, under
Fig 2. Effect of all-L and all-D Esc(1-21) on the closure of a pseudo-"wound" field produced in a monolayer of HaCaT cells. HaCaT cells were seeded
in each side of an ibidi culture insert and grown to confluence. Afterwards, they were treated with all-L (A) or all-D (C) peptide at different concentrations, as
indicated. Cells were photographed at the time of insert removal (0 h) and examined for cell migration after 3, 6, 9 and 12h from peptide addition. The
percentage of cell-covered area at each time point is reported on the y-axis. Control (Ctrl) is given by vehicle-treated cells. All data are the mean of three
independent experiments ± SEM. The levels of statistical significance between Ctrl and peptide-treated samples are indicated as follows: *, p<0.05; **,
p<0.01;***, p<0.001. (B): micrographs showing representative results of pseudo-"wound" closure induced upon treatment of keratinocytes with 0.25 μM all-L
Esc(1-21) or all-D Esc(1-21) with respect to the Ctrl sample.
doi:10.1371/journal.pone.0128663.g002
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the current assay conditions, LL-37 is less efficient than all-L Esc(1-21) in promoting migration
of HaCaT cells in vitro and exhibits a narrower “therapeutic” window.
All-L Esc(1-21) primarily promotes keratinocyte migration in vitro
Next, we examined potential mechanisms that may underlie the re-epithelialisation-promoting
properties of all-L Esc(1-21). In order to abrogate cell proliferation, HaCaT cells were pre-treat-
ed with the cell proliferation blocker, mitomycin C. As shown in Fig 5, this did not significantly
delay re-epithelialisation of the pseudo-“wound” area in monolayer culture produced by either
0.25 μM all-L Esc(1-21) or LL-37, within 12h. When the activity of mitomycin C was checked
independently, it was noted that this treatment switched the morphology of HaCaT cells to a
round cell shape, a recognized stop signal for keratinocyte cell division [70], without influenc-
ing their viability (data not shown).
Fig 3. Effect of all-L Esc(1-21) on the closure of a pseudo-"wound" field produced in a monolayer of
primary human keratinocytes. (A): two monolayers of primary keratinocytes separated by a defined
distance were treated with the peptide at different concentrations, as indicated. Cells were photographed at
the time of insert removal (0 h) and examined for cell migration after 15, 20 and 24h from peptide addition.
The percentage of cell-covered area at each time point is reported on the y-axis. Control (Ctrl) is given by
vehicle-treated cells. All data are the mean of three independent experiments ± SEM. The levels of statistical
significance between Ctrl and peptide-treated samples are indicated as follows: *, p<0.5; ***, p<0.001. (B):
micrographs showing representative results upon treatment of primary keratinocytes with all-L Esc(1-21)
(4 μM and 10 μM) with respect to the Ctrl sample. The black line marks off the cell-free area in the peptide-
treated samples after 15 and 20 h. No cell-free area was noted in samples treated with 10 μM peptide after 20
and 24h.
doi:10.1371/journal.pone.0128663.g003
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Furthermore, compared to vehicle-treated HaCaT cells (Fig 6A), typical morphological
changes associated with a migratory phenotype [71,72] were detected in HaCaT cells upon
treatment with all-L Esc(1-21). Notably, these became visible through the formation of cyto-
plasmic protrusions developing into filopodial extensions (Fig 6B), quite similar to the pheno-
typic effects that have been reported for LL-37 [68]. Overall, these observations suggest that the
re-epithelialisation-promoting properties of all-L Esc(1-21) primarily result from its ability to
stimulate keratinocyte migration, rather than keratinocyte proliferation.
Fig 4. Effect of LL-37 on the closure of a pseudo-"wound" field produced in a monolayer of HaCaT
cells. (A): two monolayers of HaCaT cells separated by a defined distance were treated with LL-37 at
different concentrations, as indicated. Cells were photographed at the time of insert removal (0 h) and
examined for cell migration after 3, 6, 9 and 12h from peptide addition. The percentage of cell-covered area at
each time point is reported on the y-axis. Control (Ctrl) is given by vehicle-treated cells. All data are the mean
of three independent experiments ± SEM. The level of statistical significance between Ctrl and peptide-
treated samples is indicated as follows: ***, p<0.001. (B): micrographs showing representative results upon
treatment of keratinocytes with LL-37 (0.25 μM, 1 μM and 4 μM) with respect to the Ctrl sample.
doi:10.1371/journal.pone.0128663.g004
Esculentin-1a(1-21)NH2 Stimulates Migration of Keratinocytes
PLOS ONE | DOI:10.1371/journal.pone.0128663 June 12, 2015 9 / 20
Fig 5. Effect of mitomycin C (Mito) on the peptides-mediated closure of a pseudo-"wound" field
produced in a HaCaT cells monolayer. (A) After removal of the ibidi culture insert, HaCaT cell monolayers
were pre-incubated or not with 3 μMMito for 30 min and subsequently treated with 0.25 μM all-L Esc(1-21) or
LL-37. Cells incubated with medium served as control (Ctrl). Samples were photographed at different time
intervals, as indicated in the legends to Figs 2 and 4, and the percentage of cell-covered area was calculated
and reported on the y-axis. All data are the mean of three independent experiments ± SEM. No statistical
significance was found between samples treated with the peptide alone or pre-incubated with Mito.
doi:10.1371/journal.pone.0128663.g005
Fig 6. Effect of all-L Esc(1-21) on the phenotype of HaCaT cells.Cells (150,000) were seeded on a glass
coverslip and treated or not with 0.25 μM peptide in DMEMg for 12h at 37°C and 5%CO2. Afterwards,
samples were washed three times with PBS and fixed with 3.7% formaldehyde for 10 min at +4°C. Then, they
were permeabilized with 0.1% Triton X-100 for 10 min at room temperature and stained with phalloidin-
fluorescein isothiocyanate (40 μM in PBS) for 30 min at room temperature, to visualize the cytoskeleton. The
nuclei were stained by adding 50 μl of Hoechst 33258 (2 μg/ml) for 10 min at room temperature. The
coverslips were mounted on slides and observed under a fluorescent microscope (KOZOOPTICS XJF800)
at 40 x magnification and photographed with a Color View II digital camera. (A): vehicle-treated control cells;
(B) peptide-treated cells. Insets represent the magnification of the image portion indicated by the white frame.
rows indicate filopodial formation.
doi:10.1371/journal.pone.0128663.g006
Esculentin-1a(1-21)NH2 Stimulates Migration of Keratinocytes
PLOS ONE | DOI:10.1371/journal.pone.0128663 June 12, 2015 10 / 20
All-L Esc(1-21) stimulates migration of HaCaT keratinocytes in a EGFR-
dependent manner
To explore whether EGFR played a similar role in the signaling transduction cascade control-
ling the Esc(1-21)-stimulated migration of cells as it had been reported for LL-37 [53], HaCaT
cells were pre-incubated with the tyrosine kinase inhibitor of EGFR, AG1478 [64], and were
subsequently exposed to the all-L enantiomer. As illustrated in Fig 7, the peptide-promoted mi-
gration of HaCaT cells was significantly impaired by inhibiting EGFR-mediated signaling, sug-
gesting that Esc(1-21)-stimulated re-epithelialisation requires EGFR activation.
Since metalloproteinases have been shown to cleave membrane-anchored EGFR ligands
and to be involved in EGFR trans-activation [73], the effect of the metalloproteinase inhibitor
GM6001 [62,63] was evaluated on the peptide-induced keratinocyte migration. Pretreatment
of HaCaT cells with GM6001 indeed counteracted the Esc(1-21)-stimulated re-epithelialisation
of the pseudo-"wound" area in keratinocyte monolayer (Fig 7) indicating a contribution of
metalloproteinase activity in the peptide-induced stimulation of keratinocytes migration.
Hereafter, we determined whether the intracellular pathway involving the activation of
STAT3 protein that has previously been demonstrated for LL-37 [53], is also implicated in Esc
(1-21)-stimulated re-epithelialisation. To this end, an ELISA assay was performed to assess the
level of STAT3 phosphorylation at Tyr 705 (active form) [74], after a 20 min incubation of
HaCaT cells with the maximally effective concentration of all-L Esc(1-21) (0.25 μM). Keratino-
cytes treated with 0.25 μM LL-37 were included as a positive control.
This showed that the amount of phospho-STAT3(Tyr 705) was significantly higher in Esc
(1-21)-treated cells compared to vehicle-treated controls (p< 0.001) and similar to that in-
duced by LL-37 (Fig 8). This indicates that Esc(1-21)-promoted HaCaT cell migration, again
similar to LL-37 [53], also involves STAT3 phosphorylation.
All-L Esc(1-21) efficiently penetrates into the cytoplasm of HaCaT cells
As this may affect the biological activities of this AMP in vivo, we finally investigated whether
Esc(1-21) remains localized on the surface of cultured keratinocytes or is internalized into the
Fig 7. Effect of AG1478 and GM6001 inhibitors on the all-L Esc(1-21)-mediated closure of a pseudo-
"wound" field produced in a HaCaT cells monolayer. After removal of the ibidi culture insert, HaCaT cell
monolayers were pre-incubated with 0.2 μMAG1478 for 15 min or with 25 μMGM6001 for 30 min and
subsequently treated with 0.25 μM all-L Esc(1-21). Cells incubated with medium served as control (Ctrl).
Samples were photographed at different time intervals, as indicated in the legend to Fig 2, and the
percentage of cell-covered area was calculated and reported on the y-axis. All data are the mean of three
independent experiments ± SEM. The levels of statistical significance between inhibitor-pretreated groups
and samples treated with the peptide alone are indicated as follows:*, p<0.05; **, p< 0.01; ***, p< 0.001.
doi:10.1371/journal.pone.0128663.g007
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cytoplasm or nucleus. HaCaT cells were exposed to rhodamine-labeled Esc(1-21) and stained
with Hoechst 33258 dye so as to permit the differential visualization of the AMP and cell nu-
clei, respectively, by fluorescence microscopy. This revealed that the fluorescently labelled pep-
tide was distributed inside the HaCaT cells and concentrated mainly at the nuclear periphery
within 30 min after administration to the culture medium (Fig 9 left panels), without entering
into the nucleus even 24h after its addition to the cells (Fig 9 right panels). Similar results were
obtained with another class of amphibian skin AMPs, i.e. the temporins [55], suggesting that
after membrane binding and indirect activation of EGFR, Esc(1-21) and likely other frog skin
linear peptides are internalized into the keratinocyte cytoplasm.
Discussion
Here, we provide the first evidence that a peptide fragment derived from the frog-skin AMP
esculentin-1a, esculentin-1a(1-21)NH2, promotes the re-epithelialisation of surrogate scratch
“wounds” by human keratinocytes in vitro, notably both in HaCaT cells and in primary epider-
mal keratinocytes, and this more effectively and at much lower cell toxicity than the prototypic
human skin AMP, LL-37. Importantly, migration of HaCaT cells upon addition of Esc(1-21)
occurs over a wider peptide concentration range (from 0.025 to 4 μM) compared to LL-37
which completely loses activity at 1 and 4 μM (Fig 4). Furthermore, although 0.25 μM is the op-
timal concentration for both AMPs, the cell migration rate induced by Esc(1-21) is higher than
that of LL-37.
This introduces Esc(1-21) as a new candidate wound healing promoter. Our study is in gen-
eral agreement with earlier reports that other frog skin-derived peptides can promote epithelial
cells migration [29,55] and wound healing in murine models, namely through the release of
transforming growth factor β1 [75]. However, the current study is the first to show that an
esculentin-1a-derived peptide promotes keratinocyte migration via an EGFR-dependent
signaling pathway.
Mechanistically, we show that the re-epithelialisation promoted by Esc(1-21) is stereospecif-
ic, possibly based on a stereoselective interaction with chiral targets, such as proteins [25,76].
Importantly, cell proliferation does not significantly contribute to the re-epithelialisation-pro-
moting effect of Esc(1-21), which appears to be mainly dependent on the stimulation of
Fig 8. Phosphorylation of STAT3 by all-L Esc(1-21). About 1 x 106 keratinocytes were stimulated with
0.25 μM all-L Esc(1-21) or LL-37 for 20 min. Control (Ctrl) was given by vehicle-treated cells. Cells were
harvested into lysis buffer and phospho-STAT3 (Tyr 705) was evaluated by performing an ELISA assay (see
Materials and methods). All data are the mean of three independent experiments ± SEM. The level of
statistical significance between peptide-treated samples and Ctrl is indicated as follows: ***, p < 0.001.
doi:10.1371/journal.pone.0128663.g008
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keratinocyte migration. As previously shown for LL-37 [53], the promotion of keratinocyte mi-
gration by Esc(1-21) requires activation of an EGFR signaling pathway. Note that erbB4 recep-
tor (another member of the EGFR family), whose activation can be hampered by the EGFR
inhibitor employed here (AG1478) [77–79], is not expressed in human keratinocytes and
HaCaT cells [80,81]. Our in vitro assays have also indicated a contribution of metalloproteinase
activity in the Esc(1-21)-induced migration of keratinocytes. This raises the question whether
the re-epithelialisation-promoting activities of this AMP require cleavage of membrane-bound
EGFR ligands and/or receptor trans-activation by metalloproteinases.
Furthermore, one of the signaling events implicates tyrosine phosphorylation and activation
of STAT3 protein [82]. This is in line with the previous demonstration that EGFR-induced cell
migration is mediated predominantly by the STAT-pathway in keratinocytes and that STAT3
plays an essential role for skin remodeling and wound healing [82,83].
Fig 9. Images of HaCaT cells treated with rhodamine-labeled all-L Esc(1-21) at different times (30 min
and 24h). Panels A and A' show bright field images. Black arrows indicate keratinocytes. B and B' show the
Hoechst fluorescence signal which indicates the nuclei position. Panels C and C' show the distribution of the
rhodamine-labeled Esc(1-21). Red fluorescence is not detectable at the level of nuclei (white arrows), but
rather in the cytoplasm and mainly concentrated at the nuclei periphery, already after a short incubation time
(C). Panels D and D' show the overlay of the two fluorescent probes. All images are z section images taken
from the mid-cell height. All bars indicate 10 μm.
doi:10.1371/journal.pone.0128663.g009
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Yet, multiple additional molecular mechanisms might participate in the enhanced migra-
tion of keratinocytes after exposure to Esc(1-21), such as the PI3K/Akt signaling pathway, like-
ly mediated not only through activation of EGFR but also through the induction of G-protein-
coupled receptor FPRL-1 [68]. Therefore, additional experiments are needed to clarify the
exact intracellular signaling events that govern Esc(1-21)-promoted keratinocyte migration. In
this context, it is interesting to note that our data also show that Esc(1-21) quickly translocates
into the cytoplasm via yet to be discovered mechanisms, possibly upon interaction with the cell
membrane and activation of EGFR; this may trigger further signaling pathways controlling ker-
atinocyte migration and efficient re-epithelialisation. However, it can currently not be excluded
that this peptide is also capable of integrating into the cell membrane (without causing cytotox-
icity) and to subsequently enter into the cytosol, or that it can be internalized via endocytosis.
The current work also encourages one to re-evaluate the potential overall benefits of frog
skin-derived AMPs in clinical medicine [28]. Skin secretions from many species of Anura
(frogs and toads), especially those belonging to the Hylidae and Ranidae family, are among the
most abundant sources for biologically-active peptides, including AMPs, presently numbering
more than a thousand [84]. Esc(1-21) in particular has been recently identified as a derivative
of the longer peptide esculentin-1a, with clinically attractive features for a potential new thera-
peutic agent. Remarkably, Esc(1-21) has the capability to preserve antibacterial activity even at
high salt concentrations [46] as well as in the presence of serum and tears [51]. This is in sharp
contrast to the properties of the key human AMPs, hBD-2 and LL-37, which completely lose
their antimicrobial efficacy at the high ionic strength (e.g., 100 mMmonovalent cations) found
at many body sites [85], such as the sputum, airway surfaces and serum/plasma [86–90]. Fur-
thermore, their antimicrobial activity is drastically reduced in biological fluids [91].
Although these mammalian AMPs certainly function as powerful microbicidal agents at the
high concentration (mg/ml) present in the phagolysosomes of neutrophils, they probably act as
immunomodulators at those physiological setting e.g. inflammatory sites, generally containing
high levels of mono and bivalent cations, where they are released by degranulation at lower
concentrations [47,90]. This would explain the lack of antibacterial activity of these AMPs
when tested, in vitro, under conditions (i.e. peptide concentrations and culture media) that bet-
ter mimic those encountered in their natural environment [88,91–94]. In contrast, the estimat-
ed concentration of peptides in the skin mucus of resting (non-stressed) frogs is within the
concentration range that shows antimicrobial activity in vitro [95], supporting the notion that
AMPs produced in amphibian skin provide remarkable chemical weapons against skin patho-
gens [96]. This may be especially important for newly metamorphosed frogs in which the adap-
tive immune system is still immature [35,97]. Another advantageous feature of Esc(1-21)
compared to classical mammalian AMPs is that, given its short sequence, it may be possible to
produce this AMP more economically. Finally, we should recall that Esc(1-21) is significantly
less cytotoxic than LL-37 toward HaCaT cells, in agreement with literature data showing that
human cathelicidins become harmful to mammalian cells, when used at high concentrations
[98].
Given the complexity of the recognized individual stages of skin wound healing in vivo [99],
it is evident that even the re-epithelialisation component of skin wound healing alone can be
very incompletely reproduced in vitro, i.e. in the absence of fibroblasts, immunocytes, and
functional perfusion and innervation. Therefore, the current results need to be followed-up,
next, at the preclinical research level in more complex human skin assays, using for example
the punch-in-a-punch design of organ-cultured full-thickness human skin [29]. However, the
ibidi culture insert system used here [55] provides an objective and highly reproducible initial
experimental screening tool for the quantitative evaluation of human keratinocyte migration
and its manipulation by candidate wound healing promoters. This simplified in vitro-surrogate
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assay for re-epithelialisation may be preferable over the classical scratch assay method, where
the gap width created with a plastic pipette tip is highly dependent on the pressure applied and
where detached cells can easily form clumps at the edges of the scratch, affecting the rate of cell
migration, thus giving potentially confounding results.
In summary, here we provide the first evidence that Esc(1-21) significantly and more effec-
tively than LL-37 stimulates human keratinocyte migration in an in vitro assay, likely in man-
ner that involves activation of EGFR and STAT3 protein. The established ability of Esc(1-21)
to kill microbes without harming mammalian cells, namely its high anti-Pseudomonal activity
also in physiologically relevant conditions [46,51] makes this short-sized AMP a particularly
attractive candidate wound healing promoter, especially in the management of chronic, often
Pseudomonas-super-infected, human skin ulcers [52,100].
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